<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/260880-compositions-comprising-nebivolol by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:14:34 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 260880:COMPOSITIONS COMPRISING NEBIVOLOL</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">COMPOSITIONS COMPRISING NEBIVOLOL</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>WO 2006/130174	PCT/US2005/041275<br>
Compositions Comprising Nebivolol<br>
Eric Davis, John O'Donnell, Peter Bottini, Preston Mason, Andrew Shaw<br>
This application is a continuation-in-part of application Ser. No, 11/141,235, filed May 31,<br>
2005, which is based on and claims priority from U.S. Provisional Patent Application Serial<br>
No, 60/577,423, Eric Davis, John O'Donnell, Peter Bottini, filed June 4,2004.<br>
Technical Field<br>
[0001]	This invention relates to compositions comprising nebivolol and one or more<br>
other active agent. More particularly, this invention relates to compositions<br>
comprising nebivolol and one or more cardiovascular agents for the treatment and/or<br>
prevention of cardiovascular diseases.<br>
-1-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Background of the Invention<br>
[0002]	Hypertension is a major health concern in the US. Approximately 50 million<br>
Americans have elevated blood pressure defined as a systolic blood pressure (SBP)<br>
≥140 mmHg or a diastolic blood pressure (DBP) ≥ 90 mmHg, In addition, individuals<br>
with blood pressure of 120/80 mmHg or higher are at increased risk of developing<br>
hypertension and are considered to be in a "pre-hypertension" state. Severity of<br>
hypertension is currently classified by stage, with Stage 1 hypertension spanning<br>
blood pressure ranges from 140/90 to 159/99 mmHg and Stage 2 including blood<br>
pressures 360/100 mmHg.<br>
[0003]	Onset of hypertension (diastolic alone or in combination with systolic)<br>
typically occurs between 25 and 55 years of age. The risk of developing hypertension<br>
increases more dramatically with increasing age. According to the CDC, 68.3% of<br>
men aged 65-74 have hypertension in the U.S. (Health United States, 2003,<br>
CDC/National Center for Health Statistics) and 70.7% of men aged over 75 have<br>
hypertension in the U.S. (Health United States, 2003, CDC/National Center for Health<br>
Statistics). In addition, 73.4% of women aged 65-74 have hypertension in the US<br>
(Health United States, 2003, CDC/National Center for Health Statistics) and 84.9 %<br>
of women aged over 75 have hypertension in the US (Health United States, 2003,<br>
CDC/National Center for Health Statistics).<br>
[0004]	Pharmaceutical formulations that stimulate, agonize, or potentiate endothelial<br>
nitric oxide production, particularly formulations that produce increased nitric oxide<br>
levels in Black Americans, are needed.<br>
-2-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Summary of the Invention<br>
[0005]	In one aspect, the present invention features a pharmaceutical composition<br>
comprising nebivolol and at least one other active agent, In a further embodiment, at<br>
least one of the active agents is a cardiovascular agent. In a further embodiment, the<br>
at least one cardiovascular agent is selected from the group consisting of ACE<br>
inhibitors (angiotensin II converting enzyme inhibitors), ARB's (angiotensin II<br>
receptor antagonists), adrenergic blockers, adrenergic agonists, agents for<br>
pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants,<br>
antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium<br>
channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors,<br>
diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic<br>
agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers<br>
(advanced glycosylation end-product crosslink breakers, such as alagebrium, see USP<br>
6,458,819), and AGE formation inhibitors (advanced glycosylation end-product<br>
formation inhibitors, such as pimagedine), and mixtures thereof. In one embodiment,<br>
the other cardiovascular agent is an ACE inhibitor or an ARB. In a further<br>
embodiment, the other cardiovascular agent includes an ACE inhibitor and an ARB.<br>
In a further embodiment, the ACE inhibitor is selected from the group consisting of:<br>
alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat,<br>
fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, spirapril,<br>
temocapril, trandolapril. In a further embodiment, the ACE inhibitor is enalapril,<br>
ramipril, or ramiprilat. In a further embodiment, the other cardiovascular agent is an<br>
ARB selected from the group consisting of candesartan, eprosartan, irbesartan,<br>
losartan, valsartan.<br>
-3-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0006]	In a further embodiment, the pharmaceutical composition comprises an<br>
amount of nebivolol in the range of between about 0.125 mg and about 40 mg. In a<br>
further embodiment, the amount of an ACE inhibitor may be in the range of between<br>
about 0.5 mg to about 80 mg, and/or the amount of ARB may be in the range of<br>
between about 1 mg and about 1200 mg.<br>
[0007]	In a further embodiment, the pharmaceutical composition comprises nebivolol<br>
and only one other active agent. In a further embodiment, the pharmaceutical<br>
composition comprises nebivolol and only one cardiovascular agent. In a further<br>
embodiment, the cardiovascular agent is selected from the group consisting of ACE<br>
inhibitors (angiotensin II converting enzyme inhibitors), ARB's (angiotensin II<br>
receptor antagonists), adrenergic blockers, adrenergic agonists, agents for<br>
pheochromocytoma, anti-anginal agents, antiarrhythmics, antiplatelet agents,<br>
anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory<br>
agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin<br>
inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors,<br>
inotropic agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers<br>
(advanced glycosylation end-product crosslink breakers, such as alagebrium, see USP<br>
6,458,819), and AGE formation inhibitors (advanced glycosylation end-product<br>
formation inhibitors, such as pimagedine). In a further embodiment, the active agent<br>
is an ACE inhibitor or and ARB.<br>
[0008]	In another aspect, the present invention features a method of treating a subject<br>
for a cardiovascular disorder comprising administering to the subject an effective<br>
amount of nebivolol in combination with at least one other cardiovascular agent. In a<br>
further embodiment, the cardiovascular disorder is selected from the group consisting<br>
-4-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
of atherosclerosis, hypertension, diabetes mellitus, hyperhomocysteinemia, heart<br>
failure, and renal failure.<br>
[0009]	In another aspect, the present invention features a method of preventing a<br>
cardiovascular disorder comprising administration to a subject an effective amount of<br>
nebivolol in combination with an effective amount of at least one other cardiovascular<br>
agent. In a further embodiment, the cardiovascular disorder is selected from the<br>
group consisting of congestive heart failure, hypertension, pulmonary hypertension,<br>
myocardial and cerebral infarctions, atherosclerosis, atherogenesis, thrombosis,<br>
ischemic heart disease, post-angioplasty restenosis, coronary artery diseases, renal<br>
failure, stable, unstable and variant (Prinzmetal) angina, cardiac edema, renal<br>
insufficiency, nephrotic edema, hepatic edema, stroke, transient ischemic attacks,<br>
cerebrovascular accidents, restenosis, controlling blood pressure in hypertension,<br>
platelet adhesion, platelet aggregation, smooth muscle cell proliferation, pulmonary<br>
edema, and vascular complications associated with the use of medical devices.<br>
[0010]	In another aspect, the present invention features a kit comprising an effective<br>
amount of nebivolol in combination with an effective amount of another<br>
cardiovascular agent.<br>
[0011]	Even though nebivolol has β-blocking properties, nebivolol is different from<br>
other classic β-blockers in that it is highly selective to the β1 adrenergic receptors and<br>
also has vasodilaring effects related to its effect on endothelial nitric oxide. It is<br>
believed mat nebivolol increases the levels of nitric oxide within the vascular<br>
endothelium through the L-arginine-nitric oxide pathway and has been shown to<br>
improve endothelial dysfunction and improve compliance of blood vessels. Nebivolol<br>
has also been shown to have antioxidant characteristics which are favorable to the<br>
-5-<br>
WO 2006/130174	PCT/US2005/041275<br>
normal functioning of the vascular endothelium. These characteristics make<br>
nebivolol an effective antihypertensive agent with favorable effects on the vascular<br>
endothelium and cardiovascular system. Nebivolol has been shown to be beneficial in<br>
the treatment of cardiovascular diseases such as hypertension, congestive heart<br>
failure, arterial stiffness and endothelial dysfunction. In part, the present invention<br>
features a composition comprising nebivolol and at least one other cardiovascular<br>
agent that is believed to work via a different mechanism and is to be used for the<br>
treatment and/or prevention of vascular diseases characterized by nitric oxide<br>
insufficiency. This invention also describes a method of reducing mortality<br>
associated with cardiovascular disease in a black patient comprising administering to<br>
the black patient a therapeutically effective amount of nebivolol or its<br>
pharmaceutically salt and at least one other cardiovascular agent. This invention also<br>
relates to a method of improving NO release in a black patient in need thereof by<br>
administering to the black patient a therapeutically safe and effective amount of<br>
nebivolol or a pharmaceutically acceptable salt thereof and at least one other<br>
cardiovascular agent, sufficient to improve NO release. This invention further<br>
describes a method for improving exercise tolerance or for improving the quality of<br>
life in a black patient in need thereof, comprising administering to the black patient a<br>
therapeutically effective amount of nebivolol or a pharmaceutically salt thereof, and at<br>
least one cardiovascular agent.<br>
[0012]	These embodiments of the present invention, other embodiments, and their<br>
features and characteristics, will be apparent from the description, drawings and<br>
claims that follow.<br>
-6-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Brief Description of the Drawings<br>
[0013]	Figure 1 depicts a comparison of NO release from Black and White donor<br>
endothelial cells after chronic treatment with ramprilat followed by treatment with<br>
nebivolol (lμM).<br>
[0014]	Figure 2 depicts a comparison of the increase in NO release from Black and<br>
White donor endothelial cells after chronic treatment with ramiprilat followed by<br>
treatment with nebivolol (1 μM).<br>
[0015]	Figure 3 depicts comparison of NO release from Black and White donor<br>
endothelial cells after chronic treatment with enalapril followed by treatment with<br>
nebivolol (lμM).<br>
[0016]	Figure 4 depicts a comparison of the increase in NO release from Black and<br>
White donor endothelial cells after chronic treatment with enalapril followed by<br>
treatment with nebivolol (lμM).<br>
Detailed Description of the Invention<br>
Definitions<br>
[0017]	For convenience, before further description of the present invention, certain<br>
terms employed in the specification, examples and appended claims are collected<br>
here. These definitions should be read in light of the remainder of the disclosure and<br>
understood as by a person of skill in the art. Unless defined otherwise, all technical<br>
and scientific terms used herein have the same meaning as commonly understood by a<br>
person of ordinary skill in the art.<br>
-7-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0018]	The articles "a" and "an" are used herein to refer to one or to more than one<br>
(i.e., to at least one) of the grammatical object of the article. By way of example, "an<br>
element" means one element or more than one element.<br>
[0019]	"About the same time" means that within about thirty minutes of administering<br>
one compound (nebivolol) to the patient, the other active compound(s) is/are<br>
administered to the patient. "About the same time" also includes simultaneous<br>
administration of the compounds.<br>
[0020]	The phrase "angiotensin converting enzyme inhibitor" or "ACE inhibitor" as<br>
used herein refers to a compound that inhibits any enzyme from converting<br>
angiotensin to any other form.<br>
[0021]	The phrase "angiotensin II receptor antagonist" or "ARB" refers to a<br>
compound that binds to a receptor site on angiotensin II but does not cause any<br>
physiological changes unless another receptor ligand is present.<br>
[0022]	The term "antagonist" is art-recognized and refers to a compound that binds to<br>
a receptor site, but does not cause a physiological change unless another receptor<br>
ligand is present.<br>
[0023]	The term "bioavailable" is art-recognized and refers to a form of the subject<br>
invention that allows for it, or a portion of the amount administered, to be absorbed<br>
by, incorporated to, or otherwise physiologically available to a subject or patient to<br>
whom it is administered.<br>
[0024]   "Black" refers to a person of African descent or an African-American person but is<br>
not necessarily limited to those of African origin (e.g., Carribean).<br>
-8-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0025]      "Therapeutically effective amount" refers to the amount of the compound and/or<br>
composition that is effective to achieve its intended purpose.<br>
[0026]     The phrase "cardiovascular agent" or "cardiovascular drug" refers to a therapeutic<br>
compound that is useful for treating or preventing a cardiovascular disease. Non-<br>
limiting examples of suitable cardiovascular agents include ACE inhibitors<br>
(angiotensin II converting enzyme inhibitors), ARB's (angiotensin II receptor<br>
antagonists), adrenergic blockers, adrenergic agonists, agents for pheochromocytoma,<br>
antianginal agents, antiarrhythmics, antiplatelet agents, anticoagulants,<br>
antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium<br>
channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors,<br>
diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic<br>
agents, renin inhibitors, vasodilators, vasopressors, AGE crosslink breakers<br>
(advanced glycosylation end-product crosslink breakers, such as alagebrium, see USP<br>
6,458,819), and AGE formation inhibitors (advanced glycosylation end-product<br>
formation inhibitors, such as pimagedine), and combinations thereof.<br>
[0027]	Cardiovascular disease or disorder refers to any cardiovascular disease or<br>
disorder known in the art, including, but not limited to, wherein the cardiovascular<br>
disease is selected from the group consisting of congestive heart failure, hypertension,<br>
pulmonary hypertension, myocardial and cerebral infarctions, atherosclerosis,<br>
atherogenesis, thrombosis, ischemic heart disease, post-angioplasty restenosis,<br>
coronary artery diseases, renal failure, stable, unstable and variant (Prinzmetal)<br>
angina, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke,<br>
transient ischemic attacks, cerebrovascular accidents, restenosis, controlling blood<br>
pressure in hypertension, platelet adhesion, platelet aggregation, smooth muscle cell<br>
-9-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
proliferation, pulmonary edema, and vascular complications associated with the use of<br>
medical devices.<br>
[0028]	The term "combination" refers to two or more different active agents which<br>
are administered at roughly about the same time (for example, where the active agents<br>
are in a single pharmaceutical preparation) or at different times (for example, one<br>
agent is administered to the subject before the other).<br>
[0029]	The terms "drug," "pharmaceutically active agent," "bioactive agent,"<br>
"therapeutic agent," and "active agent" may be used interchangeably and refer to a<br>
substance, such as a chemical compound or complex, that has a measurable beneficial<br>
physiological effect on the body, such as a therapeutic effect in treatment of a disease<br>
or disorder, when administered in an effective amount. Further, when these terms are<br>
used, or when a particular active agent is specifically identified by name or category,<br>
it is understood that such recitation is intended to include the active agent per se, as<br>
well as pharmaceutically acceptable, pharmacologically active derivatives thereof, or<br>
compounds significantly related thereto, including without limitation, salts,<br>
pharmaceutically acceptable salts, N-oxides, prodrugs, active metabolites, isomers,<br>
fragments, analogs, solvates hydrates, radioisotopes, etc.<br>
[0030]	The phrase "effective amount" refers to that amount of a substance that<br>
produces some desired local or systemic effect at a reasonable benefit/risk ratio<br>
applicable to any treatment. The effective amount of such substance will vary<br>
depending upon the subject and disease condition being treated, the weight and age of<br>
the subject, the severity of the disease condition, the manner of administration and the<br>
like, which can readily be determined by one of ordinary skill in the art.<br>
-10-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0031]	"Endothelial dysfunction" refers to the impaired ability of in any physiological<br>
processes carried out by the endothelium, in particular, production of nitric oxide<br>
regardless of cause. It may be evaluated by, such as, for example, invasive techniques,<br>
such as, for example, coronary artery reactivity to acetylcholine or methacholine, and<br>
the like, or by noninvasive techniques, such as, for example, blood flow<br>
measurements, brachial artery flow dilation using cuff occlusion of the arm above or<br>
below the elbow, brachial artery ultrasonography, imaging techniques, measurement<br>
of circulating biomarkers, such as, asymmetric dimethylarginine (ADMA), and the<br>
like. For the latter measurement the endothelial-dependent flow-mediated dilation will<br>
be lower in patients diagnosed with an endothelial dysfunction.<br>
[0032]	The phrase "endothelial nitric oxide synthase" or "eNOS" refers to enzymes<br>
that produce nitric oxide.<br>
[0033]	The phrase "nebivolol composition" refers to a composition comprising<br>
nebivolol and the two are used interchangeably. Nebivolol is a mixture of d and /<br>
isomers of α,α-[iminobismethylene]bis[6-fluoro-3,4-dihydro-2H-l -benzopyran-2-<br>
methanol]. The composition may include at least one other cardiovascular agent or at<br>
least one pharmaceutically acceptable carrier or both.<br>
[0034]	The term "pharmaceutically acceptable salts" is art-recognized and refers to<br>
the relatively non-toxic, inorganic and organic acid addition salts of compounds,<br>
including, for example, those contained in compositions of the present invention.<br>
[0035]	The term "pharmaceutically acceptable carrier" is art-recognized and refers to<br>
a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or<br>
solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying<br>
-11-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
or transporting any subject composition or component thereof from one organ, or<br>
portion of the body, to another organ, or portion of the body. Each carrier must be<br>
acceptable in the sense of being compatible with the subject composition and its<br>
components and not injurious to the patient. Some examples of materials which may<br>
serve as pharmaceutically acceptable excipients include: (1) sugars, such as lactose,<br>
glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose,<br>
and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and<br>
cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8)<br>
excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil,<br>
cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10)<br>
glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol<br>
and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar;<br>
(14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15)<br>
alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) IV fluids, including<br>
but not limited to Ringer's solution, 5% dextrose in water, and half normal saline;<br>
(19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic<br>
compatible substances employed in pharmaceutical formulations.<br>
[0036]	"Patient" refers to animals, preferably mammals, most preferably humans, and<br>
includes males and females.<br>
[0037]	"Quality of life" refers to one or more of a person's ability to walk, climb<br>
stairs, do errands, work around the house, participate in recreational activities, and/or<br>
not requiring rest during the day, and/or the absence of sleeping problems or shortness<br>
of breath.<br>
-12-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0038] The term "prophylactic" or "therapeutic" treatment is art-recognized and refers to<br>
administration to the host of one or more of the subject compositions. If it is<br>
administered prior to clinical manifestation of the unwanted condition (e.g., disease or<br>
other unwanted state of the host animal) then the treatment is prophylactic, i.e., it<br>
protects the host against developing the unwanted condition, whereas if administered<br>
after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is<br>
intended to diminish, ameliorate or maintain the existing unwanted condition or side<br>
effects therefrom).<br>
[0039]	The term "structure-activity relationship" or "(SAR)" is art-recognized and<br>
refers to the way in which altering the molecular structure of a drug or other<br>
compound alters its interaction with a receptor, enzyme, nucleic acid or other target<br>
and the like.<br>
[0040]	It will be understood that "substitution" or "substituted with" includes the<br>
implicit proviso that such substitution is in accordance with permitted valence of the<br>
substituted atom and the substituent, and that the substitution results in a stable<br>
compound, e.g., which does not spontaneously undergo transformation such as by<br>
rearrangement, cyclization, elimination, or other reaction.<br>
[0041]	The term "substituted" is also contemplated to include all permissible<br>
substituents of organic compounds. In a broad aspect, the permissible substituents<br>
include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic,<br>
aromatic and nonaromatic substituents of organic compounds. Illustrative<br>
substituents include, for example, those described herein above. The permissible<br>
substituents may be one or more and the same or different for appropriate organic<br>
compounds. For purposes of this invention, the heteroatoms such as nitrogen may<br>
-13-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
have hydrogen substituents and/or any permissible substituents of organic compounds<br>
described herein which satisfy the valences of the heteroatoms. This invention is not<br>
intended to be limited in any manner by the permissible substituents of organic<br>
compounds.<br>
[0042]	The term "synthetic" is art-recognized and refers to production by in vitro<br>
chemical or enzymatic synthesis.<br>
[0043]	The phrase "therapeutic effect" is art-recognized and refers to a local or<br>
systemic effect in animals, particularly mammals, and more particularly humans<br>
caused by a pharmacologically active substance. The term thus means any substance<br>
intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease<br>
or in the enhancement of desirable physical or mental development and/or conditions<br>
in an animal or human. The phrase "therapeutically-effective amount" means that<br>
amount of such a substance that produces some desired local or systemic effect at a<br>
reasonable benefit/risk ratio applicable to any treatment. The therapeutically effective<br>
amount of such substance will vary depending upon the subject and disease condition<br>
being treated, the weight and age of the subject, the severity of the disease condition,<br>
the manner of administration and the like, which can readily be determined by one of<br>
ordinary skill in the art.<br>
[0044]	The term "treating" is art-recognized and refers to curing as well as<br>
ameliorating at least one symptom of any condition or disease.<br>
Nebivolol<br>
[0045]	Nebivolol is a P-receptor blocking drug that is a mixture of d- and l-<br>
enantiomers, of which d-nebivolol is a highly selective β1-receptor antagonist<br>
-14-<br><br>
WO 2006/130174	PCT/US2005/041275<br><br>
[0046]	In addition to its p-receptor blocking properties, nebivolol has been shown to<br>
cause endothelium-dependent vasodilation in both normotensive and hypertensive<br>
subjects. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Nueten<br>
LV, Wooding SJ, Ritter JM., Journal of Pharmacology and Experimental<br>
Therapeutics. 1995;274:1067-1071; Tzemos N, Lim PO, MacDonald TM.,<br>
Circulation, 2001;104:511-514; Breeders MA, Doevendans PA, Bekkers BC,<br>
Bronsaer R, van Gorsel E, Heemskerk JW, Egbrink MG, van Breda E, Reneman RS,<br>
van Der Zee R., Circulation 2000;102:677-684. Bowman, A.J., CPL-H Chen, GA<br>
Ford. Br. J. Clin. Pharmac. 1994; 38:199-204. In experimental models, nebivolol has<br>
been demonstrated to stimulate NO release through P2-adrenergic receptor-mediated<br>
NO production and/or ATP efflux with consequent stimulation of P2Y-purinoceptor-<br>
mediated NO release. Breeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van<br>
Gorsel E, Heemskerk JW, Egbrink MG, van Breda E, Reneman RS, van Der Zee R.,<br>
Circulation, 2000;102:677-684; Kalinowski L, Dobrucki LW, Szczepanska-Konkel<br>
M, Jankowski M, Martyniec L, Angielski S, Malinski T., Circulation, 2003; 107:2747-<br>
2752. It has also been reported that nebivolol inhibits NO synthase uncoupling and<br>
produces systemic antioxidant effects. Mollnau H, Schulz E, Daiber A, Baldus S,<br>
-15-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Oelze M, August M, Wendt M, Walter U, Geiger C, Agrawal R, Kleschyov AL,<br>
Meinertz T, Thomas Mttazel T., Arteriosclerosis, Thrombosis, and Vascular Biology.<br>
2003;23:615-621; Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC, British<br>
Journal of Clinical Pharmacology, 2000;50:377-379.<br>
Compositions Comprising Nebivolol<br>
[0047]	In part, the present invention features compositions comprising nebivolol and<br>
at least one other active agent, wherein the at least one other active agent is a<br>
cardiovascular agent The amount of each cardiovascular agent present in the<br>
compositions may vary depending on a number of variables such as age, weight,<br>
gender, and health related issues. In general, the dosage of the cardiovascular agents<br>
will generally be in the range of about 0.01 ng to about 10 g per kg body weight,<br>
specifically in the range of about 1 ng to about 0.1 g per kg, and more specifically in<br>
the range of about 100 ng to about 10 mg per kg. In another embodiment, the amount<br>
of nebivolol in the compositions of the present invention may be anywhere from<br>
about 0.125 mg to about 40 mg. In one example, when the other cardiovascular agent<br>
is an ACE inhibitor, the amount of the ACE inhibitor may be anywhere from 0.5 mg<br>
to about 80 mg. When the other cardiovascular agent is an ARB, the amount of ARB<br>
may be anywhere from about 1 mg to about 1200 mg. The amount of the other<br>
cardiovascular agent will depend in part on the particular cardiovascular agent used.<br>
[0048]	In addition to ACE inhibitors and ARBs, additional cardiovascular agents<br>
include, but are not limited to adrenergic blockers, adrenergic agonists, agents for<br>
.   pheochromocytoma, antianginal agents, antiarrhythmics, antiplatelet agents,<br>
anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory<br>
agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin<br>
-16-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors,<br>
inotropic agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers<br>
(advanced glycosylation end-product crosslink breakers, such as alagebrium, see USP<br>
6,458,819), and AGE formation inhibitors (advanced glycosylation end-product<br>
formation inhibitors, such as pimagedine). Cardiovascular agents falling within these<br>
general categories are exemplified by the following:<br>
"Angiotensin I Converting Enzymes (ACE's) and Angiotensin II Receptor Antagonists<br>
(ARB's)"<br>
[0049]	"Angiotensin II receptor antagonists"(ARB 's) are compounds which interfere<br>
with the activity of angiotensin II by binding to angiotensin II receptors and<br>
interfering with its activity. Angiotensin I and angiotensin II are synthesized by the<br>
enzymatic renin-angiotensin pathway. The synthetic process is initiated when the<br>
enzyme renin acts on angiotensinogen, a pseudoglobulin in blood plasma, to produce<br>
the decapeptide angiotensin I. Angiotensin I is converted by angiotensin converting<br>
enzyme (ACE) to angiotensin II (angiotensin-[l-8] octapeptide). The latter is an<br>
active pressor substance which has been implicated as a causative agent in several<br>
forms of hypertension in various mammalian species, e.g., humans.<br>
[0050]	Angiotensin II receptor antagonists (ARB's) are well known and include<br>
peptide compounds and non-peptide compounds. Most angiotensin II receptor<br>
antagonists are slightly modified congeners in which agonist activity is attenuated by<br>
replacement of phenylalanine in position 8 with some other amino acid; stability can<br>
be enhanced by other replacements that slow degeneration in vivo.<br>
[0051]	Examples of angiotensin II receptor antagonists include: peptidic compounds<br>
(e.g., saralasin and related analogs); N-substituted imidazole-2-one (U.S. Pat. No.<br>
-17-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
5,087,634); imidazole acetate derivatives including 2-N-butyl-4-chloro-l-(2-<br>
chlorobenzile) imidazole-5-acetic acid (see Long et al., J. Pharmacol. Exp. Ther.<br>
247(1), 1-7 (1988)); 4,5,6,7-tetrahydro-lH-imidazo [4,5-c]pyridine-6-carboxylic acid<br>
and analog derivatives (U.S. Pat. No. 4,816,463); N2-tetrazole beta-glucuronide<br>
analogs (U.S. Pat. No. 5,085,992); substituted pyrroles, pyrazoles, and tryazoles (U.S.<br>
Pat. No. 5,081,127); phenoland heterocyclic derivatives such as 1,3-imidazoles (U.S.<br>
Pat. No. 5,073,566); imidazo-fused 7-member ring heterocycles (U.S. Pat. No.<br>
5,064,825); peptides (e.g., U.S. Pat. No. 4,772,684); antibodies to angiotensin II (e.g.,<br>
U.S. Pat. No. 4,302,386); and aralkyl imidazole compounds such as biphenyl-methyl<br>
substituted imidazoles (e.g., EP 253,310, Jan. 20,1988); ES8891 (N-<br>
morpholinoacetyl-(-l-naphthyl)-L-alanyl-(4, thiazolyl)-L-alanyl (35,45)-4-amino-3-<br>
hydroxy-5-cyclo-hexapentanoyl-N-hexylamide, Sankyo Company, Ltd., Tokyo,<br>
Japan); SKF108566 (E-alpha-2-[2-butyl-l-(carboxyphenyl) methyl] lH-imidazole-5-<br>
yl[methylane]-2-thiophenepropanoic acid, Smith Kline Beecham Pharmaceuticals,<br>
Pa.); Losartan (DUP753/MK954, DuPont Merck Pharmaceutical Company);<br>
Remikirin (RO42-5892, F. Hoffman LaRoche A G); A.sub.2 agonists (Marion Merrill<br>
Dow) and certain non-peptide heterocycles (G. D. Searle and Company). Other non-<br>
limiting examples of ARBs include candesartan, eprosartan, irbesartan, losartan, and<br>
valsartan. Other ARBs may be identified using standard assaying techniques known<br>
to one of ordinary skill in the art.<br>
[0052]	"Angiotensin converting enzyme" (ACE) is an enzyme which catalyzes the<br>
conversion of angiotensin I to angiotensin U. ACE inhibitors include amino acids and<br>
derivatives thereof, peptides, including di- and tri-peptides and antibodies to ACE<br>
which intervene in the renin-angiotensin system by inhibiting the activity of ACE<br>
thereby reducing or eliminating the formation of pressor substance angiotensin n.<br>
-18-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
ACE inhibitors have been used medically to treat hypertension, congestive heart<br>
failure, myocardial infarction and renal disease. Classes of compounds known to be<br>
useful as ACE inhibitors include acylmercapto and mercaptoalkanoyl prolines such as<br>
captopril (U.S. Pat No. 4,105,776) and zofenopril (U.S. Pat. No. 4,316,906),<br>
carboxyalkyl dipeptides such as enalapril (U.S. Pat. No. 4,374,829), lisinopril (U.S.<br>
Pat. No. 4,374,829), quinapril (U.S. Pat. No. 4,344,949), ramipril (U.S. Pat. No.<br>
4,587,258), and perindopril (U.S. Pat. No. 4,508,729), carboxyalkyl dipeptide mimics<br>
such as cilazapril (U.S. Pat. No. 4,512,924) and benazepril (U.S. Pat. No. 4,410,520),<br>
phosphinylalkanoyl prolines such as fosinopril (U.S. Pat. No. 4,337,201) and<br>
trandolapril. Other non-limiting examples of ACE inhibitors include, but are not<br>
limited to, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril,<br>
enalaprilat, fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat,<br>
spirapril, temocapril, trandolapril.<br>
Adrenergic Mockers<br>
[0053]	Non-limiting examples of adrenergic blockers, both α- and β-adrenergic<br>
blockers, that may be used in the compositions of the present invention include Beta-<br>
adrenergic receptor blockers include, but are not limited to, atenolol, acebutolol,<br>
alprenolol, befunolol, betaxolol, bunitrolol, carteolol, celiprolol, hedroxalol,<br>
indenolol, labetalol, levobunolol, mepindolol, methypranol, metindol, metoprolol,<br>
metrizoranolol, oxprenolol, pindolol, propranolol, practolol, sotalohiadolol, tiprenolol,<br>
tolamolol, timolol, bupranolol, penbutolol, trimepranol, yohimbine, 2-(3-(l,l-<br>
dimethylethyl)-amino-2-hydroxypropoxy)-3-pyridenecarbonitrilHCl, l-butylamino-3-<br>
(2,5-dichlorophenoxy)-2-propanol, 1 -isopropylamino-3-(4-(2-<br>
cyclopropyhnethoxyethyl)phenoxy)-2-propanol, 3-isopropylamino-l-(7-methylindan-<br>
-19-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
4-yloxy)-2-butanol, 2-(3-t-butylamino-2-hydroxy-propylthio)-4-(5-carbamoyl-2-<br>
thienyl)thiazole, 7-(2-hydroxy-3-t-butylaminpropoxy)phthalide. The above-identified<br>
compounds can be used as isomeric mixtures, or in their respective levorotating or<br>
dextrorotating form.<br>
Adrenergic Agonists<br>
[0054]	Non-limiting examples of adrenergic agonists, both a- and p-adrenergic<br>
agonists, that may be used in the compositions of the present invention include<br>
adrafinil, adrenalone, albuterol, amidephrine, apraclonidine, bitolterol, budralazine,<br>
carbuterol, clenbuterol, clonidine, clorprenaline, clonidine, cyclopentamine,<br>
denopamine, detomidine, dimetofrine, dioxethedrine, dipivefrin, dopexamine,<br>
ephedrine, epinephrine, etafedrine, ethymorepinephrine, fenoterol, fenoxazoline,<br>
formoterol, guanabenz, guanfacine, hexoprenaline, hydroxyamphetamine, ibopamine,<br>
indanazoline, isoetharine, isometheptene, isoproterenol, mabuterol, mephentermine,<br>
metaproterenol, metaraminol, metizoline, methoxamine, methylhexaneamine,<br>
methoxyphenamine, midodrine, modafinil, moxonidine, naphazoline, norepinephrine<br>
norfenefrine, octodrine, octopamine, oxyfedrine, oxymetazoline, phenylephrine<br>
hydrochloride, phenylpropanolamine hydrochloride, phenylpropylmethylamine,<br>
pholedrine, pirbuterol prenalterol, procaterol, propylhexedrine, protokylol,<br>
pseudoephedrine, reproterol, rilmenidine, rimiterol, ritodrine, salmeterol, solterenol,<br>
synephrine, talipexole, terbutaline, tetrahydrozoline, tiamenidine, tramazoline,<br>
tretoquinol, tuaminoheptane, tulobuterol, tymazoline, tyramine, xamoterol,<br>
xylometazoline, and mixtures thereof.<br>
Agents for Pheochromocytoma<br>
[0055]	Include but are not limited to chemotherapeutics.<br>
-20-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Antianginal agents<br>
[0056]	Include but are not limited to amlodipine besylate, amlodipine maleate,<br>
betaxolol hydrochloride, bevantolol hydrochloride, butoprozine hydrochloride,<br>
carvedilol, cinepazet maleate, metoprolol succinate, molsidomine, monatepil maleate,<br>
nitrates (including but not limited to glyceryl trinitrate (GTN, nitroglycerin, Nitro-<br>
Bid), isosorbide-5-mononitrate (5-ISMN, Ismo), amyl nitrate and nicorandil (Icorel)),<br>
primidolol, ranolazine hydrochloride, tosifen, verapamil hydrochloride).<br>
Antiarrhythmics<br>
[0057]	Non-limiting examples of antiarrhythmics that may be used in the<br>
compositions of the present invention include acebutolol, acecainide, adenosine,<br>
ajmaline, alprenolol, amiodarone, amoproxan, aprindine, aprotinolol, atenolol,<br>
azimilide, bevantolol, bidisomide, bretylium tosylate, bucumolol, butetolol, bunaftine,<br>
bunitrolol, bupranolol, butidrine hydrochloride, butobendine, capobenic acid,<br>
carazolol, carteolol, cifenline, cloranolol, disopyramide, dofetilide, encainide,<br>
esmolol, flecainide, hydroquinidine, ibutilide, indecainide, indenolol, ipratropium<br>
bromide, lidocaine, lorajmine, lorcainide, meobentine, mexiletine, moricizine,<br>
nadoxolol, nifenaolol, oxprenolol, penbutolol, pentisomide, pilsicainide, pindolol,<br>
pirmenol, practolol, prajmaline, procainamide hydrochloride, pronethalol,<br>
propafenone, propranolol, pyrinoline, quinidine, sematilide, sotalol, talinolol, tilisolol,<br>
timolol, tocainide, verapamil, viquidil, xibenolol, and mixtures thereof.<br>
-21-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Antiplatelet Agents<br>
[0058]	Non-limiting examples of antiplatelet agents that may be used in the<br>
compositions of the present invention include clopidogrel, dipyridamole, abciximab,<br>
and ticlopidine.<br>
Anticoagulants<br>
[0059]	Anti-coagulant agents are agents which inhibit the coagulation pathway by<br>
impacting negatively upon (he production, deposition, cleavage and/or activation of<br>
factors essential in the formation of a blood clot. Non-limiting examples of<br>
anticoagulants (i.e. coagulation-related therapy) that may be used in the compositions<br>
of the present invention include Aggrenox, Agrylin, Amicar, Anturane, Arixtra,<br>
Coumadin, Fragmin, Heparin Sodium, Lovenox, Mephyton, Miradon, Persantine,<br>
Plavix, Pletal, Ticlid, Trental, Warfarin. Other "anti-coagulant" and/or "fibrinolytic"<br>
agents include Plasminogen (to plasmin via interactions of prekallikrein, kininogens,<br>
Factors XII, Xllla, plasminogen proactivator, and tissue plasminogen activator[TPA])<br>
Streptokinase; Urokinase: Anisoylated Plasminogen-Streptokinase Activator<br>
Complex; Pro-Urokinase; (Pro-UK); rTPA (alteplase or activase; r denotes<br>
recombinant); rPro-UK; Abbokinase; Eminase; Streptase Anagrelide Hydrochloride;<br>
Bivalirudin; Dalteparin Sodium; Danaparoid Sodium; Dazoxiben Hydrochloride;<br>
Efegatran Sulfate; Enoxaparin Sodium; Ifetroban; Ifetroban Sodium; Tinzaparin<br>
Sodium; reteplase; Trifenagrel; Warfarin; Dextrans.<br>
[0060]	Still other anti-coagulant agents include, but are not limited to, Ancrod;<br>
Anticoagulant Citrate Dextrose Solution; Anticoagulant Citrate Phosphate Dextrose<br>
Adenine Solution; Anticoagulant Citrate Phosphate Dextrose Solution; Anticoagulant<br>
-22-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Heparin Solution; Anticoagulant Sodium Citrate Solution; Ardeparin Sodium;<br>
Bivalirudin; Bromindione; Dalteparin Sodium; Desirudin; Dicumarol; Heparin<br>
Calcium; Heparin Sodium; Lyapolate Sodium; Nafamostat Mesylate;<br>
Phenprocoumon; Tinzaparin Sodium.<br>
[0061]	Inhibitors of platelet function are agents that impair the ability of mature<br>
platelets to perform their normal physiological roles (i.e., their normal function).<br>
Platelets are normally involved in a number of physiological processes such as<br>
adhesion, for example, to cellular and non-cellular entities, aggregation, for example,<br>
for the purpose of forming a blood clot, and release of factors such as growth factors<br>
(e.g., platelet-derived growth factor (PDGF)) and platelet granular components. One<br>
subcategory of platelet function inhibitors are inhibitors of platelet aggregation which<br>
are compounds which reduce or halt the ability of platelets to associate physically<br>
with themselves or with other cellular and non-cellular components, thereby<br>
precluding the ability of a platelet to form a thrombus.<br>
[0062]	Examples of useful inhibitors of platelet function include but are not limited to<br>
acadesine, anagrelide (if given at doses exceeding 10 mg/day), anipamil, argatroban,<br>
aspirin, clopidogrel, cyclooxygenase inhibitors such as nonsteroidal anti-<br>
inflammatory drugs and the synthetic compound FR-122047, danaparoid sodium,<br>
dazoxiben hydrochloride, diadenosine 5',5'"-Pl,P4-tetraphosphate (Ap4A) analogs,<br>
difibrotide, dilazep dihydrochloride, 1,2- and 1,3-glyceryl dinitrate, dipyridamole,<br>
dopamine and 3-methoxytyramine, efegatran sulfate, enoxaparin sodium, glucagon,<br>
glycoprotein IIb/IIIa antagonists such as Ro-43-8857 and L-700,462, ifetroban,<br>
ifetroban sodium, iloprost, Integrilin (eptifibatide), isocarbacyclin methyl ester,<br>
isosorbide-5-mononitrate, itazigrel, ketanserin and BM-13.177, lamifiban, lifarizine,<br>
-23-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
molsidomine, nifedipine, oxagrelate, PGE, platelet activating factor antagonists such<br>
as lexipafant, prostacyclin (PGI2), pyrazines, pyridinol carbamate, ReoPro (i.e.,<br>
abciximab), sulfinpyrazone, synthetic compounds BN-50727, BN-52021, CV-4151,<br>
E-5510, FK-409, GU-7, KB-2796, KBT-3022, KC-404, KF-4939, OP-41483, TRK-<br>
100, TA-3090, TFC-612 and ZK-36374,2,4,5,7-tetrathiaoctane, 2,4,5,7-<br>
tetrathiaoctane 2,2-dioxide, 2,4,5-trithiahexane, theophylline, pentoxifylline,<br>
thromboxane and thromboxane synthetase inhibitors such as picotamide and<br>
sulotroban, ticlopidine, tirofiban, trapidil and ticlopidine, trifenagrel, trilinolein, 3-<br>
substituted 5,6-bis(4-methoxyphenyl)-l,2,4-triazines, and antibodies to glycoprotein<br>
IIb/IIIa as well as those disclosed in U.S. Pat. No. 5,440,020, and anti-serotonin<br>
drugs, Clopidogrel; Sulfinpyrazone; Aspirin; Dipyridamole; Clofibrate; Pyridinol<br>
Carbamate; PGE; Glucagon; Antiserotonin drags; Caffeine; Theophylline<br>
Pentoxifylline; Ticlopidine.<br>
Antihypertensives<br>
[0063]	Non-limiting examples of antihypertensives that may be used in the<br>
compositions of the present invention include amlodipine, benidipine, benazepril,<br>
candesartan, captopril, darodipine, diltiazem HC1, diazoxide, doxazosin HC1,<br>
enalapril, eprosartan, losartan mesylate, felodipine, fenoldopam, fosinopril,<br>
guanabenz acetate, irbesartan, isradipine, lisinopril, mecamylamine, minoxidil,<br>
nicardipine HC1, nifedipine, nimodipine, nisoldipine, phenoxybenzamine HC1,<br>
prazosin HC1, quinapril, reserpine, terazosin HC1, telmisartan, and valsartan.<br>
[0064]	This invention also contemplates fixed dose combinations of nebivolol with<br>
hydrochlorothiazide and at least one other additional active agent.<br>
-24-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Antilipemic Agents<br>
[0065]	Non-limiting examples of antilipemic agents that may be used in the<br>
compositions of the present invention include acipimox, aluminum nicotinate,<br>
atorvastatin, cholestyramine resin, colestipol, polidexide, beclobrate, fluvastatin,<br>
gemfibrozil, lovastatin, lysosomal acid lipase, icofibrate, niacin; PPARa agonist such<br>
as fibrates, which include, but are not limited to fenofibrate, clofibrate, pirifibrate,<br>
ciprofibrate, bezafibrate, clinofibrate, ronifibrate, theofibrate, clofibric acid,<br>
etofibrate,and gemfibrozil; pravastatin sodium, simfibrate, simvastatin, niceritrol,<br>
nicoclonate, nicomol. oxiniacic acid, etiroxate, thyropropic acid, thyroxine, actfran,<br>
azacosterol, benfluorex, beta-benzalbutyramide, carnitine, chondroitin sulfate<br>
clomestrone, detaxtran, dextran sulfate sodium, 5, 8,11,14,17-eicosapentaenoic acid,<br>
eritadenine, furazabol, meglutol, melinamide, mytatrienediol, ornithinej gamma-<br>
oryzanol, pantethine, pentaerythritol tetraacetate, alpha-phenylbutyramide, pirozadil,<br>
probucol, beta-sitosterol, sultosilic acid (piperazine salt), tiadenol, triparanol,<br>
xeribucin, and mixtures thereof.<br>
Antidiabetics<br>
[0066]	Non-limiting examples of antidiabetics that may be used in the compositions<br>
of the present invention include biguanides such as buformin, metformin, and<br>
phenformin; hormones such as insulin; sulfonylurea derivatives such as<br>
acetohexamide, l-butyl-3-metanilylurea, carbutamide, chlorpropamide, glibornuride,<br>
gliclazide, glimepiride, glipizide, gliquidone, glisoxepid, glyburide, glybuthiazole,<br>
glybuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolazamide,<br>
tolbutamide, tolcyclamide; HDL agonists; PPARy agonists such as thiazolidinediones<br>
-25-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
such as pioglitazone, rosiglitazone, and troglitazone; and others including acarbose,<br>
calcium mesoxalate, miglitol, and repaglinide.<br>
Antiinflammatory Agents<br>
[0067]	Non-limiting examples of antiinflammatory agents that may be used in the<br>
compositions of the present invention include Alclofenac; Alclometasone<br>
Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide;<br>
Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen;<br>
Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine<br>
Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen;<br>
Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac;<br>
Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Defiazacort; Desonide;<br>
Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac<br>
Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal; Difluprednate;<br>
Diftalone; Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam<br>
Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Feribufen;<br>
Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort;<br>
Flufenamic Acid; Flumizole; Flunisolide Acetate; Flunixin; Flurrixin Meglumine;<br>
Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen;<br>
Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate;<br>
Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol;<br>
Ilonidap; Indomethacin; Lndomethacin Sodium; Indoprofen; Indoxole; Intrazole;<br>
Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride;<br>
Lomoxicam; Loteprednol Etabonate; Meclofenamate Sodium; Meclofenamic Acid;<br>
Meclorisone Diburyrate; Mefenamic Acid; Mesalamine; Meseclazone;<br>
Methylprednisolone Suleptanate; Morniflumate; Nabumetone; Naproxen; Naproxen<br>
-26-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Sodium; Naproxol; Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin;<br>
Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium;<br>
Phenbutazone Sodium Glycerate; Pirfenidone; Piroxicam; Piroxicam Cinnamate;<br>
Piroxicam Olamine; Piiprofen; Prednazate; Prifelone; Prodolic Acid; Proquazone;<br>
Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex; Salnacedin;<br>
Salsalate; Salicylates; Sanguinarium Chloride; Seclazone; Sermetacin; Sudoxicam;<br>
Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone; Tenidap;<br>
Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine; Tiopinac; Tixocortol<br>
Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin;<br>
Glucocorticoids; Zomepirac Sodium. One preferred antiinflammatory agent is aspirin.<br>
Calcium Channel Blockers<br>
[0068]	Calcium channel blockers are a chemically diverse class of compounds having<br>
important therapeutic value in the control of a variety of diseases including several<br>
cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias<br>
(Fleckenstein, Cir. Res. v. 52, (suppl. l),p. 13-16 (1983); Fleckenstein, Experimental<br>
Facts and Therapeutic Prospects, John Wiley, New York (1983); McCall, D., Curr<br>
Pract Cardiol, v. 10, p. 1-11 (1985)). Calcium channel blockers are a heterogeneous<br>
group of drugs that prevent or slow the entry of calcium into cells by regulating<br>
cellular calcium channels. (Remington, The Science and Practice of Pharmacy,<br>
Nineteenth Edition, Mack Publishing Company, Eaton, Pa., p.963 (1995)). Most of<br>
the currently available calcium channel blockers, and useful according to the present<br>
invention, belong to one of three major chemical groups of drugs, the<br>
dihydropyridines, such as nifedipine, the phenyl alkyl amines, such as verapamil, and<br>
the benzothiazepines, such as diltiazem. Non-limiting examples of calcium channel<br>
blockers that may be used in the compositions of the present invention include<br>
-27-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
bepridil, clentiazem, diltiazem, fendiline, gallopamil, mibeftadil, prenylamine,<br>
semotiadil, terodiline, verapamil, amlodipine, aranidipine, barnidipine, benidipine,<br>
cilnidipine, efonidipine, elgodipine, felodipine, isradipine, lacidipine, lercanidipine,<br>
manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine,<br>
nitrendipine, cinnarizine, flunarizine, lidoflazine, lomerizine, bencyclane, etafenone,<br>
fantofarone, perhexiline, and mixtures thereof.<br>
CETP Inhibitors<br>
[0069]	A non-limiting example of a CETP inhibitor that may be used in the<br>
compositions of the present invention includes torcetrapib.<br>
COX-2 Inhibitors<br>
[0070]	Non-limiting examples of COX-2 inhibitors that may be used in the<br>
compositions of the present invention include compounds according to the following:<br>
all of the compounds and substances beginning on page 8 of Winokur WO99/20110<br>
as members of three distinct structural classes of selective COX-2 inhibitor<br>
compounds, and the compounds and substances which are selective COX-2 inhibitors<br>
in Nichtberger, U.S. Pat. No. 6,136,804, Oct. 24,2000, entitled "Combination therapy<br>
for treating, preventing, or reducing the risks associated with acute coronary ischemic<br>
syndrome and related conditions", and the compounds and substances which are<br>
selective COX-2 inhibitors in Isakson et al, PCT application WO/09641645 published<br>
Dec. 27,1996, filed as PCT/US 9509905 on Jun. 12,1995, entitled "Combination of a<br>
Cyclooxygenase-2 Inhibitor and a Leukotriene B4 Receptor Antagonist for the<br>
Treatment of Inflammations." The meaning of COX-2 inhibitor in this invention shall<br>
include the compounds and substances referenced and incorporated into Winokur<br>
WO99/20110 by reference to art therein, the compounds and substances referenced<br>
-28-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
and incorporated into Nichtberger, U.S. Pat. No. 6,136,804, Oct. 24,2000, by<br>
reference to art therein, and the compounds and substances which are COX-2<br>
inhibitors referenced and incorporated into Isakson et al, PCT application<br>
WO/09641645 published Dec. 27,1996, filed as PCT/US 9509905 on Jun. 12,1995,<br>
entitled "Combination of a Cyclooxygenase-2 Inhibitor and a Leukotriene B4<br>
Receptor Antagonist for the Treatment of Inflammations." The meaning of COX-2<br>
inhibitor in this invention also includes rofecoxib, and celecoxib, marketed as VIOXX<br>
and CELEBREX by Merck and Searle/Pfizer respectively. Rofecoxib is discussed in<br>
Winokur, WO99/20110 as compound 3, on p.9. Celecoxib is discussed as SC-58635<br>
in the same reference, and in T. Penning, Synthesis and biological evaluation of the<br>
1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-<br>
methylphenyl)-3-(trifluoromethyl)-lH-pyrozol-l-yl]benzenesulfonamide (SC-58635,<br>
celecoxib)", J. Med. Chem. Apr. 25,1997:40(9): 1347-56. The meaning of COX-2<br>
inhibitor in this invention also includes SC299 referred to as a fluorescent<br>
diaryloxazole. C. Lanzo et al, "Fluorescence quenching analysis of the association and<br>
dissociation of a diarylheterocycle to cyclooxygenasel-1 and cyclooxygenase-2:<br>
dynamic basis of cycloxygenase-2 selectivity", Biochemistry May 23,2000, vol.<br>
39(20):6228-34, and in J. Talley et al, "4,5-Diaryloxazole inhibitors of<br>
cyclooxygenase-2 (COX-2)", Med. Res. Rev. May 1999; 19(3): 199-208. The<br>
meaning of COX-2 inhibitor in this invention also includes valdecoxib, See, "4-[5-<br>
Methyl-3-phenylisoxazol-l-yl]benzenesulfonamide, Valdecoxib: A Potent and<br>
Selective Inhibitor of COX-2", J. Med. Chem. 2000, Vol. 43: 775-777, and parecoxib,<br>
sodium salt or parecoxib sodium, See, N-[[(5-methyl-3-phenylixoxazol-4yl)-<br>
phenyl]sulfonyl]propanimide, Sodium Salt, Parecoxib Sodium: A Potent and<br>
Selective Inhibitor of COX-2 for Parenteral Administration", J. Med. Chem. 2000,<br>
-29-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Vol. 43:1661-1663. The meaning of COX-2 inhibitor in this invention also includes<br>
the substitution of the sulfonamide moiety as a suitable replacement for the<br>
methylsulfonyl moiety. See, J. Carter et al, Synthesis and activity of sulfonamide-<br>
substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors." Bioorg.<br>
Med. Chem. Lett Apr. 19,1999: Vol. 9(8): 1171-74, and compounds referenced in the<br>
article "Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective<br>
cyclooxygenase-2 inhibitors", Bioorg. Med. Chem. Lett Apr. 19,1999: Vol. 9(8):<br>
1167-70. The meaning of this invention includes a COX-2 inhibitor, NS398<br>
referenced in two articles: Attiga et al, "Inhibitors of Prostaglandin Synthesis Inhibit<br>
Human Prostate Tumor Cell Invasiveness and Reduce the Release of Matrix<br>
Metalloproteinases", 60 Cancer Research 4629-4637, Aug. 15, 2000, and in "The<br>
cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in<br>
human prostate cancer cells independently of Bcl-2," Hsu et al, 275(15) J. Biol.<br>
Chem. 11397-11403(2000). The meaning of COX-2 inhibitor in this invention<br>
includes the cyclo-oxygenase-2 selective compounds referenced in Mitchell et al,<br>
"Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to<br>
NSAED therapy", Brit. J. of Pharmacology (1999) vol.128:1121-1132, see especially<br>
p. 1126. The meaning of COX-2 inhibitor in this invention includes so-called NO-<br>
NSAIDs or nitric oxide-releasing-NSAIDs referred to in L. Jackson et al, "COX-2<br>
Selective Nonsteroidal Anti-Inflammatory Drugs: Do They Really Offer Any<br>
Advantages?", Drugs, June, 2000 vol. 59(6): 1207-1216 and the articles at footnotes<br>
27, and 28. Also included in the meaning of COX-2 inhibitor in this invention<br>
includes any substance that selectively inhibits the COX-2 isoenzyme over the COX-1<br>
isoenzyme in a ratio of greater than 10 to 1 and preferably in ratio of at least 40 to 1 as<br>
referenced in Winokur WO 99/20110, and has one substituent having both atoms with<br>
-30-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
free electrons under traditional valence-shell-electron-pair-repulsion theory located on<br>
a cyclic ring (as in the sulfylamine portion of celecoxib), and a second substituent<br>
located on a different ring sufficiently far from said first substituent to have no<br>
significant electron interaction with the first substituent. The second substituent<br>
should have an electronegativity within such substituent greater than 0.5, or the<br>
second substituent should be an atom located on the periphery of the compound<br>
selected from the group of a halogen F, Cl, Br or I, or a group VI element, S or O.<br>
Thus for purposes of this last included meaning of a COX-2 inhibitor, one portion of<br>
the COX-2 inhibitor should be hydrophilic and the other portion lipophilic. Also<br>
included as a COX-2 inhibitor are compounds listed at page 553 in Pharmacotherapy:<br>
A Pathophysiologic Approach, Depiro et al (McGraw Hill 1999) including<br>
nabumetone and etodolac. Recognizing that there is overlap among the selective<br>
COX-2 inhibitors set out in this paragraph, the intent of the term COX-2 inhibitor is to<br>
comprehensively include all selective COX-2 inhibitors, selective in the sense of<br>
inhibiting COX-2 over COX-1. The inventors add to the class of COX-2 inhibitors<br>
useful in the invention the drug bearing the name etoricoxib referenced in the Wall<br>
Street Journal, Dec. 13,2000, manufactured by Merck. See, also, Chauret et al., "In<br>
vitro metabolism considerations, including activity testing of metabolites, in the<br>
discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)," Bioorg. Med.<br>
Chem. Lett. 11(8): 1059-62 (Apr. 23,2001). Another selective COX-2 inhibitor is<br>
DFU [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-<br>
furanone] referenced in Yergey et al, Drug Metab. Dispos. 29(5):638-44 (May 2001).<br>
The inventors also include as a selective COX-2 inhibitor the flavonoid antioxidant<br>
silymarin, and an active ingredient in silymarin, silybinin, which demonstrated<br>
significant COX-2 inhibition relative to COX-1 inhibition. The silymarin also showed<br>
-31-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
protection against depletion of glutathione peroxidase. Zhao et al, "Significant<br>
Inhibition by the Flavonoid Antioxidant Silymarin against 12-O-tetracecanoylphorbol<br>
13-acetate-caused modulation of antioxidant and inflammatory enzymes, and<br>
cyclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis:<br>
implications in the prevention of stage I tumor promotion," Mol. Carcinog. December<br>
1999, Vol 26(4):321-33 PMID 10569809. Silymarin has been used to treat liver<br>
diseases in Europe.<br>
[0071]	A number of the above-identified COX-2 inhibitors are prodrugs of selective<br>
COX-2 inhibitors, and exert their action by conversion in vivo to the active and<br>
selective COX-2 inhibitors. The active and selective COX-2 inhibitors formed from<br>
the above-identified COX-2 inhibitor prodrugs are described in detail in WO<br>
95/00501, published Jan. 5,1995, WO 95/18799, published Jul. 13,1995 and U.S.<br>
Pat. No. 5,474,995, issued Dec. 12,1995. Given the teachings of U.S. Pat. No.<br>
5,543,297, entitled: "Human cyclooxygenase-2 cDNA and assays for evaluating<br>
cyclooxygenase-2 activity," a person of ordinary skill in the art would be able to<br>
determine whether an agent is a selective COX-2 inhibitor or a precursor of a COX-2<br>
inhibitor, and therefore part of the present invention.<br>
-32-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
"Direct thrombin inhibitors"<br>
[0072]	Non limiting examples of direct thrombin inhibitors include hirudin, hirugen,<br>
Hirulog, argatroban, PPACK, and thrombin aptamers.<br>
Diuretics<br>
[0073]	Non-limiting examples of diuretics that may be used in the compositions of<br>
the present invention include althiazide, bendroflumethiazide, benzthiazide,<br>
buthiazide, chlorthalidone, cyclopentbiazide, cyclothiazide, epitbiazide, ethiazide,<br>
fenquizone, indapamide, hydroflumethiazide, methyclothiazide, meticrane,<br>
metolazone, paraflutizide, polythiazide, quinethazone, teclothiazide,<br>
trichloromethiazide, chlormerodrin, meralluride, mercamphamide, mercaptomerin<br>
sodium, mercumatilin sodium, mercurous chloride, mersalyl, acefylline, 7-<br>
morpholinomethyl-theophylline, pamabrom, protheobromine, theobromine,<br>
canrenone, oleandrin, spironolactone, acetazolamide, ambuside, azosemide,<br>
bumetanide, butazolamide, clopamide, clorexolone, disulfamide, ethoxzolamide,<br>
furosemide, mefruside, methazolamide, piretanide, torsemide, tripamide, xipamide,<br>
aminometradine, amisometradine, amanozine, amiloride, arbutin, chlorazanil,<br>
ethacrynic acid, etozolin, hydracarbazine, isosorbide, mannitol, metochalcone,<br>
muzolimine, perhexiline, ticrynafen, triamterene, urea, and mixtures thereof.<br>
Depending on the diuretic employed, potassium may also be administered to the<br>
patient in order to optimize the fluid balance while avoiding hypokalemic alkalosis.<br>
The administration of potassium can be in the form of potassium chloride or by the<br>
daily ingestion of foods with high potassium content such as, for example, bananas or<br>
orange juice.<br>
-33-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0074] Endothelin Receptor Antagonists<br>
[0075]	Non-limiting examples of an endothelin receptor antagonist that may be used<br>
in the compositions of the present invention include bosentan, sulfonamide endothelin<br>
antagonists, BQ-123, SQ 28608, and the like); and mixtures thereof.<br>
HMG-CoA Reductase Inhibitor (Statins)<br>
[0076]	HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase is the<br>
microsomal enzyme that catalyzes the rate limiting reaction in cholesterol<br>
biosynthesis (HMG-CoA6Mevalonate). An HMG-CoA reductase inhibitor inhibits<br>
HMG-CoA reductase, and as a result inhibits the synthesis of cholesterol. A number<br>
of HMG-CoA reductase inhibitors have been used to treat individuals with<br>
hypercholesterolemia. More recently, HMG-CoA reductase inhibitors have been<br>
shown to be beneficial in the treatment of stroke (Endres M, et al., Proc Natl Acad Sci<br>
USA, 1998, 95:8880-5).<br>
[0077]	HMG-CoA reductase inhibitors useful for co-administration with the agents of<br>
the invention include, but are not limited to, simvastatin (U.S. Pat. No. 4,444,784),<br>
lovastatin (U.S. Pat. No. 4,231,938), pravastatin sodium (U.S. Pat. No. 4,346,227),<br>
fluvastatin (U.S. Pat. No. 4,739,073), atorvastatin (U.S. Pat. No. 5,273,995),<br>
cerivastatin, and numerous others described in U.S. Pat. Nos. 5,622,985; 5,135,935;<br>
5,356,896; 4,920,109; 5,286,895; 5,262,435; 5,260,332; 5,317,031; 5,283,256;<br>
5,256,689; 5,182,298; 5,369,125; 5,302,604; 5,166,171; 5,202,327; 5,276,021;<br>
5,196,440; 5,091,386; 5,091,378; 4,904,646; 5,385,932; 5,250,435; 5,132,312;<br>
5,130,306; 5,116,870; 5,112,857; 5,102,911; 5,098,931; 5,081,136; 5,025,000;<br>
-34-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
5,021,453; 5,017,716; 5,001,144; 5,001,128; 4,997,837; 4,996,234; 4,994,494;<br>
4,992,429; 4,970,231; 4,968,693; 4,963,538; 4,957,940; 4,950,675; 4,946,864;<br>
4,946,860; 4,940,800; 4,940,727; 4,939,143; 4,929,620; 4,923,861; 4,906,657;<br>
4,906,624 and 4,897,402, the disclosures of which patents are incorporated herein by<br>
reference.<br>
[0078]	Other non-limiting examples of HMG-CoA reductase inhibitors that may be<br>
used in the compositions of the present invention include mevastatin, pitavastatin,<br>
rosuvastatin, gemcabene, and probucol.<br>
Inotropic Agents<br>
[0079]	Non-limiting examples of inotropic agents that may be used in the<br>
compositions of the present invention include acefylline, acetyldigitoxins, 2-amino-4-<br>
picoline, amrinone, benfurodil hemisuccinate, bucladesine, camphotamide,<br>
convallatoxin, cymarin, denopamine, deslanoside, digitalin, digitalis, digitoxin,<br>
digoxin, dobutamine, docarpamine, dopamine, dopexamine, enoximone,<br>
erythrophleine, fenalsomine, gitalin, gitoxin, glycocyamine, heptaminol, hydrastinine,<br>
ibopamine, lanatosides, loprinine, milrinone, nerifolin, oleandrin, ouabain,<br>
oxyfedrine, pimobendan, prenalterol, proscillaridin, resibufogenin, scillaren,<br>
scillarenin, strophanthin, sulmazole, theobromine, vesnarinone, xamoterol, and<br>
mixtures thereof.<br>
"Renin inhibitors"<br>
[0080]	Renin inhibitors are compounds which interfere with the activity of renin.<br>
Renin inhibitors include amino acids and derivatives thereof, peptides and derivatives<br>
thereof, and antibodies to renin. Examples of renin inhibitors that are the subject of<br>
United States patents are as follows: urea derivatives of peptides (U.S. Pat. No.<br>
-35-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
5,116,835); amino acids connected by nonpeptide bonds (U.S. Pat. No. 5,114,937);<br>
di- and tri-peptide derivatives (U.S. Pat. No. 5,106,835); amino acids and derivatives<br>
thereof (U.S. Pat. Nos. 5,104,869 and 5,095,119); diol sulfonamides and sulfinyls<br>
(U.S. Pat. No. 5,098,924); modified peptides (U.S. Pat No. 5,095,006); peptidyl beta-<br>
aminoacyl aminodiol carbamates (U.S. Pat. No. 5,089,471); pyrolimidazolones (U.S.<br>
Pat. No. 5,075,451); fluorine and chlorine statine or statone containing peptides (U.S.<br>
Pat. No. 5,066,643); peptidyl amino diols (U.S. Pat. Nos. 5,063,208 and 4,845,079);<br>
N-morpholino derivatives (U.S. Pat. No. 5,055,466); pepstatin derivatives (U.S. Pat<br>
No. 4,980,283); N-heterocyclic alcohols (U.S. Pat. No. 4,885,292); monoclonal<br>
antibodies to renin (U.S. Pat. No. 4,780,401); and a variety of other peptides and<br>
analogs thereof (U.S. Pat. Nos. 5,071,837, 5,064,965, 5,063,207, 5,036,054,<br>
5,036,053, 5,034,512, and 4,894,437).<br>
Vasodilators<br>
[0081]	Non-limiting examples of vasodilators that may be used in the compositions of<br>
the present invention include bencyclane, cinnarizine, citicoline, cyclandelate,<br>
ciclonicate, diisopropylamine dichloroacetate, eburnamonine, fasudil, fenoxedil,<br>
flunarizine, ibudilast, ifenprodil, isosorbide dinitrate, isosorbide mononitrate,<br>
lomerixine, nafronyl, nicametate, nicergoline, nimodipine, papaverine, pentifylline,<br>
tinofedrine, vancamine, vinpocetine, viquidil, amotriphene, bendazol, benfurodil<br>
hemisuccinate, benziodarone, chloracizine, chromonar, clobenfurol, clonitrate,<br>
cloricromen, dilazep, dipyridamole, droprenilamine, efloxate, erythrityl tetranitrate,<br>
etafenone, fendiline, floredil, ganglefence, heart muscle extract, hexestrol bis(alpha-<br>
diethylaminoethyl ether), hexobendine, hydralazine compound, itramin tosylate<br>
khellin, lidoflazine, mannitol hexanitrate, medibazine, nitroglycerin, isosorbide<br>
mononitrate, isosorbide dinitrate, and other nitrates, pentaerythritol tetranitrate,<br>
-36-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
pentrinitrol, perhexiline, pimefylline, prenylamine, propatyl nitrate, pyridofylline,<br>
trapidil, tricromyl, trimetazidine, trolnitrate phosphate, visnadine, aluminum<br>
nicotinate, bamethan, bencyclane, betahistine, bradyldnin, brovincamine, bufeniode,<br>
buflomedil, butalamine, cetiedil, ciclonicate, cinepazide, cinnarizine, cyclandelate,<br>
diisopropylamine dichloroacetate, eledoisin, fenoxedil, flunazine, hepronicate,<br>
ifenprodil, iloprost, inositol niacinate, isoxsuprine, kallidin, kallikrein, moxisylyte,<br>
nafronyl, nicametate nicergoline, nicofuranose, nicotinyl alcohol, nylidrin,<br>
pentifylline, pentoxifylline, piribedil, prostaglandin El, suloctidil, tolazoline,<br>
xanthinol niacinate, and mixtures thereof.<br>
Note that "hydralazine compound" refers to a compound having the formula:<br><br>
wherein a, b and c are each independently a single or a double bond; R1 and R2 are<br>
each independently a hydrogen, an alkyl, an ester or a heterocyclic ring; R3 and R4 are<br>
each independently a lone pair of electrons or a hydrogen, with the proviso that at<br>
least one of R1, R2, R3 and R4 is not a hydrogen. Examples of hydralazine compounds<br>
include, but are not limited to budralazine, cadralazine, dihydralazine, endralazine,<br>
hydralazine, pildralazine, todralazine and the like.<br>
Vasopressors<br>
[0082]	Non-limiting examples of vasopressors that may be used in the compositions<br>
of the present invention include amezinium methyl sulfate, angiotensin amide,<br>
dimetofrine, dopamine, etifelmin, etilefrin, gepefrine, metaraminol, methoxamine,<br>
midodrine, norepinephrine, pholedrine, synephrine, and mixtures thereof.<br>
-37-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
AGE Crosslink Breakers (advanced glycosylation end-product crosslink breakers)<br>
[0083]	Non-limiting examples of AGE crosslink breakers that may be used in the<br>
compositions of the present invention include Alagebrium.<br>
AGE Formation Inhibitors (advanced glycosylation end-product formation inhibitors)<br>
[0084]	Non-limiting examples of AGE formation inhibitors that may be used in the<br>
compositions of the present invention include Pimagedine.<br>
Other actives:<br>
[0085]	Non-limiting examples of other active ingredients that may be combined with<br>
these nebivolol compositions include, but are not limited to, the following<br>
representative classes of compounds, as well as their pharmaceutically acceptable<br>
salts, isomers, esters, ethers and other derivatives:<br>
-38-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0086]	Analgesics and anti-inflammatory agents, such as aloxiprin, auranofin,<br>
azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac,<br>
fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indomeihacin, ketoprofen,<br>
ketorolac, leflunomide, meclofenamic acid, mefenamic acid, nabumetone, naproxen,<br>
oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, rofecoxib, sulindac,<br>
tetrahydrocannabinol, tramadol and tromethamine;<br>
[0087]	antihelminthics, such as albendazole, bephenium hydroxynaphthoate,<br>
catnbendazole, dichlorophen, ivennectin, mebendazole, oxamniquine, oxfendazole,<br>
oxantel embonate, praziquantel, pyrantel embonate and thiabendazole;<br>
[0088]	anti-asthma agents, such as zileuton, zafirlukast, terbutaline sulfate,<br>
montelukast, and albuterol;<br>
[0089]	anti-bacterial agents, such as alatrofloxacin, azithromycin, baclofen,<br>
benzathine penicillin, cinoxacin, ciprofloxacin HC1, clarithromycin, clofazimine,<br>
cloxacillin, demeclocycline, dirithromycin,  doxycycline,   eiythromycin,<br>
ethionamide, furazolidone, grepafloxacin, imipenem, levofloxacin, lorefloxacin,<br>
moxifloxacin HC1, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, rifampicin,<br>
rifabutin, rifapentine, sparfloxacin,   spiramycin, sulphabenzamide, sulphadoxine,<br>
sulphamerazine, ulphacetamide, sulphadiazine, sulphafurazole, sulphamethpxazole,<br>
sulphapyridine, tetracycline, trimethoprim, trovafloxacin, and vancomycin;<br>
[0090]	anti-viral agents, such as abacavir, amprenavir, delavirdine, efavirenz,<br>
indinavir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, and stavudine;<br>
-39-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0091]	anti-depressants, such as amoxapine, bupropion, citalopram, clomipramine,<br>
fluoxetine HC1, maprotiline   HC1, mianserin HC1, nortriptyline HC1, paroxetine HC1,<br>
sertraline HC1, trazodone HC1, triraipramine maleate, and venlafaxine HC1;<br>
[0092]	anti-epileptics, such as beclamide, carbamazepine, clonazepam, ethotoin,<br>
felbamate, fosphenytoin sodium, lamotrigine, methoin, methsuximide,<br>
methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide,<br>
phenobarbitone, phenytoin, phensuximide, primidone, sulthiame, tiagabine HC1,<br>
topiramate, valproic acid, and vigabatrin;<br>
[0093]	anti-fungal agents, such as amphotericin, butenafine HC1, butoconazole<br>
nitrate, clotrimazole, econazole nitrate, fluconazole, flucytosine, griseofulvin,<br>
itraconazole,   ketoconazole, miconazole, natamycin, nystatin, sulconazole nitrate,<br>
oxiconazole, erbinafine HC1, terconazole, tioconazole and undecenoic acid;<br>
[0094]	anti-gout agents, such as allopurinol, probenecid and sulphinpyrazone;<br>
[0095]	anti-malarials, such as amodiaquine, chloroquine, chlorproguanil HC1,<br>
halofantrine HC1, mefloquine HC1, proguanil HC1, pyrimethamine and quinine<br>
sulfate;<br>
[0096]	anti-migraine agents, such as dihydroergotamine mesylate, ergotamine<br>
tartrate, frovatriptan, methysergide maleate, naratriptan HC1, pizotifen maleate,<br>
rizatriptan benzoate, sumatriptan succinate, and zolmitriptan;<br>
[0097]	anti-muscarinic agents, such as atropine, benzhexol HC1, biperiden,<br>
ethopropazine HC1, hyoscyamine, mepenzolate bromide, oxyphencyclimine HC1 and<br>
tropicamide;<br>
-40-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0098]	anti-neoplastic agents and immunosuppressants, such as aminoglutethimide,<br>
amsacrine, azathioprine, bicalutamide, bisantrene, busulfan, camptothecin,<br>
capecitabine, chlorambucil, cyclosporin, dacarbazine, ellipticine, estramustine,<br>
etoposide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate,<br>
mitomycin, mitotane, mitoxantrone, mofetil mycophenolate, nilutamide, paclitaxel,<br>
procarbazine HC1, sirolimus, tacrolimus, tamoxifen citrate, teniposide, testolactone,<br>
topotecan HC1, and toremifene citrate;<br>
[0099]	anti-protozoal agents, such as atovaquone, benznidazole, clioquinol,<br>
decoquinate, diiodohydroxyquinoline, diloxanide furoate, dinitolmide, furazolidone,<br>
metronidazole, nimorazole, nitrofurazone, ornidazole and tinidazole;<br>
[00100]	anti-psychotics, such as aripiprazole, clozapine, ziprasidone,<br>
haloperidol, molindone, loxapine, thioridazdne, molindone, thiothixene, pimozide,<br>
fluphenazine, risperidone mesoridazine, quetiapine, trifluoperazine, chlorprotbixene,<br>
chlorproraazine, perphenazine, trifluopromazine, olanzapine;<br>
[00101]	anti-thyroid agents, such as carbimazole, paricalcitol, and<br>
propylthiouracil;<br>
[00102]	anti-tussives, such as benzonatate;<br>
[00103]	anxiolytics, sedatives, hypnotics and neuroleptics, such as alprazolam,<br>
amylobarbitone, barbitone,    bentazepam, bromazepam, bromperidol, brotizolam,<br>
butobarbitone, carbromal, chlordiazepoxide, chlormethiazole, chlorpromazine,<br>
chlorprothixene, clonazepam, clobazam, clotiazepam, clozapine,    diazepam,<br>
droperidol, ethinamate, fluanisone, flunitrazepam, triflupromazine, flupenthixol<br>
decanoate, fluphenthixol decanoate, flurazepam, gabapentin, haloperidol, lorazepam,<br>
-41-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
lormetazepam, medazepam, meprobamate, mesoridazine, methaqualone,<br>
methylphenidate, midazolam, molindone, nitrazepam, olanzapine, oxazepam,<br>
pentobarbitone, perphenazine pimozide, prochloiperazine, pseudoephedrine,<br>
quetiapine, risperidone, sertindole, sulpiride, temazepam, thioridazine, triazolam,<br>
zolpidem, and zopiclone;<br>
[00104]	corticosteroids, such as beclomethasone, betamethasone, budesonide,<br>
cortisone acetate, desoxymethasone, dexamethasone, fludrocortisone acetate,<br>
flunisolide, fluocortolone, fluticasone propionate, hydrocortisone,<br>
methylprednisolone, prednisolone, prednisone and triamcinolone;<br>
[00105]	anti-parkinsonian agents, such as apomorphine, bromocriptine mesylate,<br>
lisuride maleate, pramipexole, ropinirole HC1, and tolcapone;<br>
[00106]	gastrointestinal agents, such as bisacodyl, cimetidine, cisapride,<br>
diphenoxylate HC1, domperidone, famotidine, lansoprazole, loperamide, mesalazine,<br>
nizatidine, omeprazole, ondansetron HCL, rabeprazole sodium, ranitidine HC1 and<br>
sulphasalazine;<br>
[00107]	keratolytics, such as acitretin, calcipotriene, calcifediol, calcitriol,<br>
cholecalciferol, ergocalcifetol, etretinate, retinoids, Targretin, and tazarotene;<br>
[00108]	lipid regulating agents, such as atorvastatin, bezafibrate, cerivastatin,<br>
ciprofibrate, clofibrate, fenofibrate, fluvastatin, gemfibrozil, pravastatin, probucol,<br>
and simvastatin;<br>
[00109]	muscle relaxants, such as dantrolene sodium and tizanidine HC1;<br>
-42-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[00110]	nutritional agents, such as calcitriol, carotenes, dihydrotachysterol, essential<br>
fatty acids, non-essential fatty acids, phytonadiol, vitamin A, vitamin B.sub.2, vitamin<br>
D, vitamin E and vitamin K;<br>
[00111]         opioid analgesics, such as codeine, dextropropoxyphene, diamorphine,<br>
dihydrocodeine, fentanyl, meptazinol, methadone, morphine, nalbuphine and<br>
pentazocine;<br>
[00112]	sex hormones, such as clomiphene citrate, cortisone acetate, danazol,<br>
dehydroepiandrosterone, ethynyl estradiol, finasteride, fludrocortisone,<br>
fluoxymesterone, medroxyprogesterone acetate, megestrol acetate, mestranol,<br>
methyltestosterone, norethisterone, norgestrel, oestradiol, conjugated estrogens,<br>
progesterone, rimexolone, stanozolol, stilbestrol, testosterone and tibolone;<br>
[00113]	stimulants, such as amphetamine, dexamphetamine, dexfenfluramine,<br>
fenfluramine and mazindol;<br>
[00114]	drugs for rheumatoid arthritis such as methotrexate, auranofin,<br>
aurothioglucose and gold sodium thiomalate;<br>
[00115]	drugs for osteoporosis such as alendronate and raloxifene;<br>
[00116]	local anesthetics;<br>
[00117]	anti-herpes drugs such as acyclovir, valacyclovir and famciclovir;<br>
[00118]	anti-emetics such as ondansetron and granisetron;<br>
-43-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[00119]         Flavonoids and Isoflavonoids include the anthocyanidins and anthocyanins;<br>
proanthocyanidins; flavan-3-ols; flavonols; flavones; flavanones; isoflavanones; salts<br>
and esters thereof. This development is however, not limited to flavonoid compounds<br>
isolated from plant, part of plant or extracts of Astragalus Membranaceus, but<br>
encompasses any suitable flavonoid compound isolated from different sources or<br>
chemically synthesized. In addition, any suitable known or not yet discovered<br>
flavonoid compound, and isoflavonoid compound, is within the scope of the present<br>
technology. A number of flavonoids and isoflavonoids are described in USDA-Iowa<br>
State University Database on the Isoflavone Content of Foods, Release 1.3-2002, and<br>
in USDA Database for the Flavonoid Content of Selected Foods-2003<br>
(http://www.nal.usda. gov/fnic/foodcomp/Data/isoflav/isoflav.html) and<br>
(http://www.nal.usda.gov/fnic/foodcomp/Data/Flav/flav.html) (both of them herewith<br>
incorporated by reference). It will be evident to any skilled person how to choose the<br>
suitable flavonoid and/or isoflavonoid compound for the purpose of the present<br>
development For example, flavonoid compounds for the purpose of the present<br>
development may be, but are not limited to, (-)-epictechin, (+)-catechin, procyanidin<br>
B2, quercetin dehydrate, taxifolin, resveratrol, and the like.<br>
[00120]         Carotenoids, generally are tetraterpenes originating from the mevalonate and<br>
deoxyxylulose phosphate pathways (older sources sometimes refer to their source as<br>
the 'isoprenoid' pathway). Two molecules of the C20 compound<br>
geranylgeranyldiphosphate (GGDP) condense to form the symmetrical carotenoid<br>
skeleton.<br>
-44-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[00121]	Carotenoids are divided into two subclasses, i.e., more polar compounds called<br>
xanthophylls, or oxycarotenoids, and the nonpolar hydrocarbon carotenes.<br>
[00122]	Terms such as carotenoid analog and carotenoid derivative may generally refer<br>
to in some embodiments chemical compounds or compositions derived from a<br>
naturally occurring carotenoid or simply to synthetic carotenoids. In some<br>
embodiments, terms such as carotenoid analog and carotenoid derivative may<br>
generally refer to chemical compounds or compositions which are synthetically<br>
derived from non-carotenoid based parent compounds; however, which ultimately<br>
substantially resemble a carotenoid derived analog. In certain embodiments, terms<br>
such as carotenoid analog and carotenoid derivative may generally refer to a synthetic<br>
derivative of a naturally occurring carotenoid. Examples of carotenoids are provided<br>
in the book "Carotenoids Handbook," edited by G. Britton et al, 2004, which is herein<br>
incorporated by reference.<br>
[00123]	It will be evident to any skilled person how to choose the suitable carotenoid<br>
compound for the purpose of the present development.<br>
[00124]	Examples of carotenoids include astaxanthin, zeaxanthin, lutein, lycopene,<br>
beta-carotene.<br>
[00125]	Other non-limiting examples of naturally occurring carotenoids include:<br>
Aaptopurpurin; Actinioerythrin; Actinioerythrol; Adonirubin; Adonixanthin; A.g.470;<br>
A.g.471; Agelaxanthin C; Aleuriaxanthin; Alloxanthin; Amarouciaxanthin A;<br>
Amarouciaxanthin B; Anchovyxanthin; 3,4'-Anhydrodiatoxanthin;<br>
-45-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Anhydrodeoxyflexixantbin; Anhydroeschscholtzxanthin; Anhydrolutein;<br>
Anhydroperidinin; Anhydrorhodovibrin; Anhydrosaproxanthin; Anhydrowarmingol;<br>
Arihydrowarmingone; Antheraxanthin; Aphanicin; Aphanicol; Aphanin; Aphanol;<br>
Aphanizophyll; 8'-Apo-beta-caroten-8'-al; l0'-Apo-beta-caroten-l0'- al; 12'-Apo-beta-<br>
caroten-12'al; 14'-Apo-beta-caroten-14'-al; 6'-Apo- psi-caroten-6'-al; 8'-Apo-psi-<br>
caroten-8'-al; beta-Apo-2-carotenal; beta-Apo-3-carotenal; beta-Apo-4-carotenal;<br>
beta-Apo-2'-carotenal; beta-Apo-8'-carotenal; beta-Apo-l0'-carotenal; beta-Apo-12'-<br>
carotenal; beta-Apo-14'-carotenal; Apo-8,8'-carotenedial; 8'-Apo-beta- carotene-3,81-<br>
diol; 4'-Apo-beta-caroten-4'-oic acid; 8'-Apo-beta- caroten-8'-oic acid; l0'-Apo-beta-<br>
caroten-l0'-oic acid; 12'-Apo-beta- caroten-12'-oic acid; beta-Apo-2'-carotenoic acid;<br>
beta-Apo-2'- carotenoic acidmethylester; beta-Apo-8'-carotenoic acid; beta-Apo-10'-<br>
carotenoic acid; beta-Apo-12'-carotenoic acid; 8'-Apo-beta- caroten-3-ol; beta-Apo-21-<br>
carotenol; Apo-7-fucoxanthinol; Apo-2- lycopenal; Apo-3-lycopenal; Apo-61<br>
lycopenal; Apo-8'-lycopenal; Apo-101- violaxanthal; Apo-12'-violaxanthal;<br>
Apoviolaxantbinal; Apo-2-zeaxantbinal; Apo-3-zeaxanthinal; Apo-4-zeaxantbinal;<br>
Astacein; Astacene; Astacene dipalmitate; Astaxanthin; Asterinic acid;<br>
Asteroidenone; Asym. zeta- carotene; Aurochrome; Auroxanthin; Azaftin;<br>
Azafrinaldehyde;<br>
[0126]	Bacterial phytoene; Bacterioerythrin alpha; Bacterioerythrin beta;<br>
Bacteriopurpurin alpha; Bacterioruberin; alpha-Bacterioruberin; Bacterioruberin<br>
diglycoside; Bacterioruberin monoglycoside; alpha-Bacterioruberin monomethyl<br>
ether; Bisanhydrobacterioruberin; 3,4,3,4'-Bisdehydro-beta-carotene;<br>
Bisdehydrolycopene; 2,2'-Bis(4-hydroxy-3-methyl-2-butenyl)-beta,beta-carotene;<br>
2,2l-Bis[3-(glucosyloxy)-3-methylbutyl]-3,4,3,s4'-tetradehydro-l,2,ll,21-tetrahydro-<br>
psiJpsi-carotene-l,ll-diol;2,2'-Bis[4-(beta,D-glucopyranosyloxy)-3-methyl-2-<br>
-46-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
butenyl]-gamma,gamma-carotene; 2,2'-Bis(4-hydroxy-3-metiiyl-2-butenyl)-<br>
gamma,gamma-carotene;2,2'-Bis(4-hydroxy-3-methyl-2-butenyl)-[epsi],[epsi]-<br>
carotene;2J2'-Bis(3-hydroxy-3-methylbutyl-3,4,3l,4l-tetradehydro-l,2,l,2'tetrahydro-<br>
psi,psi- carotene-l,l'-diol; 2,2'-Bis(3-methyl-2-butenyl)-[epsi],[epsi]-carotene; 2,2'-<br>
Bis-methyl-butenyl-S.S'-tetradehydro-l -dihydro-psi.psi -caroten-1 -ol; 2,2'-<br>
Bis(3-methyl-2-butenyl)-3,4,3',4l-tetradehydro-,r,2'-tetrahydro-psi,psi-carotene-<br>
l,-diol;2,2l-Bis(3-methyl-2-butenyl)-l,22'-tetrahydro-psi,psi-carotene-l,r-diol;<br>
2,2'-Bis(O-methyl-5-C-metb.ylpentosyloxy)-3,4,3',4'-tetradehydro-l,2,2-<br>
tetrahydropsi, psi-carotene-l.l'-diol; 3,3'-Bis(rhamnosyloxy)-beta,beta-carotene; 2,2'-<br>
Bis(rhamnosyloxy)-3,4,3 ',4'-tetradebydro-1,2,1 ',2'-tetrahydro-psi, psi-carotene-1,1'-<br>
diol; Bixin;<br>
[0127]	Caloxanthin; Calihaxanthin; Canthaxanthin; Capsanthin; Capsantbin epoxide;<br>
Capsanthinone; Capsanthone; Capsochrome; Capsorubin; Capsorubindione;<br>
Capsorubone; Carangoxantbin; 16'-Carboxyl-3',4'-dehydro- gamma-carotene;<br>
Carcinoxanthin; Caricaxanthin; beta-Carotenal; psi, psi-Caroten-20-al; Carotene;<br>
Carotene X; alpha-Carotene; beta- Carotene; beta,beta-Carotene; beta,gamma-<br>
Carotene; beta,[epsi]- Carotene; beta,[phi]-Carotene; beta,psi-Carotene; gamma-<br>
Carotene; gamrna,gamma-Carotene; gamma,psi-Carotene; [delta]-Carotene; [epsi] -<br>
Carotene; [epsi] (l)-Carotene; [epsi],[epsi]-Carotene; [epsi],psi -Carotene; zeta-<br>
Carotene; zeta-Carotene, asym.; eta-Carotene; [theta]-Carotene; xi-Carotene; [phi]-<br>
Carotene; [phi],[phi]-Carotene; [pbi],X-Carotene; [phi],psi-Carotene; X,X-Carotene;<br>
psi-Carotene; psi,alpha-Carotene; psi,psi-Carotene; [theta-Carotene; beta- Carotene-<br>
5,6,5',6'-diepoxide; beta-Carotene 5,8,5',8'-diepoxide; beta, beta-Carotene'-diol;<br>
beta,beta-Carotene-2,3-diol; beta,beta- Carotene-3,4-diol; beta,beta-Carotene-3,3'-<br>
-47-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
diol; beta,beta- Carotene-4,4'-diol; beta,[epsi]-Carotene-3,2'-diol; beta,[epsi]-<br>
Carotene-3,3'-diol; beta,psi-Carotene-2,3-diol; beta,psi-Carotene- 3,3'-diol;<br>
[epsi],[epsi]-Carotene-3,3'-diol; [phi],[phi]-Carotene-3,3'- diol; psi,psi-Carotene-<br>
16,16'-diol; beta,beta-Carotene-3,3'-diol dipalmitate; beta,[epsi]-Carotene-3,3'-diol<br>
dipalmitate; beta,beta- Carotene-2,2'-dione; beta,beta-Caxotene-3,4-dione; beta,beta-<br>
Carotene-4,4'dione; beta,psi-Carotene-3,4-dione; [epsi],[epsi]- Carotene-3,3'-dione;<br>
beta,chi-Carotene-3',6'-dione; beta,X-Carotene- 3,4-dione; beta,psi-Carotene-4,4'-<br>
dione; beta,[phi]-Carotene-3,4- dione; psi,psi-Carotene-4,4'-dione; alpha-Carotene<br>
5,6-epoxide; beta-Carotene 5,6-epoxide; zeta-Carotene epoxide; Carotene oxide;<br>
beta,beta-Carotene-3,4,3',4'-tetrol; beta,beta-Carotene-2,3,2',3'- tetrol; beta,beta-<br>
Carotene-'-tetrone; chi,chi-Carotene-3, 6s3',6-tetrone; beta,beta-Carotene-<br>
2,3,2'-triol; beta,beta- Carotene-2,3,3'-triol; beta.beta-Carotene-S^^'-triol; beta,beta-<br>
Carotene-3,4,4'-triol; beta,[epsi]-Carotene-3,4,3'-triol; beta,[epsi]- Carotene-3,19,31-<br>
triol; beta,[epsi]-Carotene-3,20,3'-triol; beta, beta-Carotene-3,4,4'-trione; beta.beta-<br>
Caroten-2-ol; beta,beta- Caroten-3-ol; beta,beta-Caroten-4-ol; beta,[epsi]-Caroten-2-<br>
ol; beta,[epsi]-Caroten-3-ol; beta,[epsi]-Caroten-3'-ol; beta,[epsi]- Caroten-4-ol;<br>
beta,[phi]-Caroten-3-ol; beta,X-Caroten-3-ol; beta, psi-Caroten-3-ol; beta,psi-<br>
Caroten-4'-ol; [epsi],psi-Caroten-3-ol; [phi],[phi]-Caroten-3-ol; [phi],[phi]-Caroten-<br>
I6-0I; [phi][phi]-Caroten- 20-ol; Carotenonaldehyd; beta-Carotenone; beta,beta-<br>
Caroten-2-one; beta,beta-Caroten-4-one; beta,[epsi]-Caroten-2-one; beta,[epsi]-<br>
Caroten-4-one; beta,psi-Caroten-4-one; gamma-Caroten-4-one; alpha- Carotene;<br>
Celaxanthin; Chiriquixanthin A; Chiriquixanthin B; Chlorellaxanthin; Chlorobactene;<br>
Chloroxanthin; Chrysanthemaxanthin; Citranaxanthin; alpha-Citraurin; beta-Citraurin;<br>
beta-Citraurinene; beta-Citraininol; Citroxantbin; Compound X; C.p.:<br>
Corynebacterium poinsettiae; Corynexanthin; Corynexanthin glucoside; C.p.; C.p.;<br>
-48-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
C.p.; Crocetin; gamma-Crocetin; Crocetindial(dehyde); Crocetin diglucosyl ester,<br>
Crocetin dimethyl ester; Crocetin gentiobiosyl glucosyl diester; Crocetin glucosyl<br>
methyl diester; Crocetin monogentiobiosyl ester; Crocetinsemialdehyde; Crocin;<br>
Crocoxanthin; Crustaxanthin; Cryptocapsin; Cryptocapsone; Cryptochrome; alpha-<br>
Cryptoeutreptiellanone; beta- Cryptoeutreptiellanone; Cryptoflavin;<br>
Cryptomonaxanthin; Cryptoxanthene; Cryptoxanthin; alpha-Cryptoxanthin; beta-<br>
Cryptoxanthin; Cryptoxanthin 5,6,5',6' diepoxide; Cryptoxanthin 5,6,5',8' diepoxide;<br>
Cryptoxanthin 5,8, 5',8' diepoxide; Cryptoxanthin 5,6-epoxide; Cryptoxanthin 5,8-<br>
epoxide; Cryptoxanthol; Cucurbitaxanthin; Cyclic zeta-carotene; Cynthiaxanthin;<br>
Decahydro-beta-carotene; 1,2,7,8,11,12,7',8', 11', 12'- Decahydro-psi,psi-carotene;<br>
7,8,11,12,15,7',8',1 l',12',15' Decahydro- psi,psi-carotene; 1,2,7,8,11,12,7',8',1l',12'-<br>
Decahydro-psi,psi- caroten-l-ol; Decahydrolycopene; Decaprenoxanthin;<br>
Decaprenoxanthin diglucoside; Decaprenoxanthin monoglucoside;<br>
Deepoxyneoxanthin; Dehydro- see also Bisdehydro-, Didehydro-,<br>
MonodehydroDehydroadonirubin; Dehydroadonixantbin; Dehydrocarotene II;<br>
Dehydrocarotene III; Dehydro- beta-carotene; 3,4-Dehydro-beta-carotene; 3',4'-<br>
Dehydro-gamma- carotene; S'-Dehydrocryptoxanthin; Dehydrogenans-P;<br>
Dehydrogenans-P; Dehydrogenans-P; Dehydrogenans-P; Dehydrogenans-P 439<br>
mono-OH; dehydrogenans-Phytoene; dehydrogenans-Phytofluene;<br>
Dehydrohydroxyechinenone; 3'-Dehydrolutein; 3,4-Dehydrolycopen-l6-al;<br>
Dehydrolycopene; 3,4-Dehydrolycopene; 15,15'-Dehydrolycopersene; 7',8', 11', 12'-<br>
Dehydrononapreno xanthin; ll',12'-Dehydrononaprenoxanthin; 3',4'-Dehydro-17 '(or<br>
18')-oxo-gamma-carotene; Dehydropapilioerythrin; 11,12-Dehydrophytoene; ll',12'-<br>
Dehydrophytoene; 2'-DehydropIectaniaxanthin; Dehydroretrocarotene; 3,4-<br>
Dehydrorhodopin; Dehydrorhodovibrin; 3',4'- Dehydrorubixanthin; Dehydrosqualene;<br>
-49-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
7,8,7',8'-Dehydrozeaxanthin; 7,8- Dehydrozeinoxanthin; Demethyl(ated) spheroidene;<br>
Deoxyflexixanthin; Deoxylutein I; Deshydroxydecaprenoxanthin; Diadinochrome;<br>
Diapocarotene-6,6'-dioic acid; 8,8'-Diapocarotene-8,8'-dioic acid; 4,4'-Diapocaroten- .<br>
4-oic acid; 4,4'-Diaponeurosporene; 4,4'- Diaponeurosporen-4-oic acid; 4,4'-<br>
Diapophytoene; 4,4'-Diapophytofluene; 4,4'-Diapo-7,8,ll,12-tetrahydro lycopene;<br>
Diatoxanthin; Didehydro-, see also Dehydro-, Monodehydro 3',4'-Didehydro-2'-apo-<br>
beta-caroten-2-al; 34'-Didehydro-2'-apo-beta-caroten-2'-ol; 7,8-<br>
Didehydroastaxanthin; 3', 4l-Didehydro-beta,psi-caroten-16'-al; 3,4-Didehydro-<br>
psi,psi- caroten-16-al; 3,4-Didehydro-beta,beta-carotene; 4,4'-Didehydro-beta -<br>
carotene; 3,4-Didehydro-beta,[epsi]-earotene; 3,4-Didehydro-beta, [phi]-carotene;<br>
3,4-Didehydro-beta,X-carotene; 3',4'-Didehydro-beta, psi-carotene; 3',4'-Didehydro-<br>
gamma,psi-carotene; 7,8-Dideb.ydro- [phi],[phi]-carotene; 7,8-Didehydro-[phi],X-<br>
carotene; 3,4-Didehydro-psi, psi-carotene; 7,8-Didehydro-beta,beta-carotene-3,3'-diol;<br>
7,8- Didehydro-beta,[epsi]-carotene-3,3'-diol; 3,4-Didehydro-beta,beta- carotene-2,2'-<br>
dione; S'-Didehydro-betajpsi-caroten-16-oic acid; 4'-Didehydro-beta.beta-<br>
caroten-3-ol; 3',4'-Didehydro-beta,beta- caroten-4-ol; 7,8-Didehydro-beta,[epsi]-<br>
caroten-3-ol; 7,8-Didehydro- beta,[phi]-caroten-3-ol; 7,8-Didehydro-beta,X-caroten-<br>
3-ol; 3',4'- Didehydro-beta,psi-caroten-3-ol; 3'-'Didehydro-betajpsi-caroten- 16'-ol;<br>
3',4'-Dideliydro-beta,psi-caroten-l 8'-ol; 3',4'-Didehydro- beta,beta-caroten-4-one;<br>
3',4'-Didehydro-beta,psi-caroten-4-one; 7',8l-Didehydro-beta,beta-carotene3,4,3l-triol;<br>
3,4-Didehydro-1,2- dihydro-psi,psi-carotene; 3,4-Didehydro-l ,2-dihydro-psi,psi-<br>
caroten-20-al;6,7-Didehydro-5,6-dihydro-beta,beta-carotene-3,3'-diol;3',4'-<br>
Didehydro-l',2'-dihydro-beta,psi-carotene-3,r-diol;3',4'-Didehydro-ll,2l-dihydro-<br>
-50-'<br><br>
WO 2006/130174	PCT/US2005/041275<br>
beta,psi-carotene-r,2l-diol;3',4'-Didehydro-r,2l-dihydro-beta,psi-carotene-4,2l-<br>
dione; 3,4-Didehydro-l,2-dihydro- psi,psi-carotene-l,2-diol; 7',8'-Didehydro-5,6-<br>
dihydro-beta,beta-carotene-3,5,6,3'-tetrol;6J7-Didehydro-5,6-dihydro-beta,beta-<br>
carotene-3,5,3'-triol; 7-8'-Didehydro-5,6-dihydro-beta,beta-carotene- 3,5,3'-triol; 3',4'-<br>
Didehydro-1 ',2'-dihydro-beta,psi-carotene-2,1 ',2- triol; 1', 16'-Didehydro-1 2-<br>
dihydro-beta,psi-caroten-2'-ol; 3',4'- Didehydro-1,2'-diliydro-beta,psi-caroten-l '-ol;<br>
S'-Didehydro-l',- dihydro-beta,psi-caroten-2'-ol; 3,4-Didehydro-l,2-dihydro-<br>
psi,psi- caroten-1-ol; S'-Didehydro-lS'-hydroxy-gamma-carotene; 7,8-<br>
Didehydroisorenieratene; 3',4'-Didehydro-4-keto-gamma-carotene; 7,8-<br>
Didehydrorenieiatene;4',5l-Didehydro-4,5'-retro-beta,beta-carotene;4l,5'-Didehydro-<br>
4,5'-retro-beta,psi-carotene; Didehydroretro-gamma- carotene; 4',5I-Didehydro-4,5I-<br>
retro-beta,beta-carotene-3,3'-diol;4', 5'-Didehydro-4,5'-retro-beta,beta-carotene-3,3'-<br>
dione; l0'.ll- Didehydro-5,8,11',121 tetrahydro-10'-apo-beta-carotene-3,5,8-triol; 6',<br>
7'-Didehydro-5,6,5',6l tetrahydro-beta,beta-carotene-3,5,6,3l,5l- pentol; 6,7-<br>
Didehydro-5,6,5',6'-tetohydro-beta,beta-carotene-3,5,3', 5' tetrol; 3,4-Didehydro-<br>
l,2,7',8'-tetra hydro-psi,psi-caroten-l-ol; Didehydrotrikentriorhodin; 7,8-<br>
Didehydrozeaxanthin; Didemethylated spirilloxantbin; l,2,l',2'-Diepoxy-2,2'-b is (3-<br>
hydroxy-3-methylbutyl)3,4- didehydro-1,2,1 ^'-tetrahydro-psi.psi-carotene; Diepoxy-<br>
beta- carotene; 5,8,5',8'-Diepoxycryptoxanthin; 5,6,5',6'-Diepoxy-5,6,5',6'- tetrahydro-<br>
idehydro-1 ',2'-dihydro-beta,psi-carotene-2,1 ',2- triol; 1', 16'-Didehydro-1 2-<br>
dihydro-beta,psi-caroten-2'-ol; 3',4'- Didehydro-1,2'-diliydro-beta,psi-caroten-l '-ol;<br>
S'-Didehydro-l',- dihydro-beta,psi-caroten-2'-ol; 3,4-Didehydro-l,2-dihydro-<br>
psi,psi- caroten-1-ol; S'-Didehydro-lS'-hydroxy-gamma-carotene; 7,8-<br>
Didehydroisorenieratene; 3',4'-Didehydro-4-keto-gamma-carotene; 7,8-<br>
Didehydrorenieiatene;4',5l-Didehydro-4,5'-retro-beta,beta-carotene;4l,5'-Didehydro<br>
-51-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
beta,beta-caroten-3-ol; 5,6,5',8'-Diepoxyzeaxanthin; 5,8,5',8'-Diepoxyzeaxanthin;<br>
Digentiobiosyl 8,8'-diapocarotene-8,8'-dioate; Di-(beta,D-glucopyranosyi)-4,4'-<br>
diapocarotene-4,4'-dioate; Diglucosyl 8,8'-diapocarotene-8,8'-dioate;<br>
Dihydroanhydrorhodovibrin; 9',10'-Dihydro-9'-apo-beta-carotene-3,9'- dione; 9',10'-<br>
Dihydro-9'-apo-[epsi]-carotene-3,9'-dione; 7',8'-Dihydro-7'-apo-beta-caroten-8'-one;<br>
5',6'-Dihydro-5'-apo-18'-nor-beta-caroten-6'- one; 7,8-Dihydroastaxantbin; beta-<br>
Dihydrocarotene; l,l'-Dihydro-beta-carotene; 3,4-Dihydro-beta-carotene; 7,7'-<br>
Dihydro-beta-carotene; 7, 8'-Dihydro-beta,psi-carotene; 7',8'-Dihydro-gamma-<br>
carotene; 7',8'- Dihydro-gamma,psi-carotene; 7l,8'-Dihydro-[delta]-carotene; 7',8'-<br>
Dihydro-[epsi],psi-carotene; 1,2-Dihydro-zeta-carotene; 1,2-Dihydro- psi,psi-<br>
carotene; 7,8-Dihydro-psi,psi-carotene; 7,8-Dihydro-beta ,beta-carotene 3,3'-diol;<br>
7,8'-Dihydro-beta,psi-carotene 3,17'- diol;9'.l0'-Dihydro-beta,psi-carotene-3,17-diol;<br>
7,8'-Dihydro- [epsi],psi-carotene-3,17'-diol; l,2-Dihydro-psi,psi-carotene-l,20- diol;<br>
5,6-Dihydro-beta,beta-carotene 3,5,6,3'-tetrol; 5,6-Dihydro- beta,beta-carotene 3,5,3'-<br>
triol; r,2'-Dihydro-beta,psi-caroten l'-ol; 7',8'-Dihydro-beta,psi-caroten3-ol; l',2'-<br>
Dihydro-[phi],psi- caroten-l'-ol; l,2-Dihydro-psi,psi-caroten-l-ol; 5,6-Dfliydro-beta,<br>
beta-carotene-3,5,6,3'-tetrol; 5,6-Dihydro-beta,[epsi]-carotene-3,5,6,3'-tetrol; 7,8 (or<br>
7',8)-Dihydrodecaprenoxanthin monoglucoside; l',2'- Dihydro-3',4'-dehydro-3,4-<br>
dihydroxy-gamma-carotene; l,2-Dihydro-3,4- dehydrolycopene; l,2-Dihydro-3,4-<br>
dehydro-1-OH-lycopene; 7,8-Dihydro-4,4'- diapocarotene; 7.8'-Dihydro-<br>
diapocaroten-4-al; 7',8'-Dihydro-4,4'- diapocaroten-4-oic acid; r-Dihydro-3,4'-<br>
didehydro-3,l'-dihydroxy- ganuna-caroten-2'yl rhamnoside; l'-Dihydro-1-<br>
dihydroxy-4- ketotorulene; l',2'-Dihydro-3,1-dihydroxytorulene glucoside; l',2'-<br>
Dihydro-3,1dihydroxytorulene rhamnoside; r,2'-Dih.ydro-4,2'- diketotorulene; 3'-<br>
Dihydro-[boxH]-doradecin; 1,2'-Dihydro-1'-glucosyl-3,4-dehydrotorulene; l',2'-<br>
-52-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Dihydro-l'-glucosyl-4-ketotorulene; 1,2'- Dihydro-l'-hydroxy-gamma-carotene; l',2'-<br>
Dihydro-11-hydroxychiorobactene; l'-Dihydro-2-hydroxy-3,4'-dehydro-4,keto-<br>
gamma-carotene; 1,2'-Dihydro-r-hydroxy-3,4-dehydrotorulene glucoside; l',2'-<br>
Dihydro-1-hydroxy-4-keto-gamraa-carotene; r,2'-Dihydro-r- hydroxy-4-<br>
ketotorulene; 1,2'-Dihydro-1-hydroxy-4-ketotorulene glucoside; l'^'-Dihydro-l'-<br>
hydroxysphe roideneone; 1,2'-Dihydio-l'-hydroxytorulene glucoside; l',2'-Dihydro-<br>
1-hydroxytorulene rhanmoside; 1,2-Dihydrolycopene; l',2'-Dihydrolycopene; 7,8-<br>
Dihydrolycopene; 1,2- Dihydro-l-methoxy-lycopen-20-al; Dihydromethoxylycopene;<br>
5,6-Dihydro-4- methoxy-lycopen-6-one; 1,2-Dihydroneurosporene; l',2'-<br>
Dihydroneurosporene; 1,2-Dihydro-l-OH-lycopene; 1,2'-Dihydro-l'-OH-torulene; 2'-<br>
Dihydrophillipsiaxanthin; Dihydrophytoene; 1,2-Dihydrophytoene; l',2'-<br>
Dihydrophytoene; 1,2-Dihydrophytofluene; 1,2'-Dihydrophytofluene; 7,8-Dihydro-<br>
8,7'-retro-beta,beta-carotene; 7,8'-Dihydrorhodovibrin; 7,8 (or 7',8')-<br>
Dihydrosarcinaxanthin; 3,4-Dihydrospheroidene; 1,12'-Dihydrospheroidene; 3,4-<br>
Dihydrospirilloxanthin; 3,3'- Dihydroxycanthaxanthin; 3,3'-Diliydroxy-alpha-<br>
carotene; 3,4-Dihydroxy- beta-carotene; 2,3-Dihydroxy-beta,beta-carotene-4,4'-dione;<br>
3,3'- Dihydroxy-[epsi]-carotene; 2,3'-Dihydroxy-beta,beta-carotene-4,4'- dione; 3,3'-<br>
Dihydroxy-beta)beta-carotene-4,4'-diorxe;3,3'-Dihydroxy-beta,[epsi]-carotene-4,2l-<br>
dione; 3,3'-Dihydroxy-beta,Chi-carotene, 6'-dione; 3,3'-Dihydroxy-chi,chi-carotene-<br>
6,6'-dione; 2,3-Dihydroxy- beta,beta-caroten-4-one; 3,3'-Dihydroxy-beta,beta-<br>
caroten-4-one; 3,2'-Dihydroxy-beta,[epsi]-caroten-4-one; 3,3'-Dihydroxy-beta,[epsi]-<br>
caroten-4-one; S^'-Dihydroxy-betahi-caroten-e'-one; 3,8-Dihydroxy- chi,X-caroten-<br>
6-one; 3,3'-Dihydroxydeh S.S'-Dihydroxy^.SJydro-beta-carotene; 3,3'- Dihydroxy-7,8-dehydro-beta-<br>
carotene;'.ihydroxy-beta,[epsi]-caroten; 3,3'-Diliydroxy-7,8-<br>
dehydro-beta-carotene-5,6-epoxide; 3,3'-Dihydroxy-2,3-didehydro-beta,beta-<br>
-53-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
carotene-4,4'-dione;3,3'-Dihydroxy-7,8-didehydro-beta,beta-carotene-4,4l-dione;<br>
3',8'- Dihydroxy-didehydro-beta.chi-carotene--dione; 3,3'-Dihydroxy- 2,3-<br>
didehydro-beta,beta-caroten-4-one; -Dihydroxy--didehydro-betajbeta-caroten-<br>
4-one; 3,4'-Dihydroxy-2,3-didehydro-beta,beta- caroten-4-one; 3,3'-Dihydroxy-2,3-<br>
didehydro-beta,[epsi]-caroten-4-one; 3,8-Dihydroxy-7',8'-didehydro-chi,X-caroten-6-<br>
one; 3,6'-Dihydroxy-7,8- didehydro-6',7-dihydro-beta,[epsi]-carotene-3l,8'-dione; 3,3'-<br>
Dihydroxy- 7,8-didehydro-7',8'dihydro-beta,chi-carotene-6l,8l-dione; 3,1'- Dihydroxy-<br>
3',4'-didehydro-r,2'-dihydro-beta,psi-caroten-4-one; 1 ',2'- Dihydroxy-3',4'-didehydro-<br>
l',2'-dihydro-beta,psi-caroten-4-one;3,5-Dihydroxy-6,7-didehydro-5,6,7',8l-<br>
tetrah.ydro-7l-apo-beta-caroten-8'-one;6,3'-Dihydroxy-7l,8'-didehydro-5,6,7,8-<br>
tetrahydro-beta,beta-carotene-3,8-dione;3,3'-Dihydroxy-5,8,5',8l-diepoxy-beta-<br>
carotene; 5,6- Dih.ydroxy-5,6-dihydro-10'-apo-beta-caroten-10'-al; 5,6-Dihydroxy-5,6-<br>
dihydro-lO'-apo-beta-caroten-lO'-oicacid; 5,6-Dihydroxy-5,6-dihydro 12-apo-beta-<br>
caroten-12'-oic acid; 3,3'-Dib.ydroxy-7,8-dihydro-beta, beta-carotene-4,4'-dione; 3,1'-<br>
Dihydroxy-r,2'-dihydrotorulene; r,2'- Dihydroxy-r,2'-dihydrotorulene; 3,3'-<br>
Dihydroxy-4,4'-diketo-beta-carotene; 3,3'-Dihydroxy-2,2'-dinor-beta,beta-carotene-<br>
4,4'-dione-3,3'-diacylate; 3,19-Dihydroxy-3',6'-dioxo-7,8-didehyro-beta,chi- caroten-<br>
17-al; 1,1 '-Dihydroxy-2,2'-dirhamnosyl-l,2,1 ',2'-tetrahydro-3,4, 3',4'-<br>
tetrahydrolycopene; 3,3'-Dihydroxyechinenone; 3,3'-Dihydroxy-5,6- epoxy-<br>
alphacarotene; 3,3'-Dihydroxy-5,8-epoxy-alpha-carotene; 3,3'- Dihydroxy-5,6-epoxy-<br>
beta-carotene; 3,3'-Dihydroxy-5,8-epoxy-beta- carotene; 2-(Dihydroxyisopentenyl)-<br>
2'-isopentenyl-beta-carotene; 3,3'- Dihydroxyisorenieratene; 3,3'-Dihydroxy-4-keto-<br>
gcarotene; 3,3'- Dihydroxyluteochrome; Dihydroxylycopene; 3,r-Dihydroxy-2'-(5-C-<br>
methylpentosyloxy)-3',4'-didehydro-ll,2'-dihydro-beta,psi-caroten-4-one;<br>
Dihydroxyneurosporene; 2',3'-Dihydroxy-2-nor-beta,beta-carotene- 3,4-dione; 3,3'-<br>
- 54 -<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Dihydroxy-2-nor-13-beta,beta-carotene-4,4'-dione-3-acylate;3,3'-Dihydroxy-2-nor-<br>
13-beta,beta-carotene-4,4'-dione-3,3'- di-acylate; 1,2-Dihydroxyphytofluene;<br>
Dihydroxypirardixanthin; 3,3'- Dihydroxyretro-beta-carotene; 3,3'-Dihydroxy-<br>
2,3,2l,3l-tetradehydro-beta,beta-carotene-454'-dione;3)3'-Dihydroxy-7,8,7l;8l-<br>
tetradehydro-beta,beta-carotene-4,4'-dione;3,3'-Dihydroxy-2s3,2l53l-teradehydro-<br>
beta,beta-carotene-4,4'-dione dipalmitate; 3,3'-Dihydroxy-7,8,7',8'- tetradehydro-<br>
beta,beta-caroten-4-one; 1,1'-Dihydroxy-3,4,3,4-tetradehydro-l,2,1,2'-tetrahydrod-<br>
psi,psi-carotene-2,2'-dione; 3,8'- Dihydroxy-5',6',7^8'-te1iahydro-5'-apo-l 8'-nor-beta-<br>
caroten-6'-one; 1, 1-Dihydroxy-l,2,1,2'-tetrahydro-zeta-carotene; 5,5'-Dihydroxy-<br>
5,6,5', tetradehydro-beta,beta-carotene-454'-dione;3,3'-Dihydroxy-7,8,7;8-<br>
tetrahydro-cbi,chi-carotene-6,6'-dione; 9',10'-Dihydro-beta- zeacarotene 3,17'-iol;<br>
Diketo-, see also Dioxo- or -dione 2,2'- Diketobacterioruberin; 3,4-Diketo-beta-<br>
carotene; 4,4'-Diketo-beta- carotene; 4,4'-Diketo-gamma-carotene; 4,4'-<br>
Diketocynthiaxanthin; 3,3'- Diketodehydro-beta-carotene; 4,4'-Diketolycopene;<br>
Diketopirardixanthin; 3,3'-Diketoretro-beta-carotene; 3,3'-Diketoretrodehydro-beta-<br>
carotene; 2,2'-Diketospirilloxanthin; 4,4'-Diketo-7,8,7',8l-tetrade hydrozeaxanthin;<br>
3,3'-Dimethoxy-beta,beta-carotene; 3,3'-Dimethoxy- beta,[epsi]-carotene; 3,3'-<br>
Dimethoxy-ganuna-carotene; 3,3'-Dimethoxy- 3',4'-dehydro-gainma-carotene; 1,1'-<br>
Dimethoxy-3,4-didehydro-1,2,1 ',2',7', 8'-hexahydro-psi,psi-carotene; 1,1 '-Dimethoxy-<br>
3,4-didehydro-l,l',2', 7',8'-hexahydro-psi,psi-caroten-2-one; l,l'-Dimethoxy-3,4-<br>
didehydro- 1,2,1 ',2'-tetrahydro-psi,psi-carotene; 1,1 '-Dimethoxy-3 ',4'-didehydro-1,<br>
2,1 ',2'-tetrahydro-psi,psi-caroten-4-one; 1,1 '-Dimethoxy-1,2,7,8,1', 2'-hexahydro-<br>
psi,psi-carotene; l,l'-Dimethoxy-l,2,7,8,11,12,1,2,'- octahydro-psi,psi-carotene; 1,1'-<br>
Dimethoxy-3,4,3',4'-tetradehydro-1,2,1 ',2l-tetrahydro-psi,psi-carotene; 1,1'-<br>
Dimethoxy-3,4,3',4'-tetradehydro-1,2,1 ',2-tetrahydro-ps,psi-carotene-2,2-dione;<br>
-55-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
1,1'- Dimethoxy-l,2,1,2-tetrahydro-psi,psi-caroten-20-al; 1,1'-Dimethoxy- 1,2,1',2'-<br>
tetrahydro-psi,psi-carotene; 1,1 '-Dimethoxy-1,2,1 ',2'- tetrahydro-psi,psi-carotene-4,4'-<br>
dione; 1,1 '-Dimethoxy-1,2,1,2- tetrahydrolycopene; l.l'-Dimethoxy-l,1,2,2'<br>
tetrahydroneurosporene;Dimethylcrocetin;Dimethyl-6,6'-diapocarotene-6,6-dioate;<br>
Dimethyl-8,8-diapocarotene-8,8-dioate:Dineapolitanosyl-8,8'-diapocarotene-8,8'-<br>
dioate; 2,2-Dinor-beta,beta-carotene-3,4,3',4'tetrone; Dinoxanthin; 3, 3'-Dioxi-4-oxo-<br>
beta-carotene; Dioxo-, see also Diketo- or -dione 5,6- Dioxo-10'-apo-5,6-seco-beta-<br>
caroten-l0'-al; 5,6,5',6'-Diseco-beta, beta-carotene 5,6,5',6'-tetrone;<br>
7,8,1 l,12J13,14,15,7,8,11,1,2',15-Dodecahydro-13,15':14,15'biscyclo-15,15,-seco-<br>
psi,psi-caroten-15-ol; Dodecahydrolycopene; alpha-Doradecin; beta-Doradecin;<br>
alpha- Doradexanthin; beta-Doradexanthin;<br>
[0128]	Echinenone; Echininone; Eloxantbin; 6-Epikarpoxanthin; 3'- Epilutein; 5,6-<br>
Epoxy-alpha-carotene; 5,8-Epoxy-alpha-carotene; 5,8-Epoxy-beta-carotene; 1,2-<br>
Epoxy-1,2,7,8,11,12,7',8',1 l',12'-decahydro- psi,psi-carotene; 5,6-Epoxy-7',8'-<br>
dideb.ydro-5,6-dihydro-beta,beta-carotene-3,3'-diol; 5,8-Epoxy-7',8'-didehydro-5,8-<br>
dihydro-beta,beta-carotene-3,3'-diol; l',2'-Epoxy-3,4-didehydro-l,2'-dihydro-<br>
beta,psi- caroten-2-ol; 5,8-Epoxy-alpha-carotene; 5,8-Epoxy-beta-carotene; 1,2-<br>
carotene-3,5,19 (or 19'), 3'-tetrol; 5l,6'-Epoxy-6,7-didehydro-5,6,5l,6l- tetrahydro-<br>
beta,psi- caroten-2-ol; 5,8-Epoxy-alpha-carotene; 5,8-Epoxy-beta-carotene; 1,2-<br>
beta,beta-carotene-3,5,3'-triol 3-acetate; 5',8'- Epoxy-6,7-didehydro-5,6,5',8'-<br>
beta,psi- caroten-2-ol; 5,8-Epoxy-alpha-carotene; 5,8-Epoxy-beta-carotene; 1,2-<br>
carotene-3,12'-diol; 5,8- Epoxy-5,8-dihydro-10'-apo-beta-carotene-3,10'-diol; 5,8-<br>
Epoxy-5,8-dihydro-12'-apo-beta-carotene-3,12'-diol; 5,6-Epoxy-5,6-dihydro-beta,<br>
beta-carotene; 5,8-Epoxy-5,8-dihydro-beta,beta-carotene; 5,6-Epoxy- 5,6-dihydro-<br>
-56-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
beta,[epsi]-Ecarotene; 5,8-Epoxy-5,8-dihydro-beta,[epsi]- carotene; 1,2-Epoxy-l,2'-<br>
dihydro-beta,psi-carotene; l',2'-Epoxy- l',2'-dihydro-[epsi]5psi-carotene; 1,2-Epoxy-<br>
l,2-dihydro-psi,psi- carotene; 5,6-Epoxy-5,6-dihydro-psi,psi-carotene; 5,6-Epoxy-5,6-<br>
dihydro-beta,beta-carotene-3,3'-diol; 5,8-Epoxy-5,8-dihydro-beta, beta-carotene-3,31-<br>
diol; 5,6-Epoxy-5,6-dihydro-beta,[epsi]-carotene-3, 3'-diol; 5,6-Epoxy-5,6-dihydro-<br>
beta,[epsi]-carotene-3,3'-dioldipalmitate; 5,8-Epoxy-5,8-dihydro-beta,[epsi]-<br>
carotene-3,3'-diol; 5,6- Epoxy-5,6-dihydro-betaepsi-carotene-3,3'-triol; 5,8-<br>
Epoxy-5,8- dihydro-beta,[epsi]-carotene-3,3',6'-triol; 5,6-Epoxy-5,6-dihydro-beta,<br>
beta-caroten-2-ol; 5,6-Epoxy-5,6-dihydro-beta,beta-caroten-3-ol; 5,8-Epoxy-5,8,<br>
dihydro-beta,beta-caroten-3-ol; 5,6-Epoxy-5,6- dihydro-beta,[epsi]-caroten-2-ol; 5,6-<br>
Epoxy-5,6-dihydro-beta,psi-caroten-3-ol; 5,8-Epoxy-5,8-dihydro-beta,psi-caroten-3-<br>
ol; 5,8-Epoxy- 3,3'-dihydroxy-alpb.a-carotene; 5,6-Epoxy-3,3'-dihydroxy-<br>
7',8'didehydro-5,6,7,8-tetrahydrod-beta,beta-caroten-8-one; 5',6'-Epoxy-3,3'-<br>
dihydroxy-7,8-didehydro-5,6'-dihydro-lO,1 l,20-trinor-beta,beta- caroten-19',11'-<br>
olide; 5,6, Epoxy-3,3-dihydroxy-4,7, didehydro-5,6 dihydro-10,11,20-trinor-<br>
betajbeta-caroten-19-olide 3-acetate; 5', 6'-Epoxy-3,3'-dihydroxy-7,8-didehydro-<br>
5,6-dihydro-l0.11,20-trinor-beta ,beta-caroten-19',11-olide 3-acetate; 5,6-Epoxy-<br>
3,3'-dihydroxy-5,6-dihydro-beta,cbi-caroten-6'-one; 5,8-Epoxy-3,3'-dihydroxy-5,8-<br>
dihydro- beta,chi-caroten-6'-one; 5', 6'-Epoxy-3,3'-dihydroxy-7,8-didehydro-<br>
beta,[epsi]-caroten-l 1,19'-olide; 1,2'-Epoxy-2'-(2,3-epoxy- 3-methylbutyl)-2-(3-<br>
hydroxy-3-methylbutyl)-3',4'-dideb.ydro-l,2,r,2'-tetrahydro-psi,psi-caroten-l-ol; 1,2-<br>
Epoxy-l,2,7,8,7',8'-hexahydro-psi,psi-carotene; 5,6-Epoxy-3-hydroxy-8'-apo-beta-<br>
caroten-8'-al; 5,6-Epoxy-5,6-dihydro-10'-apo-beta-carotene-3,10'-diol; 5,8-Epoxy-3-<br>
hydroxy-gamma-carotene; 5,8-Epoxy-3-hydroxy-5,8-dihydro-8'-apo-beta-caroten-8'-<br>
al; 5,6-Epoxy-3-hydroxy-5,6-dihydro-10'-apo-beta-caroten-10'- al 502; 5,6-Epoxy-3-<br>
-57-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
hydroxy-5,6-dihydro-12'-apo-beta-caroten-12'-al;5, 5-Epoxy-3-hydroxy-5,6,7,8,<br>
tetrahydro-7'-apo-beta-caroten-8'-one; 5,8-Epoxylutein; 1,2-Epoxy-<br>
1,2,7,8,1 l,12,7',8'octahydro-psi,psi-carotene; 1,2-Epoxy-l A7,8,7',8',l 1',12'octahydro-<br>
psi,psi-carotene; l'2,'-Epoxy.7,8,11,12,1,2,7,8'-octahydro-beta-si-caroten-ol;<br>
1,2- Epoxyphytoene; 5,8-Epoxyrubixanthin; 5,8,'-Epoxy-5,6,5,8'-tetrahydro-<br>
beta,beta-carotene-3,5,6,3'-tetrol; 5',6'-Epoxy-5,6,5',6l-tetrahydro-beta,beta-carotene-<br>
3,5,6,3'-tetrol;5,6-Epoxy-3',4',7',8'-tetradehydro-5,6-dihydro-beta,beta-caroten-4-<br>
one;5,6-Epoxy-3,3',5', 19'-tetra-hydroxy-6,7'-didehydro-5,67,85,6-hexahydro-<br>
beta,beta- caroten-8-one 3'-acetate 19'-hexanoate; 5,6-Epoxy-3,3',5'-trihydroxy-6', 7'-<br>
didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; 5,6-Epoxy-3,3',51-<br>
trihydroxy-6',7'-didehydro-5,6,7,8,5l,6l-hexahydro-beta, beta-caroten-8-one 3'-acetate;<br>
one;5,6-Epoxy-3,3',5', 19'-tetra-hydroxy-6,7'-didehydro-5,67,85,6-hexahydro-<br>
beta,beta-caroten-19', 1 l'-olide; 5,6'-Epoxy-3,5,3'-trihydroxy-6,7-didehydro-5,6,5,6<br>
tetrah.ydro-10,1 l,20-trinor-beta,beta-caroten-19',11'-olide 3-acetate; 4',5'-Epoxy-<br>
3,6,3l-trihydroxy-7,8,4',5I,7',8l-hexab.ydro-gainma,[epsi]-caroten-8-one; 5,6-<br>
Epoxyzeaxanthin; 5,8-Epoxyzeaxanthin; Eschscholtzxanthin; Eschscholtzxanthone;<br>
4'-Ethoxy-beta,beta-caroten- 4-one; 4'-Ethoxy-4-keto-beta-carotene; Euglenanone;<br>
Euglenarhodon; Eutreptiellanone;<br>
[0129]	Flavacin; Flavochrome; Flavorhodin; Flavoxanthin; Flexixanthin;<br>
Foliachrome; Foliaxanthin; Fritschiellaxanthin; Fucochrome; Fucoxanthin;<br>
Fucoxanthinol; Fucoxanthol;<br>
[0130]	Gazaniaxanthin; beta,D-Gentiobiosyl beta,D-glucosyl 8, 8'-diapocarotene-8,8'-<br>
dioate; Gentiobiosyl hydrogen-8,8'-dioate; Gentiobiosyl neapolitanosyl 8,8'-<br>
diapocarotene-8,8'-dioate; beta,D- Glucosyl hydrogen-4,4'-diapocarotene-4,4'-dioate;<br>
4'-beta,D-Glucosyl 4- hydrogen-7',8'-dihydro-4,4'-diapocarotene-4,4'-dioate; beta,D-<br>
-58-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Glucosyl hydrogen-8,8'-diapocarotene-8,8-dioate; beta,D-Glucosyl methyl-8,8'-<br>
diapocarotene-8,8'-dioate; Glucopyranosyloxy (see Glucosyloxy); 4- Glucosyloxy-4,4'<br>
diaponeurosporene; r-Glucosyloxy-3,4'-didehydro-1,2'-dihydro-beta,psi-carotene;<br>
l-Glucosyloxy-3,4-didehydro-l,2-dihydro-psi,psi-carotene; 2'-Glucosyloxy-3',4'-<br>
didehydro-1,2'-dihydro-beta,psi-carotene-3,1-diol; l'-Glucosyloxy-3,4'-didehydro-<br>
1,2-dihydro-beta,psi-caroten-3-ol;1-Glucosyloxy-3l,4l-didehydro-1,2'-dihydro-<br>
beta,psi-caroten-2'-ol; l'-Glucosyloxy-3',4 '-didehydro-r,2'-dihydro- beta,psi-caroten-<br>
4-one; l-Glucosyloxy-3,4-didehydro-l,2,7,8'- tetrahydro-psi,psi-carotene; 1-<br>
Glucosyloxy-l,2-dihydro-psi,psi-caroten-20-al; l-Glucosyloxy-1,2'-dihydro-beta,psi-<br>
carotene; 1'- Glucosyloxy-l',2'-dihydro-[phil].psi-carotene; l-Glucosyloxy-1,2-<br>
dihydro- psi,psi-carotene; 4-Glucosyloxy-7,8-dihydro-4,4'-diapocarotene; 1'-<br>
Glucosyloxy-2'-hydroxy-3',4'-didehydro-1,2-dib.ydro-beta,psi-caroten-4-one;2-(4-<br>
Glucosyloxy-3-methyl-2-butenyl)-2'-(4-hydroxy-3-methyl-2-butenyl)-<br>
gamma,gamma-carotene;2-(4-Glucosyloxy-3-methyl-2-butenyl)-2'-(4-hydroxy-3-<br>
methyl-2-butenyl)-[epsi],[epsi]-carotene;2-(4-Glucosyloxy-3-methyl-2-butenyl)-2'-<br>
(4-hydroxy-3-methyl-2-butenyl)-7,8-dihydro-[epsi],[epsi]-carotene;2'-(4-<br>
Glucosyloxy-3-methyl-2-butenyl)-2-(3-methyl-2-butenyl)-[epsi],[epsi]-caroten-18-ol;<br>
2-[3-(Glucosyloxy)-3-methylbutyl]-2'-(3-hydroxy-3-methylbutyl)-3,4,3',4'-<br>
tetradehydro-1,2,1'. 2'-tetrahydro-psi,psi-carotene-l, l'-diol; 1 '-Glucosyloxy-3,4,3',4'-<br>
tetradehydro-l'2'-diliydro-beta.psi-carotene; Glycymerin; Guaraxanthin;<br>
[0131]	Halocynthiaxanthin; Helenien; Heteroxanthin; Hexadecahydrolycopene;<br>
2,3,2l,3',4,5-Hexadehydro-4,5'-retro-beta,beta- carotene; 1,2,7,8,11,12-Hexahydro-<br>
psi,psi-carotene; 1,2,7,8,1',2'- Hexahydro-psi,psi-carotene; 1,2,7,8,7,8-Hexahydro-<br>
psi.psi- carotene; 7,8,1 l.12'.S'-Hexahydro-psi.psi-carotene; 7,8,11,12,7',8'-<br>
Hexahydro-beta,psi-caroten-2-ol; 15,7',8',1 l,12',15'-Hexahydro-beta ,psi-caroten-2-<br>
-59-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
ol; 1,2,7',8',1 11,12-Hexahydro-psi,psi-caroten-l-ol; 7,8,1 l,12,7',8'-Hexahydro-psi,psi-<br>
caroten-16-ol; 7,8,11,12,7',8!- Hexahydro-4,4'-diapocarotene; 1,2,7,8,11,12-<br>
Hexahydrolycopene; 1,2',7', 8'11,12'-Hexahydrolycopene; 7,8,11,12,7',8'-<br>
Hexahydrolycopene; 7,8,1',2',7',8'-Hexahydrolycopene;  7,8,1',2',7',8'<br>
Hexahydrospirilloxanthin; 19'- Hexanoyloxyfucoxanthin; 19-<br>
Hexanoyloxyparacentrone; l-Hexosyl-l,2-dihydro- 3,4-didehydroapo-8'-lycopenol;<br>
O-Hexosyl-1 '-hydroxy-1 ',2'-diliydro-gamma- carotene; O-Hexosy-1 -4-keto-1 '-<br>
hydroxy-1,2'-dihydro-3',4'-didehydro- gamraa-carotene; Hopkinsiaxanthin; Hydroxy-,<br>
see also Monohydroxy-, OH or -ol3-Hydroxy-beta-apo-2-carotenal; 3-Hydroxy-8'-<br>
apo-beta-caroten- 8'-al; 3-Hydroxy-10'-apo-beta-caroten-10'-al: 3-Hydroxy-12'-apo-<br>
beta- caroten-12'-al; S-Hydroxy-8'-apo-[epsi]-caroten-8'-al; 3-Hydroxy-8'-apo- beta-<br>
caroten-8'-oic acid; 9'-Hydroxy-9'-apo-beta-caroten-3-one; 9'- Hydroxy-9'-apo-[epsi]-<br>
caroten-3-one; Hydroxyasteroidenone; 3- Hydroxycanthaxanthin; 3-Hydroxy-<br>
beta,psi-caroten-18'-al; 3-Hydroxy- alpha-carotene; 3'-Hydroxy-alpha-carotene; 4-<br>
Hydroxy-alpha-carotene; 2-Hydroxy-beta-carotene; 3-Hydroxy-beta-carotene; 4-<br>
Hydroxy-beta- carotene; 3-Hydroxy-gamma-carotene; 4'-Hydroxy-gamma-carotene;<br>
3- Hydroxy-[delta]-carotene; 2-Hydroxy-beta,beta-carotene-4,4'-dione; 3- Hydroxy-<br>
beta,beta-carotene-4,4'-dione; 3'-Hydroxy-beta,beta- carotene-3,4-dione; 4'-Hydroxy-<br>
beta,beta-carotene-3,4-dione; 3- Hydroxy-beta,[epsil]-carotene-4,3'-dione; 3'-Hydroxy-<br>
beta,[epsi]- carotene-3,4-dione; 3-Hydroxy-beta,chi-carotene-3',6'-dione; 3'- Hydroxy-<br>
beta,beta-carotene-3,4,4'-trione; 2'-Hydroxy-beta,beta- caroten-2-one; 2-Hydroxy-<br>
beta,beta-caroten-4-one; 3-Hydroxy-beta, beta-caroten-4-one; 3'-Hydroxy-beta,beta-<br>
caroten-4-one; 4'-Hydroxy- beta,beta-caroten-4-one; 3-Hydroxy-beta,[epsi]-caroten-4-<br>
one; 3- Hydroxy-beta,[epsi]-caroten-3'-one; 3'-Hydroxy-betajChi-caroten-6'- one;<br>
3Hydroxy-beta,psi-caroten-4'-one; 3-Hydroxy-beta,psi-caroten- 4-one; 3-Hydroxy-<br>
-60-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[epsi],[epsi]-caroten-3'-one; 3'-Hydroxy-psi,psi- caroten-4-one; 3-<br>
Hydroxycitranaxanthin; 3-Hydroxy-7,8-dehydro-alpha- carotene; 3'-Hydroxy-3,4-<br>
dehydro-beta-carotene; 3-Hydroxy-3,4'-dehydro- gamma-carotene; 4-Hydroxy-4,4'-<br>
diaponeurosporene; 3-Hydroxy-2,3-didehydro-betasbeta-carotene-4s4'-dione; 2-<br>
Hydroxy-3,4-didehydro- beta,beta-caroten-2-one; 3-Hydroxy-2,3-didehydro-<br>
beta,beta- caroten-4-one; 3-Hydroxy-2,3-didehydro-beta,[epsi]-caroten-4-one; 3-<br>
Hydroxy-2,3-didehydro-beta,X-caroten-4-one; 3-Hydroxy-2,3-didehydro-beta,[phi]-<br>
caroten-4-one; 3-Hydroxy-3',4'-didehydro-beta,psi- caroten-4-one; 3-Hydroxy-7,8-<br>
didehydro-7,8-dihydrd-7'-apo-beta-carotene-4,8'-dione; 3-Hydroxy-7,8-didehydro-<br>
7,8'-dihydro-7-apo-beta-caroten-8'-one; 3-Hydroxy-7,8'-didehydro-7,8-dihydro-<br>
chi,X-carotene-6, 8-dione; 1-Hydroxy-3,4-didehydro-l',2'-dihydro-betajpsi-caroten-<br>
4- one; r-Hydroxy-3,4-didehydro-1,2-dihydro-beta.psi-caroten-2-'-one; 2'-Hydroxy-<br>
3',4'Tdidehydro-1,2'-dihydro-betajpsi-caroten-one; 5- Hydroxy-4',5'-didehydro-4,5-<br>
dihydro-4,5'-retro-beta,beta-carotene-3, 3'-dione,3'-Hydroxy-2'.3'-didehydro-2--nor-<br>
beta,beta-carotene-3,4,4-trione;3'-Hydroxy-4,5'-didehydro-4,5'-retro-beta,beta-<br>
caroten-3-one; 3-Hydroxy-5,8,5',8'-diepoxy-beta-carotene; 3-Hydroxy-7,8-dihydro-<br>
7'- apo-beta-caroten-8'-one; 3-Hydroxy-5,6'-dihydro-5'-apo-18-nor-beta- caroten-6'-<br>
one; l-Hydroxy-l,2-dihydro-psi,psi-caroten-20-al; 1'- Hydroxy-1,2'-dihydro-gamma-<br>
carotene; 3-Hydroxy-7,8-dihydro-chi,X- carotene-6,8-dione; 4'-Hydroxy-5',6'-<br>
dihydro-beta,beta-caroten-4-one; l'-Hydroxy-1,2'-dihydro-beta,psi-caroten-4-one; 8'-<br>
Hydroxy-7',8'- dihydrocitranaxanthin; 4-Hydroxy-7',8'-dihydro-4,4'-diapocarotene; 4'-<br>
Hydroxy-5',6'-dihydroechinenone; 1 '-Hydroxy-1 ',2'-diliydro-2-isopentenyl- 2'-<br>
(hydroxyisopentenyl)torulene; 1-Hydroxy-1,2-dihydrolycopene; 1-Hydroxy- 1,2-<br>
dihydroneurosporene; 1-Hydroxy-1,2'-dihydroneurosporene; 1-Hydroxy-1,2-<br>
dihydrophytoene; 1 (or l)-Hydroxy-l,2 (or 1,2')-dihydrophytofluene; 8'-Hydroxy-<br>
-61-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
7',8'-dihydroreticulataxanthin; 1-Hydroxy-1',2'-dihydrospheroidene;2-Hydroxy-<br>
1,2'-dihydrotorulene; 2-Hydroxy-1,2'- dihydrotorulene-1,2'-oxide; 5-Hydroxy-5,6-<br>
dihydrozeaxanthin; 3-Hydroxy- 3,4-diketo-alpha-carotene; 3-Hydroxy-4,4'-diketo-<br>
beta-carotene; 3'- Hydroxy-3,4-diketo-beta-carotene; 2'-Hydroxy-3,1-dimethoxy-3',4'-<br>
didehydro-1,2-dihydro-beta,psi-caroten-4--one-Hydroxy-3,4'-dioxo-beta-carotene;<br>
2-Hydroxyechinenone; 3-Hydroxyechinenone; 3'- Hydroxyechinenone; 4'-<br>
Hydroxyechinenone; 3-Hydroxy-5,8-epoxy-beta- carotene; 3'-Hydroxy-3,6-epoxy-<br>
didehydro-1,2-dihydro-beta,psi-caroten-4--one-Hydroxy-3,4'-dioxo-beta-carotene;<br>
dihydro-beta,beta-caroten-4- one; 3'-Hydroxyeuglenanone; 2I-Hydroxyflexixanthin; 1-<br>
Hydroxy-1,2,7',8, ll'.12-hexahydrolycopene; l'-Hydroxy-3,4,1,2,11'<br>
12'hexahydrospheroidene; 2-(4-Hydroxy-3-hydroxymethyl-2-butenyl)-2'-(3-methyl-<br>
2-butenyl)-beta,beta-carotene; 3-Hydroxyisorenieratene; 3- Hydroxy-4-keto-alpha-<br>
carotene; 3-Hydroxy-3'-keto-alpha-carotene; 3- Hydroxy-4-keto-beta-carotene; 3-<br>
Hydroxy-4'-keto-beta-carotene; 4- Hydroxy-4'-keto-beta-carotene; l'-Hydroxy-2'-<br>
keto-l',2'-dihydrotorulene; 3-Hydroxy-3'-keto-retrodehydrocarotene; 19-<br>
Hydroxylutein; 16-Hydroxylycopene; 3-Hydroxy-3'-methoxy-beta-carotene; l1-<br>
Hydroxy-l-methoxy-3,4-didehydro-1,2,1,2,7,8-hexahydro-psi,psi-caroten-2--one;<br>
l'-Hydroxy-l-methoxy-1,2,1,27,8'-hexahydro-psijpsi-caroten-one; l'-Hydroxy-l-<br>
methoxy-3,4,3,4'-tetradehydro-1,2,1,2'-tetrahydro-psi-si-caroten-one; 1'-<br>
Hydroxy-1 -methoxy-1,2,1 ',2'-tetrahydro-psi,psi -caroten-4-one; 2-(4-Hydroxy-3 -<br>
methyl-2-butenyl)-beta,beta-carotene; 2-(4-Hydroxy-3 -methyl-2-butenyl)-[epsi] ,psi-<br>
carotene; 2-(3- Hydroxymethyl-but-2-enyl)-7',8'-dihydro-[delta]-carotene; 2-(4-<br>
Hydroxy-3-metiiyl-2-butenyl)-7',8'-dihydro-[epsi],psi-carotene;2-(4-Hydroxy-3-<br>
metb.yl-2-butenyi)-2'-(3-methyl-2-butenyl)-[epsi],[epsi]-carotene;2-(4Hydroxy-3-<br>
methyl-2-butenyl)-2'-(3-methyl-2-butenyl)-[epsi],[epsi]- caroten-18-ol; 2'-(4-<br>
-62-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Hydroxy-3-methyl--butenyl-(3-meihyl-buteny-3,4'-didehydro-l,2'-dihydro-<br>
beta,psi-caroten-r-ol; 2 (or 2')-(4- Hydroxy-3-methyl-2-butenyl)-2' (or 2)-(3-methyl-<br>
2-butenyl)-3',4'-didehydro-1,2'-dihydro-[epsi])psi-caroten-r-ol;2'-(4-Hydroxy-3-<br>
methyl-2-butenyl)-2-(3-methyl-2-butenyl)-7,8 (or 7',8)-dihydro-[epsi], [epsi]-caroten-<br>
18-ol; 2-(4-Hydroxy-3-methyl-2-butenyl)-7,8,7',8'- tetrahydro-[epsi],psi-carotene; 2-<br>
(4-Hydroxy-3-methyl-2-butenyl)-7',8', 11,12'-tetrahydro-[epsi],psi-carotene; 16-(3-<br>
Hydroxy-3-methylbuiyl)- 16'-(3-methyl-2-butenyl)-7,8,l 1,12,15,7,8',1 l,12,15-<br>
decahydro-psi,psi-carotene;2-(3-Hydroxy-3-methylbutyl)-2'-(3-methyl-2-butenyl)-<br>
3,4,3',4'-tetradehydro-l,2,1,2'-tetrahydro-psi,psi-carotene-l,r-diol; 2- Hydroxy-<br>
monocyclic-phytofluene; 4-Hydroxymyxoxanthophyll; Hydroxyneurosporene; 15-<br>
Hydioxy-7,8',9',10',11, 12'.13'.14'-octahydro- 6'-apo-beta-caroten-7'-one; l'-<br>
Hydroxy-3,4,7,8,l',2',l l',12'- octahydrospheroidene; 3'-Hydroxy-4-oxo-beta-carotene;<br>
3-Hydroxy-4-oxo-2, 3-dehydro-beta-carotene; 4'-Hydroxy-3-oxoechinenone;<br>
Hydroxyphytoene; Hydroxyphytofluene; 4'-Hydroxy-4-oxo-pirardixanthin; 2-<br>
Hydroxyplectaniaxantbin; S-Hydroxy-4,5.-retro-5'-apo-beta-caroten-5'- one; 3-<br>
Hydroxy-4,12'-retro-beta,beta-carotene-3'.12'-dione; 3'- Hydroxyrubixantbin; 3'-<br>
Hydroxy-5,6-seco-beta,beta-carotene-5,6-dione; 3-Hydroxysemi-beta-carotenone; 3-<br>
Hydroxysintaxanthin; Hydroxyspheroidene; Hydroxyspheroidenone;<br>
Hydroxyspirilloxanthin; 8'-Hydroxy-5'.6',7'.8'-tetrahydro-5'-apo-l8-nor-beta-caroten-<br>
6'-one; 4'- Hydroxy-5,6,5',6'-tetrahydro-beta,beta-caroten-4-one; l-Hydroxy-3,4, 3',4'-<br>
tetradebydro-l,2-dihydro-psi,psi-caroten-2-one; l-Hydroxy-1,2, 7',8'-<br>
tetrahydrolycopene; 1-Hydroxy-3,4,l',2'-tetrahydrospheroidene; 3- Hydroxytorulene;<br>
16'-Hydroxytorulene; 18'-Hydroxytorulene; 3-Hydroxy-3', 4'-triketo-beta-carotene; 3-<br>
Hydroxy-beta-zeacarotene; 5- Hydroxyzeaxanthin;<br>
-63-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0132]	Idoxanthin; Isoagelaxanthin A; Isobixin; Isocarotene; Iso- zeta-carotene; Iso-<br>
zeta-carotene; Isocrocetin; Isocryptoxanthin; Isofucoxanthin; Isofucoxanthinol;<br>
Isolutein; Isomethylbixin; Isomytiloxanthin; 2-Isopentenyl-3,4-dehydrorhodopin;<br>
Isorenieratene; beta-Isorenieratene; 3,3'-Isorenieratenediol; 3-Isorenieratenol;<br>
Isotedaniaxanthin; Isotedanin; Isozeaxanthin;<br>
[0133]	Karpoxanthin; Keto-, see also oxo or -one Ketocapsanthin; 4-Ketocapsanthin;<br>
4-Keto-alpha-carotene; 4-Keto-beta-carotene; 4-Keto- gamma-carotene; 4-<br>
Ketocynthiaxanihin: 4-Keto-3',4'-dehydro-beta- carotene; 4-Keto-r,2'-dihydro-r-<br>
hydroxytorulene; 2-Keto-7',8'- dihydrorhodovibrin; 4-Keto-3,3'-dihydroxy-alpha-<br>
carotene; 4'-Keto-3- hydroxy-gamma-carotene; 4-Keto-3'-hydroxylycopene; 4-<br>
Ketolutein 332 4- Ketomyxol 2'-(methylpentoside); 4-Ketomyxoxanthophyll; 2-Keto-<br>
OH- spirilloxanthin; 4-Ketophleixanthophyll; 2-Ketorhodovibrin; 41- Ketorubixanthin;<br>
2-Ketospirilloxanthin; 4-Ketotoralene; 4-Ketozeaxanthin;<br>
[0134]	Lactucaxanthin; Latochrome; Latoxantbin; leprotene; Lilixanthin;<br>
Loniceraxanthin; Loroxanthin; Lusomycin; Lutein; Lutein dimethyl ether; Lutein<br>
dipalmitate; Lutein epoxide; Luteochrome; Luteol; Luteoxanthin; Lycopenal;<br>
Lycopen-20-al; Lycopene; Lycopene-16,16'-diol; Lycopene 1,2-epoxide; Lycopene<br>
5,6-epoxide; Lycopen-16-ol; Lycopen-20-ol; Lycopersene; Lycophyll; Lycoxanthin;<br>
[0135]	Mactraxanthin; Manixanthin; l-Mannosyloxy-3,4-didehydro-l, 2-dihydro-8'-<br>
apo-psi-caroten-8'-ol; 3'-Methoxy-beta,beta-caroten-3- ol; 3-Methoxy-beta,X-<br>
carotene; 1,2,7,8,11,12,1,2,7,8, decahydro-psi.psi-carotene; l'-<br>
Methoxy-1,2,7,8,1 l,12,r,2',7',8'- decahydro-psi,psi-caroten-l-ol; l-Methoxy-3,4-<br>
didehydro-1,2-dihydro- psi,psi-caroten-20-al; 1 '-Methoxy-3 ',4'-didehydro-1',2'-<br>
dihydro-beta ,psi-carotene; 1-Methoxy-3,4-didehydro-l,2-dihydro-psi,psi-carotene; 1-<br>
Methoxy-3,4-didehydro-1,2,7,8,11,12-hexahydro-psi.psi-carotene; 1-Methoxy-3',41-<br>
-64-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
didehydro-1,2,7,8,1',2'-hexahydro-psi,psi-caroten-1 - ol; 1 -Methoxy-3,4-didehydro-<br>
1,2,7',8'-tetrahydro-psi,psi-carotene; 1'- Methoxy-3',4'-didehydro-l ,2,1 ',2'-tetrahydro-<br>
psi,psi-caroten-l-ol; l-Methoxy-3;4-didehydro-l,2,7,8'-tetrahydro-psi,psi-caroten-2-<br>
one; 1- Methoxy-l,2-dihydro-psi,psi-caroten-20-al; l-Methoxy-l,2-dihydro-psi ,psi-<br>
carotene; 1-Methoxy-l,2'-dihydro-beta,psi-caroten-4'-one; 1'- Methoxy-l',2'-dihydro-<br>
X,psi-caroten-4'-one; l-Methoxy-l,2-dihydro-psi, psi-caroten-4-one; l'-Methoxy-<br>
1,2'-dihydro-3',4'-dehydro-gamma- carotene; l-Methoxy-l,2-dihydro-3,4-<br>
dehydrolycopene; l-Methoxy-1,2- dihydro-3,4-didehydrolycopen-20-al; 1-Methoxy-<br>
1,2-dihydrolycopene; 4-Methoxy-5,6-dihydrolycopene; 1-Methoxy-1,2-<br>
dihydroneurosporene; 1-Methoxy- 1,2-dihydrophytoene; 1-Methoxy-1,2-<br>
dihydrophytofluene; 1-Methoxy-1',2'- dihydrospheroidene; 3-Methoxy-19,3'-<br>
dihydroxy-7,8-didehydro-beta,chi- carotene-6',8'-dione; l-Methoxy-1,2,7,8,11,12-<br>
hexahydro-psi,psi-carotene; 1'-Methoxy-l,2,7,8,r,2'-hexahydro-psi,psi-caroten-l-ol;<br>
1- Methoxy-1,2,7',8'11,12'-hexahydro-psi,psi-caroten-4-one; 1-Methoxy- l'-hydroxy-<br>
l,2,r,2'-tetrahydrophytofluene; l-Methoxy-2-keto-7',8'- dihydro-3,4-<br>
dehydrolycopene;Methoxylycopenal; l-Methoxy-1,2,7,8,7',8', 11', 12'-octahydro-<br>
psi,psi-carotene; r-Metiioxy-l,2,7,8,ll,12,r,2'- octahydro-psi,psi-caroten-l-ol; 1-<br>
Methoxy-4-oxo-1,2-dihydro-8'-apo- psi-caroten-8'-al; 1 -Methoxy-4-oxo-1,2-dihydro-<br>
12'-apo-psi-caroten- 12'-al; Methoxyphytoene; Methoxyphytofluene;<br>
Methoxyspheroidene; 1'- Methoxy-3 ,4,3,4,-teradehydro-1,2,1 ',2l-tetrahydro-psi,psi-<br>
caroten-1-ol; l-Methoxy-l,2,7l,8'-tetrahydro-psi,psi-carotene; l-Methoxy-1,2,71, 8'-<br>
tetrahydro-psi,psi-caroten-4-one; l-Methoxy-l,2,7',8'-tetrahydro-3,4-<br>
dehydrolycopene; 3Methoxy-l 9,3',8'-trihydroxy-7,8-didehydro-beta,chi -caroten-6'-<br>
one; Methyl 4'-apo-beta-caroten-4'-oate; Methyl 8'-apo- beta-caroten-8'-oate; Methyl<br>
6'-apo-psi-caroten-6'-oate; Methyl apo- 6'-lycopenoate; Methylbixin; 2-(3-Methyl-2-<br>
-65-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
butenyl)-beta,beta-caroten-18 (or 18')-ol; 2-(3-Methyl-2-butenyl)-3,4-didehydro-l,2-<br>
dihydro-psi, psi-caroten-1-ol; 2-(3-Methyl-2-butenyl)-7,8,7',8'-tetrahydro-[epsi], psi-<br>
caroten-18-ol; Methyl 3',4'-didehydro-beta,psi-caroten-16'-oate; Methyl 1-hexosyl-<br>
l,2-dihydro-3,4-didehydro-apo-8'-lycopenoate; Methyl hydrogen 6,6-diapocarotene-<br>
dioate; Methyl l-mannosyloxy-3,4-didehydro-l, 2-dihydro-8'-apo-psi-caroten-8'-oate;<br>
Methyl 1'-methoxy-4'-oxo-1,2'- dihydro-X,psi-caroten-16 (or 17 or 18)-oate; 2'-(O-<br>
Methyl-5-C- methylpentosyloxy)-3',4'-didehydro-1 ',2'-dihydro-beta,psi-carotene-3, 1 '-<br>
diol; Metridene; Mimulaxanthin; Monadoxanthin; Monoanhydrobacterioruberin;<br>
Monodehydro-beta-carotene; Monodehydrolycopene; Monodemethyl(ated)<br>
spirilloxanthin; Monoepoxy-, see Epoxy-Monohydroxy cyclophytoene; Monohydroxy<br>
cyclophytofluene; Mutatochrome; Mutatoxanthin; Mytiloxanthin; Mytiloxanthinone;<br>
Myxobactin; Myxobactone; Myxol 2'-glucoside; Myxol 2'-O-methyl-<br>
methylpentoside; Myxol 2'-rhamnoside; Myxoxanthin; Myxoxanthol;<br>
Myxoxanthophyll;<br>
[0136]	Neocarotene; Neochrome; Neo-beta-carotene B; Neo-beta- cryptoxantbin A;<br>
Neoxanthin; Neoxanthin 3-acetate; Neurosporaxanthin; Neurosporaxanthin methyl<br>
ester; Neurosporene; Nonaprenoxanthin; 2'-Nor- astaxanthin diester; Norbixin;<br>
Nostoxanthin;<br>
[0137]	Octahydro-beta-carotene; 1,2,7,8,1 l,12,7',8'-Octahydro- psi,psi-carotene;<br>
7,8,11,12,7',8',1 l',12'-Octahydro-psi,psi- carotene; 1,2,7,8,1 l,12,7',8'-Octahydro-<br>
psi,psi-carotene-l 1,2-diol; 1,27,8,1 ',2',7',8'-Octahydro-psi,psi-carotene-l, 1 '-diol;<br>
1,2,7,8,11,12, 7',8'-Octahydro-psi,psi-caroten-l-ol; 7,8,11,12,7',8',11 ,12'- Octahydro-<br>
beta,psi-caroten-2-ol; l,2,7,8,11,12'-Octahydro-psi,psi-caroten-l-ol;<br>
7,8,11,12,7',8',1 l'.12'-Octahydro-4,4'-diapocarotene; Octahydrolycopene;<br>
5,6,7,8,5',6',7',8'-Octahydrolycopene; 7,8,11,12,7', 8',1 l',12'-Octahydrolycopene;<br>
-66-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
3,4,3',7,8',11,12- Octahydrospirilloxanthin; OH, see also Hydroxy- or -ol OH-<br>
Chlorobactene; OH-Chlorobactene glucoside; OH-Lycopene; 2-OH-<br>
Monocyclophytoene; 2-OH- Monocyclophytofluene; OH-Neurosporene; OH-<br>
Okenone; OH-P 481; OH-P 482; OH- P 511; OH-R; OH-Rhodopin; OH-Sintaxanthin<br>
5,6-epoxide; OH-Spheroidene; OH- Spheroidenone; OH-7,8,11,12-<br>
Tetrahydrolycopene; OH-Y; Okenone; Ophioxanthin; Oscillaxanthin; Oscillol 2,2'-<br>
di(O-methyl-methylpentoside); Oscillol 2,2'-dirhamnoside; Ovoester; Oxo-, see also<br>
Keto or -one 3- Oxocanthaxanthin; 4'-Oxo-4,4'-diapocaroten-4-oic acid; 8'-Oxo-8,8'-<br>
diapocarotenoic acid; 3-Oxoechinenone; 4-Oxosaproxanthin; 16'-Oxotorulene; 6'-<br>
Oxychrysanthemaxanthin; P 412; P 444; P 450; P 452; P 481; P 500; P 518; l'-[(chi -<br>
O-Palmitoyl-beta,D-glucosytyoxyl-3,4'-didehydro-l',2'-dihydro-beta, psi-caroten-2'-<br>
ol; Papilioerythrin; Papilioerythxinone; Paracentrone; Parasiloxanthin; Pectenol;<br>
Pectenolone; Pectenoxanthin; Pentaxanthin; Peridinin; Peridininol; Persicachrome;<br>
Persicaxanthin; Phillipsiaxanthin; Philosamiaxanthin; Phleixanthophyll;<br>
Phleixanthophyll palmitate; Phoeniconone; Phoenicopterone; Phoenicoxanihin;<br>
Physalien; Physoxanthin; Phytoene; C (30)-Phytoene; Phytoene l,2-(ep)oxide;<br>
Phytoenol; Phytofluene; Phytofluene epoxide; Phytofluenol; Pigment R; Pigment X;<br>
Pigment Y; Plectaniaxanthin; Poly-cis-gamma-carotene; Poly-cis-psi- carotene; Poly-<br>
cis-lycopene; Prasinoxanthin; Prelycopersene pyrophosphate; Prephytoene<br>
pyrophosphate; Pro-gamma-carotene; Prolycopene; Proneurosporene;<br>
Protetrahydrolycopene; Pseudo-alpha-carotene; Pyrenoxanthin; Pyrrhoxanthin;<br>
Pyrrhoxanthinol;<br>
[0138]	7-cis: Renieracistene; Renierapurpurin; Renieratene; Reticulaxanthin;<br>
Retinylidenetiglic acid; Retrobisdehydro(-beta-) carotene; Retrodehydro(-beta-<br>
)carotene; Retrodehydro-gamma-carotene; Retrodehydrozeaxanthin;<br>
-67-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Rhamnopyranosyloxy-, see Rhamnosyloxy-2'-0- Rhamnosyl-4-ketomyxol; 2'-O-<br>
Rhamnosylmyxol; 3'-Rhamnosyloxy-beta,beta- caroten-3-ol; l-Rhamnosyloxy-3',4'-<br>
didehydro-r,2'-dihydro-beta,psi-carotene; 2'-Rhamnosyloxy-3,4-didehydro-1,2'-<br>
dihydro-beta,psi- carotene-3,1 '-diol; 2'-Rhamnosyloxy-3',4'-didehydro-1 ',2'-dihydro-<br>
beta, psi-carotene-3,4,l'-triol; 1'-Rhamnosyloxy-3',4'-didehydro-1,2'- dihydro-<br>
beta,psi-caroten-3-ol; Rhodoauranxanthin; Rhodopin; Rhodopin(- 20-)al; Rhodopinal<br>
glucoside; Rhodopin glucoside; Rhodopinol; Rhodopurpurin; Rhodotorulene;<br>
Rhodovibrin; Rhodoviolascin; Rhodoxanthin; Roserythrin; Rubichrome; Rubixanthin;<br>
Rubixanthin 5,6-epoxide; Rubixanthone;<br>
[0139]	Salmon acid; Salmoxanthin; Saproxanthin; Sarcinaxantbin; Sarcinaxanthin<br>
diglucoside; Sarcinaxanthin monoglucoside; Sarcinene; 5,6- Seco-beta,beta-carotene-<br>
5,6-dione; 5,6-Seco-beta,[epsi]-carotene-5,6-dione; Semi-alpha-carotenone; Semi-<br>
beta-carotenone; Sidnyaxanthin; Sintaxanthin; Siphonaxanthin; Siphonein; Sodium-<br>
3,19-dihydroxy-7,8-di- dehydro-beta,Chi-carotene-3,6'-dione 3-sulfate; Sodium-3,19-<br>
dihydroxy-3',6'-dioxo-7,8-didehydro-beta,chi-caroten-17'-al 3-sulfate; Sodium-<br>
3,19,3'-trihydroxy-7,8-didehydro-6l-oxo-beta,chi-caroten-17'- oate 3-sulfate; Sodium-<br>
3,19,17'-trihydroxy-7,8-didehydro-beta,chi- carotene-3 ',6'-dione 3-sulfate;<br>
Sphaerobolin; Spheroidene; Spheroidenone; Spirilloxanthin; Sulcatoxanthin;<br>
[0140]	Tangeraxanthin; Taraxanthin; Taraxanthin dipahnitate; Taraxien;<br>
Tareoxanthin; Tedaniaxanthin; Tedanin; Ternstroemiaxanthin; Tethyatene; 7,8,7',8'-<br>
Tetradehydroastaxanthin; 3,4,3,4'-Tetradehydro- beta,beta-carotene; 3,4,3',4'-<br>
Tetradehydro-psi,psi-carotene; 7,8,7',8'-Tetradehydro-beta,beta-carotene-3,3'-diol;<br>
3,4,3',4'- Tetradehydro-beta,beta-carotene-2,2'-dione;3',4',7',8'-Tetradehydro-<br>
beta,beta-caroten-3-ol; 3,4,3',4'Tetradehydrolycopene; 6,7,6,7- Tetradehydro-<br>
5,6,5',6'-tetrahydro-beta,beta-carotene-3,3'-diol;6,7, 6,7'-Tetradehydro-5,6,5,6'-<br>
-68-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
tetrahydro-beta,beta-carotene-3,5,3,5,-tetrol;7,8,7,8'-Tetradehydrozeaxanthin;<br>
3,4,3',4'-Tetradehydrobisanhydrobacterioruberin;5,6,5',6'-Tetrahydrocanthaxanthin;<br>
7,8,7',8'-Tetrahydrocapsorubin; Tetrahydro-beta-carotene; 7,8,7',8'- Tetrahydro-<br>
beta,beta-carotene; 7,8,11,12'-Tetrahydro-beta,psi- carotene; 7',8',11',12'-Tetrahydro-<br>
gamma-carotene; 7',8',11,12- Tetrahydro-gamma,psi-carotene; 1,2,7,8-Tetrahydro-<br>
psi,psi- carotene; l,2,1,2'-Tetrahydro-psi,psi-carotene; 7,8,11,12-Tetrahydro- psi.psi-<br>
carotene; 7,8,7',8'-Tetrahydro-psi,psi-carotene; 5,6,5', 6'-Tetrahydro-beta,beta-<br>
carotene-4,4'-diol; 7,8,7',8'-Tetrahydro- beta,beta-carotene-3,3'-diol; 7,8,9,10'<br>
Tetrahydro-beta,psi- carotene-3,17'-diol; 1,2,1 ',2'-Tetrahydro-psi,psi-carotene-l, 1 '-<br>
diol; 5,6,5',6'-Tetrahydro-beta,beta-carotene-4,4'-dione; 5,6,5',6'- Tetrahydro-<br>
beta,beta-carotene-3,5,6,3',5',6'-hexol; 1,2,7,8- Tetrahydro-psi,psi-caroten-l -ol;<br>
l,2,7',8'-Tetrahydro-psi,psi- caroten-1-ol; 7,8,1 l,12-Tetrahydro-4,4'-diapocarotene;<br>
7,8,7,8'- Tetrahydro-4,4'-diapocarotene; Tetrahydrolycopene; 1,2,1',2'-<br>
Tetrahydrolycopene; 5,6,5',6'-Tetrahydrolycopene; 7,8,11,12- Tetrahydrolycopene;<br>
7,8,7',8'-Tetrahydrolycopene; 7',8',11',12'- Tetrahydrolycopene; 1,2,1',2'-<br>
Tetrahydrolycopene-l.l'-diol; l,2,r,2'- Tetrahydroneurosporene; 3,4,11',12'-<br>
Tetrahydrospheroidene; 3,4,7,8- Tetrahydrospirilloxanthin; 3,4,3',4'-<br>
Tetrahydrospirilloxanthin; 3,4,3',4'- Tetrahydrospirilloxanthin-20-al; 5,6,5',6'-<br>
Tetrahydro-3,4,3',4'-tetrol 4,4'-disulfate; 2,3,2l,3'-Tetrahydroxy-beta,beta-carotene-<br>
4,4'-dione; 2,3,2',3'-Tetrahydroxy-beta,beta-caroten-4-one; 3,19,3',17'- Tetrahydroxy-<br>
beta,chi-caroten-6'-one 3-sulfate; 3,5,3',5'- Tetrahydroxy-6',7'-didehydro-5,8,5',6'-<br>
tetrahydro-beta,beta-caroten-8-one;3,3',5,5'-Tetrahydroxy-6'-hydro-7-dehydro-beta-<br>
carotene; 3,4,3',4'- Tetrahydroxypirardixanthin; 3,4,3',4'-Tetrahydroxy-5,6,5',6'-<br>
tetrahydro- beta,beta-carotene; (3,4,3'4')-Tetraketo-beta-carotene; 4,5,4',5'- Tetraketo-<br>
beta-carotene; Thiottiece-425; Thiothece-460; Thiothece-474; Thiothece-478;<br>
-69-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Thiothece-484; Thiothece-OH-484; Tilefishxanthin I; Tilefishxanthin II;<br>
Tilefishxanthin III; Tilefishxanthin IV; Torularhodin; Torularhodinaldehyde;<br>
Torularhodin methyl ester; Torulenal; Torulene; Torulenecarboxylic acid; 2,3,2'-<br>
Trihydroxy-beta,beta-caroten-4-one;3,3,4,'-Trihydroxy-betajbeta-caroten-4--one;<br>
3,4,3'-Trihydroxy-beta, chi-caroten-6'-one; 3,3l,5'-Trihydroxy-6',7'-dehydro-alpha-<br>
carotene; 3,3',8'-Trihydroxy-7,8-didehydro-beta,chi-carotene-4,6'-dione; 3,3', 8'-<br>
Trihydroxy-7,8-didehydro-beta,chi-caroten-6'-one; 3,19,3'-Trihydroxy-7,8-<br>
didehydro-beta,chi-caroten-6'-one 3-sulfate; 3,1',2'- Trihydroxy-3',4'-didehydro-1,2'-<br>
dihydro-beta,psi-caroten-4-one; 3,5,19-Trihydroxy-6,7-didehydro-5,6,7',8'-<br>
tetrahydro-7'-apo-beta-caroten-8'- one 3-acetate 19-hexanoate; 3,5,6'-Trihydroxy-6,7-<br>
didehydro-5,6,7',8'-tetrahydro-beta,[epsi]-carotene-3',8'-dione;3,5,3'-Trihydroxy-5,6-<br>
dihydro-beta-carotene; 3,3,5'-Trihydroxy-5,6'-dihydro-beta-carotene 5',6-epoxide;<br>
3,19,3'-Trihydroxy-7,8-dihydro-beta,[epsi]-caroten-8-one;3,19,3'-Trihydroxy-7,8-<br>
dihydro-beta,beta-caroten-8-one 19-laurate; 3,6,3'-Trihydroxy-7,8-dihydro-<br>
gamma,[epsi]-caroten-8-one; 3,3',19- Trihydroxy-7,8-dihydro-8-oxo-alpha-carotene;<br>
3,3',6'-Trihydroxy-5,8- epoxy-alpha-carotene; 3,4,4'-Trihydroxypirardixanthin; 1,1',2'-<br>
Trihydroxy-3,4,3',4'-tetradehydro-l,2,r,2'-tetrahydro-psi,psi- caroten-2-one; 3,4,4'-<br>
Trihydroxy-5,6,5',6'-tetrahydro-beta,beta- carotene; Trikentriorhodin; 3,4,4'-Triketo-<br>
beta-carotene; 3,1',2'- Trimethoxy-3,4'-didehydro-1,2 dihydro-beta,psi-caroten-4-<br>
one; Triophaxanthin; Triphasiaxanthin; Trisanhydrobacterioruberin; Trollein;<br>
Trollichrome; Trolliflavin; Trolliflor, Trollixanthin; Tunaxanthin; Uriolide;<br>
Vaucheriaxanthin; Violaxanthin; Violeoxanthin; Violerythrin; Warmingol;<br>
Warmingone; Webbiaxanthin; Xanthophyll; Xanthophyll K (1); Xanthophyll K ( 1)S;<br>
Xanthophyll dipalmitate; Xanthophyll epoxide; alpha-Zeacarotene; beta-Zeacarotene;<br>
beta (1)- Zeacarotene; alpha-Zeacarotene-3,17'-diol; beta-Zeacarotene-3,17'- diol;<br>
-70-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
beta-Zeacaroten-3-ol; Zeaxanthene; Zeaxanthin; Zeaxanthin diepoxide; Zeaxanthin<br>
dimethyl ether; Zeaxanthin dirhamnoside; Zeaxanthin dipahnitate; Zeaxanthin 5,6-<br>
epoxide; Zeaxanthin 5,8-epoxide; Zeaxanthin furanoxide; Zeaxanthin monomethyl<br>
ether; Zeaxanthin monorhamnoside; Zeaxanthol; and Zeinoxanthin.<br>
[0141]	The above list of naturally occurring carotenoids is meant to be a non-limiting<br>
example of naturally occurring carotenoids. This list is not comprehensive as more<br>
naturally occurring molecules are being discovered which will fall within the category<br>
of carotenoids.<br>
Sulfonylureas<br>
[0142]	Non-limiting examples of sulfonylureas include, but are not limited to<br>
acetohexamide, DiaBeta, glibenclamide, gliclazide, glipizide (Glucotrol),<br>
glyclopyramide, chlorpropamide, tolazamide, tolbutamide, glimepiride (Amaryl),<br>
tolbutamide and meglitinide analogues (for example, repaglinide, nateglinide,<br>
meglitmide and mitiglinide (KAD-1229)) and the like.<br>
Niacin and related derivatives<br>
[0143]	The term niacin is the generic descriptor for nicotmic acid (pyridine-3-<br>
carboxylic acid) and its derivatives. Non-limiting examples of nicotinic acid<br>
derivatives include nicofuranose, Acipimox (5-methyl pyrazine-2-carboxylic acid 4-<br>
oxide), niceritrol, probucol, isonicotinic acid, Cholexamin, oxiniacic acid,<br>
nicoclonate, nicomol, NIASPAN, nicerikol and tocopherol nicotinate.<br>
[0144]	Further examples of other active agents which may be suitable for this<br>
invention include, without limitation: abecarnil, acamprostate, acavir, acebutolol,<br>
aceclofenac, acemetacin, acetaminophen, acetaminosalol, acetanilide, acetohexamide,<br>
-71-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
acetophenazine maleate, acetophenazine, acetoxolone, acetoxypregnenolone,<br>
acetretin, acrisorcin, acrivastine, acyclovir, adinazolam, adiphenine hydrochloride,<br>
adrafinil, adrenolone, agatroban, ahnitrine, akatinol, alatrofloxacin, albendazole,<br>
albuterol, aldioxa, alendronate, alfentanil, alibendol, alitretinoin, allopurinol,<br>
allylamines, allylestrenol, alminoprofen, almotriptan, alosetron, aloxiprin, alprazolam,<br>
alprenolol, amantadine, ambucetamide, amidephrine, amidinomycin, amiloride,<br>
aminoaiylcarboxylic acid derivatives, aminoglutethimide, aminoglycosides,<br>
aminopentamide, aminopromazine, aminorex, amiodarone, amiphenazole, amiprilose,<br>
amisulpride, amitriptyline, amlexanox, amlodipine, amodiaquine, amosulalol,<br>
amotriphene, amoxapine, amoxicillin, amphecloral, amphetamine, amphomycin,<br>
amphotericin, ampicillin, ampiroxicam, amprenavir, amrinone, amsacrine, amyl<br>
nitrate, amylobarbitone, anagestone acetate, anastrozole, andinocillin, androstenediol,<br>
androstenediol-17- acetate, androstenediol- 17-benzoate, androstenediol-3-acetate,<br>
androstenediol-3-acetate-17- benzoate, androstenedione, androsterone acetate,<br>
androsterone benzoate, androsterone propionate, androsterone, angiotensin,<br>
anidulatungin, aniracetam, apazone, apicycline, apoatropine, apomorphine,<br>
apraclonidine, aprepitant, aprotinin, arbaprostil, ardeparin, aripiprazole, arnikacin,<br>
arotinolol, arstiinol, arylacetic acid derivatives, arylalkylamines, arylbutyric acid<br>
derivatives, arylcarboxylic acids, arylpiperazines, arylpropionic acid derivatives,<br>
aspirin, astemizole, atenolol, atomoxetine, atorvastatin, atovaquone, atropine,<br>
auranom, azapropazone, azathioprine, azelastine, azetazolamide, azithromycin,<br>
baclofen, bambuterol, bamethan, barbitone, barnidipine, basalazide, beclamide,<br>
beclobrate, befimolol, bemegride, benazepril, bencyclane, bendazac, bendazol,<br>
bendroflumethiazide, benethamine penicillin, benexate hydrochloride, benfurodil<br>
hemisuccinate, benidipine, benorylate, bentazepam, benzhexol, benziodarone,<br>
-72-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
benznidazole, benzoctamine, benzodiazepine derivatives, benzodiazepine,<br>
benzonatate, benzphetamine, benzylmorphine, beperiden, bephenium<br>
hydroxynaphthoate, bepridil, betahistine, betamethasone, betaxolol, bevantolol,<br>
bevonium methyl sulfate, bexarotene, bezadoxifine, bezafibrate, bialamicol,<br>
biapenem, bicalutamide, bietamiverine, bifonazole, binedaline, binifibrate, biricodar,<br>
bisacodyl, bisantrene, bisoprolol, bitolterol, bopindolol, boswellic acid, bradykinin,<br>
bretylium, bromazepam, bromocriptine, bromperidol, brotizolam, brovincamine,<br>
buciclate, bucloxic acid, bucumolol, budralazine, buieniode, bufetolol, buflomedil,<br>
bufuralol, bumetanide, bunitrolol, bupranolol, buprenoiphine, bupropion, buspirone,<br>
busulfan, butalamine, butorphanol, butaverine, butenatme, butidrine hydrochloride,<br>
butobarbitone, butoconazole nitrate, butoconazole, butofilol, butropium bromide,<br>
cabergoline, calcifediol, calcipotriene, calcitriol, caldibine, cambendazole,<br>
camioxirole, camostat, campesterol, camptothecin, candesartan, candoxatril,<br>
capecitabine, caprate, capsaicin, captopril, caiazolol, carbacephems, carbamates,<br>
carbamazepine, carbapenems, carbarsone, Carbatrol, carbenoxolone, carbimazole,<br>
carbromal, carbuterol, carisoprodol, carotenes, caroverine, carteolol, carvedilol,<br>
cefaclor, cefazolin, cefbuperazone, cefepime, cefoselis, ceftibuten, celecoxib,<br>
celiprolol, cephaeline, cephalosporin C, cephalosporins, cephamycins, cerivastatin,<br>
certoparin, cetamolol, cetiedil, cetirizine, cetraxate, chloracizine, chloiambucil,<br>
chlorbetamide, chlordantoin, chlordiazepoxide, chlonnadinone acetate,<br>
chloimetbiazole, chloroquine, chlorothiazide, chlorpheniramine, chlorphenoxamide,<br>
chlorphentermine, chlorproguanil, chlorpromazine, chlorpropamide, chlorprothixene,<br>
chlortetracycline, chlorthalidone, cholecalciferol, chromonar, ciclesonide, ciclonicate,<br>
cidofovir, ciglitazone, cilansetron, cilostazol, cimetidine, cimetropium bromide,<br>
cinepazet maleate, cinnamedrine, cinnarizine, cinolazepam, cinoxacin, ciprofibrate,<br>
-73-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
ciprofloxacin, cisapride, cisplatin, citalopram, citicoline, clarithromycin, clebopride,<br>
clemastine, clenbuterol, clidanac, clinofibrate, clioquinol, clobazam, clobenfurol,<br>
clobenzorex, clofazimine, clofibrate, clofibric acid, cloforex, clomipramine,<br>
clonazepam, clonidine, clonitrate, clopidogrel, clopirac indomethacin, cloranolol,<br>
cloricroraen, clorprenaline, clortermine, clotiazepam,: clotrimazole, cloxacillin,<br>
clozapine, cmepazide, codeine methyl bromide, codeine phosphate, codeine sulfate,<br>
codeine, colloidal bismuth subcitrate, cromafiban, cromolyn, cropropamide,<br>
crotethamide, curcumin, cyclandelate, cyclarbamate, cyclazocine, cyclexedrine,<br>
cyclizine, cyclobenzaprine, cyclodrine, cyclonium iodide, cyclopentamine,<br>
cyclosporin, cypionate, cyproheptadine, cyproterone acetate, cytarabine, dacarbazine,<br>
dalfopristine, dantrolene sodium, dapiprazole, darodipine, decanoate, decitabine,<br>
decoquinate, dehydroemetine, delavirdine, delaviridine, demeclo cycline,<br>
denopamine, deramciclone, descitalopram, desipramine, desloratadine, 3-<br>
ketodesogeskel, desomorphine, desoxymethasone, detomidine, dexamphetamine,<br>
dexanabinol, dexchlorpheniramine, dexfenfluramine, dexmethylphenidate,<br>
dexrazoxane, dextroamphetamine sulfate, dextroamphetamine, dextropropoxyphene,<br>
DHEA, diacetate, diamoiphine, diazemine, diazepam, diaziquinone, diazoxide,<br>
dibromopropamidine, dichlorophen, diclofenac, dicoumaiol, didanosine,<br>
dideoxyadenosine, diethylpropion, difemerine, difenamizole, diflunisal, digitoxin,<br>
digoxin, dihydroergotamine, dihydrocodeine, dihydrocodeinone enol acetate,<br>
dihydroergotamine mesylate, dihydroergotamine, dihydrogesterone,<br>
dihydromorphine, dihydropyridine derivatives, dihydrostreptomycin,<br>
dihydrotachysterol, dihydroxyaluminum acetylsalicylate, diiodohydroxyquinoline,<br>
diisopromine, dilazep, dilevalol, diltiazem, diloxanide furoate, diloxanide, diltiazem,<br>
dimefline, dimenhydrinate, dimethisterone, dimetotrine, dimorpholamine,<br>
-74-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
dinitolmide, dioxaphetyl butyrate, dioxethedrine, diphemethoxidine,<br>
diphenhydramine, diphenoxylate, diphetarsone, dipivefrin, diponium bromide,<br>
dipyridamole, dirithromycin, disopyramide, divalproex sodium, dofetilide,<br>
domperidone, donepezil, dopexamine, dopradil, dosmalfate, doxapratn, doxazosin,<br>
doxefazepam, doxepin, doxycycline, drofenine, dromostanolone propionate,<br>
dromostanolone, dronabinol, droperidol, droprenilamine, d-threo -methylphenidate,<br>
duloxetine, ebrotidine, ebumamonine, ecabet, ecenofloxacin, econazole nitrate,<br>
edavarone, edoxudine, efavirenz, effivarenz, efloxate, eledoisin, eletriptan,<br>
elgodipine, ellipticine, emepronium bromide, emetine, enalapril, enanthate, encainide,<br>
enlopitat, enoximone, enprostil, entacapone, epanolol, ephedrine, epinastine,<br>
epinephrine, epirubicin, eplerenone, eprosartan, ergocalciferol, ergoloid mesylates,<br>
ergotamine, ertapenmn, erythromycin, erytlirityl tetranitrate, esaprazole, escitalopram,<br>
esmolol, esomeprazole, esonarimod, estazolam, estradiol benzoate, estramustine,<br>
eskiol succinate, estrone acetate, estrone sulfate, etafedrine, etafenone, ethacrynic<br>
acid, ethamivan, ethinamate, ethinyleskadiol 3-acetate, ethinyleskadiol 3-benzoate,<br>
ethinylestradiol, ethionamide, ethisterone (17a-ethinyltestosterone), ethopropazine,<br>
ethotoin, ethoxyphenamine, ethylestrenol, ethylmorphine, ethylnorepinephrine,<br>
ethynodiol diacetate, etodolac, etofibrate, etoposide, etoricoxib, etretinate, everolimus,<br>
exalamide, examestane, examorelin, ezemitibe, falecalcitriol, famciclovir, famotidine,<br>
fantofarone, farapenum, farglitazar, fasudil, felbamate, felodipine, fenalamide,<br>
fenbuLen, fenbutrazate, fendiline, fenfluramine, fenoldopam, fenoprofen, fenoterol,<br>
fenoverine, fenoxazoline, fenoxedil, fenpiprane, fenproporex, fenspiride, fentanyl,<br>
fexofenadine, flavoxate, flecainide, flopropione, floredil, floxuridine, fluconazole,<br>
flucytosine, fludarabine, fludiazepam, fludrocortisone, flulenamic acid, flunanisone,<br>
flunarizine, flunisolide, flunitrazepam, fluocortolone, fluoxetine, flupentbixol<br>
-75-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
decanoate, fluphenazine decanoate, fluphenazine enanthate, fluphenazine,<br>
fluproquazone, flurazepam, flurbiprofen, flurogestone acetate, fluticasone propionate,<br>
fluvastatin, fluvoxamine, fominoben, fonnoterol, foscarnet, foscarnet, fosinopril,<br>
fosphenytoin, frovatriptan, fudosteine, fumagillin, furazolidone, furazolidone,<br>
furfurylmethyl amphetamine, furosemide, gabapentin, gabexate, gaboxadol,<br>
galanthamine, gallopamil, gammaparin, ganciclovir, ganglefene, gefamate,<br>
gemcitabine, gemfibrozil, gepirone, gestadene, ghrelin, glatiramer, glaucarabin,<br>
glibenclamide, gliclazide, glimepiride, glipizide, gluconic acid, glutamic acid,<br>
glyburide, glyceryl trinitrate, glimepiride, granisetron, grepafloxacin, griseofulvin,<br>
guaiazulene, guanabenz, guanfacine, halofankine, haloperidol decanoate, haloperidol,<br>
haloxazolam, hepronicate, heptanoate, hexobendine, hexoprenaline, hydramitrazine,<br>
hydrazides, hydrocodone, hydrocortisone, hydromorphone, hydroxyamphetamine,<br>
hydroxymethylprogesterone acetate, hydroxymethylprogesterone,<br>
hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxyprogesterone,<br>
hymecromone, hyoscyamine, ibopamine, ibudilast, ibutenac, ibuprofen, ibutilide,<br>
idoxuridine, ifenprodil, igmesine, iloprost, imatinib, imidapril, imidazoles, imipenem,<br>
imipramine, imolamine, incadronic acid pergolide, indanazoline, indenolol, indinavir,<br>
indomethacin, indoramin, inosine pranobex, inositol niacinate, iodoquinol, ipidracine,<br>
iproniazid, irbesartan, irinotecan, irsogladine, isobutyrate, isocaprate esters,<br>
isoetharine, isometheptene, isoproterenol, isosorbide dinitrate, isosorbide mononitrate,<br>
isosorbide dinitrate, isoxsuprine, isradipine, itasetron, itraconazole, itramintosylate,<br>
ivermectin, kallidin, kallikrein, kanamycin, ketarnine, ketoconazole, ketoprofen,<br>
ketorolac, ketotifen, labetalol, lafutidine, lamifiban, lamivudine, lamotrigine,<br>
lanatoside c, lansoprazole, lasofoxifene, leflunomide, leminoprazole, lercanidipine,<br>
lesopitron, letrozole, leucovorin, levalbuterol, levallorphan, levetiracetam,<br>
-76-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
levetriacetam, levobunolol, levodopa, levofloxacin, levophacetoperane, levorphanol,<br>
lidocaine, lidoflazine, lifibrol, limaprost, linezolid, lintitript, liranaftate, lisinopril,<br>
lisuride, lobeline, lobucavir, lodoxamide, lomefloxacin, lomerizine, lomustine,<br>
loperamide, lopinavir, loprazolam, loracarbef, loratadine, lorazepam, lorefloxacin,<br>
lonnetazepam, losartan, lovastatin, lovastatin, loxapine succinate, loxapine, 1-threo<br>
methylphenidate, lumiracoxib, lysine acetylsalicylate, lysozyme, lisuride, mabuterol,<br>
mafenide, magnesium acetylsalicylate, malgramostin, mannitol hexanitrate,<br>
maprotiline, mazindol, mebendazole, meclizine, meclofenamic acid,<br>
mecloxaminepentapiperide, medazepam, medibazine, medigoxin, medrogestone,<br>
medroxyprogesterone acetate, mefenamic acid, mefenorex, mefloquin, mefloquine,<br>
megestrol acetate, melengestrol acetate, melphalan, memantine, mepenzolate<br>
bromide, meperidine, mephenoxalone, mephentermine, mepindolol, mepixanox,<br>
meprobamate, meptazinol, mercaptopurine, meropenum, mesalamine, mesalazine,<br>
mesoridazine besylate, mesoridazine, metaclazepam, metamfepramone,<br>
metampicillin, metaproterenol, metaraminol, methacycline, methadone hydrochloride,<br>
methadone, methamphetamine, methaqualone, methamphetamine, methoin,<br>
methotrexate, methoxamine, methsuximide, methylhexaneamine, methylphenidate d-<br>
threo-methylphenidate, methylphenidate, methylphenobarbitone, methylprednisolone,<br>
methysergide, metiazinic acid, metizoline, metoclopramide, metolazone, metoprolol,<br>
metoxalone, metripranolol, metronidazole, mexiletine, metaxalone, mianserin,<br>
mibefradil, miconazole, midazolam, midodrine, miglitol, milnacipran, milrinone,<br>
minoxidil, mirtazapine, misoprostol, mitomycin, mitotane, mitoxantrone, mizolastine,<br>
modafinil, mofebutazone, mofetil, molindone hydrochloride, molindone,<br>
molsidomine, monatepil, montelukast, Monteplase, moprolol, moricizine, morphine<br>
hydrochloride, morphine sulfate, morphine, morpholine salicylate, mosapramine,<br>
-77-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
moxifloxacin, moxisylyte, moxonidine, mycophenolate, nabumetone, nadolol,<br>
nadoxolol, nadroparin, nafamostat, nafronyl, naftopidil, nalbuphine, nalidixic acid,<br>
nalmefene, naloipbine, naloxone, naltrexone, nandrolone benzoate, nandrolone<br>
cyclohexanecarboxylate, nandrolone cyclohexane-propionate, nandrolone decanoate,<br>
nandrolone furylpropionate, nandrolone phenpropionate, naphazoline, naproxen,<br>
naratriptan, natamycin, nateglinide, nedocromil, nefazodone, nefopam, nelfinavir,<br>
nemonapride, neomycin undecylenate, neomycin, neokofin, nesiritide, n-<br>
ethylamphetamine, nevirapine, nexopamil, nicametate, nicardipine, nicergoline,<br>
nicofibrate, nicofuranose, nicomorphine, nicorandil, nicotinyl alcohol, nicoumalone,<br>
nifedipine, nifenalol, nikeihamide, nilutamide, nilvadipine, nimodipine, nimorazole,<br>
nipradilol, nisoldipine, nitisonone, nitrazepam, nitrofurantoin, nitrofiirazone,<br>
nitroglycerin, nizatidine, norastemizole, norepinepbrine, norethynodrel, norfenefrine,<br>
norfloxacin, norgestimate, norgeskel, norgestrienone, normethadone, normethisterone,<br>
normorphine, norpseudoephedrine, nortriptyline, novantrone, nylidrin, nystatin,<br>
octamylamine, octodrine, octopamine, ofloxacin, olanzapine, olanzapine, olapatadine,<br>
olmesartan, Olapatadine, olsalazine, omapatrilat, omeprazole, ondansetron, opium,<br>
oprevelkin, orlistat, ornidazole, ornoprostil, oseltamivir, oxaliplatin, oxamniquine,<br>
oxandrolone, oxantel embonate, oxaprozin, oxatomide pemirolast, oxatomide,<br>
oxazepam, oxcarbazepine, oxfendazole, oxiconazole, oxiracetam, oxolinic acid,<br>
oxprenolol, oxycodone, oxyfedrine, oxymetazoline, oxymorphone, oxypheributazone,<br>
oxyphencyclimine, ozagrel, paclitaxel, palonosetron, pantoprazole, papaverine,<br>
paricalcitol, paramethadione, parecoxib, pariprazole, paromomycin, paroxetine,<br>
parsalmide, pazinaclone, pemoline, penbutolol, penciclovir, penicillin G benzathine,<br>
penicillin G procaine, penicillin V, penicillins, pentaeryfhritol tetranitrate,<br>
pentaerythritol tetranitrate, pentapiperide, pentazocine, pentifylline, pentigetide,<br>
-78-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
pentobarbitone, pentorex, pentoxifylline, pentrinitrol, pirbuterol, pirenzepine,<br>
pergolide, perhexiline, perindopril erbumine, perospone, perphenazine pimozide,<br>
peiphenazine, phanquinone, phenacemide, phenacetin, phenazopyridine,<br>
phencarbamide, phendimetrazine, phenelzine, phenindione, phenmetrazine,<br>
phenobarbitone, phenoperidine, phenothiazines, phenoxybenzamine, phensuximide,<br>
phentermine, phentolamine, phenylsalicylate, phenylacetate, phenylbutazone,<br>
phenylephrine hydrochloride, phenylpropanolamine hydrocbloride,<br>
phenylpropanolamine hydrochloride, phenylpropyl-methylamine, phenytoin,<br>
phloroglucinol, pholedrine, physostigmine salicylate, physostigmine, phytonadiol,<br>
phytosterols, piapenum, picilorex, piclamilast, picrotoxin, picumast, pifarnine,<br>
pilsicainide, pimagedine, pimeclone, pimecrolimus, pimefylline, pimozide,<br>
pinaverium bromide, pindolol, pioglitazone, piperacillin, piperazine estrone sulfate,<br>
piperazine derivatives, piperilate, piracetam, piribedil, pirifibrate, piroxicam,<br>
pitavastatin, pizotyline, plaunotol, polaprezinc, polybenzarsol, polyestrol phosphate,<br>
practolol, prahiacasan, pramipexole, pranlukast, pravastatin, prazepam, praziquantel,<br>
prazosin, pregabalin, prenalterol, prenylamine, pridinol, prifinium bromide,<br>
primidone, primipramine, probenecid, probucol, procainamide, procarbazine,<br>
procaterol, prochlorperazine, proguanil, pronefhalol, propafenone, propamidine,<br>
propatyl nitrate, propentoffyline, propionate, propiram, propoxyphene, propranolol,<br>
propylhexedrine, propylthiouracil, protokylol, protriptyline, proxazole,<br>
pseudoephedrine, purines, pyrantel embonate, pyrazoles, pyrazolones, pyridofylline,<br>
pyrimethamine, pyrimidines, pyrrolidones, quazepam, quetiapine, quetuapine,<br>
quinagolide, quinapril, quinestrol, quinfamide, quinidine, quinine sulfate, quinolones,<br>
quinupritin, rabalzotan, rabeprazole sodium, rabeprazole, racefimine, ramahroban,<br>
ramipril, ranitidine, ranolazine, ransoprazole, rasagiline, rebamipide, refludan,<br>
-79-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
repaglinide, repinotan, repirinast, reproterol, reserpine, retinoids, ribavirin, rifabutine,<br>
rifampicin, rifapentine, rilmenidine, riluzole, rimantadine, rimiterol, rioprostil,<br>
risperidone, ritanovir, ritapentine, ritipenem, ritodrine, ritonavir, rivastigrnine,<br>
rizatriptan, rociverine, rofecoxib, rohypnol, rolipram, remoxipride, ronifibrate,<br>
ropinirole, ropivacaine, rosaprostol, rosiglitazone, rosuvastatin, rotinolol, rotraxate,<br>
roxatidine acetate, roxindole, rubitecan, salacetamide, salicin, salicylamide, salicylic<br>
acid derivatives, salmeterol, saquinavir, saquinavir, scopolamine, secnidazole,<br>
selegiline, semotiadil, sertindole, sertraline, sibutramine, sildenafil, simvastatin,<br>
siramesine, sirolimus, sitaxsentan, sofalcone, somotiadil, sorivudine, sotalol,<br>
soterenol, sparfloxacin, spasmolytol, spectinomycin, spiramycin, spizofurone,<br>
stavudine, streptomycin, succinylsulfathiazole, sucralfate, sufentanil, sulconazole<br>
nitrate, sulfacetamide, sulfadiazine, sulfaloxicacid, sulfarside, sulfmalol, sulindac,<br>
suloctidil, sulphabenzamide, sulphacetamide, sulphadiazine, sulphadoxine,<br>
sulphafurazole, sulphamerazine, sulphamethoxazole, sulphapyridine, sulphasalazine,<br>
sulphinpyrazone, sulpiride, sulthiame, sultopride, sulbroponium, sumanirole,<br>
sumahriptan, sunepihon, superoxide dismutase, suplatast, suramin sodium,<br>
synephrine, tacrine, tacrolimus, tacrolimus, tadalafil, talinolol, talipexole, tamoxifen,<br>
tamsulosin, targretin, tazanolast, tazarotene, tazobactam, tecastimezole, teclozan,<br>
tedisamil, tegaserod, telenzepine, telmisartan, temazepam, teniposide, teprenone,<br>
terazosin, terbinafine, terbinafine, terbutaline sulfete, terbutaline, terconazole,<br>
terfenadine, terodiline, terofenamate, tertatolol, testolactone, 4-dihydrotestosterone,<br>
tetracyclics, tetracycline, tetrahydrocannabinol, tetrahydrozoline, thalidomide,<br>
theofibrate, thiabendazole, thiazinecarboxamides, thiocarbamates, thiocarbamizine,<br>
thiocarbarsone, thioridazine, thiothixene, tiagabine, tiamenidine, tianeptine,<br>
tiaprofenic acid, tiaramide, ticlopidine, tigloidine, tilisolol, timolol, tinidazole,<br>
-80-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
tinofedrine, tinzaparin, tioconazole, tipranavir, tirapazamine, tirofiban, tiropramide,<br>
titanicene, tizanadine, tizanidine, tizinadine, tocainide, tolazamide, tolazoline,<br>
tolbutamide, tolcapone, tolciclate, tolfenamic acid, toliprolol, tolteridine, tolterodine,<br>
tonaberstat, topiramate, topotecan, torsemide, toremifene cibrate, toremifene,<br>
tosufloxacin, tramadol, tramazoline, trandolapril, tranilast, tranylcypromine, trapidil,<br>
traxanox, trazodone, tretoquinol, triacetin, triamcinolone, triamterine, triamterene,<br>
triazolam, trifluoperazine hydrochloride, trifluoperazine, triflupromazine,<br>
trihexyphenidyl, trimazosin, trimebutine, trimetazidine, trimethoprim, trimgestone,<br>
trimipramine, trimoprostil, trithiozine, troglitazone, trolnibrate phosphate,<br>
tromethamine, tropicamide, trovafloxacin, troxipide, tuaminoheptane, tulobuterol,<br>
tymazoline, tyramine, undecanoate, undecenoic acid, urinastatin, valacyclovir,<br>
valdecoxib, valerate, valganciclovir, valproic acid, valsartan, vancomycin, vardenafil,<br>
venlafaxine, venorelbine, verapamil, vidarabine, vigabakin, vincamine, vinpocetine,<br>
viomycin, viquidil, visnadine, vitamin a derivatives, vitamin a, vitamin b2, vitamin d,<br>
vitamin e, vitamin k, voglibose, voriconazole, xaliproden, xamoterol, xanthinol<br>
niacinate, xenytropium bromide, xibenolol, ximelagatran, xylometazoline, yohimbine,<br>
zacopride, zafirlukast, zalcitabine, zaleplon, zanamivir, zatebradine, ziconotide,<br>
zidovudine, zileuton, zimeldine, zinc propionate, ziprasidone, zolimidine,<br>
zolmitriptan, zolpidem, zonisamide, zopiclone, and mixtures thereof.<br>
Formulation<br>
[0145]	The nebivolol compositions of the present invention may be administered by<br>
various means, depending on their intended use, as is well known in the art. For<br>
example, if compositions of the present invention are to be administered orally, they<br>
may be formulated as tablets, capsules, granules, powders, suspensions or syrups.<br>
-81-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Alternatively, formulations of the present invention may be administered parenterally<br>
as injections (intravenous, intramuscular or subcutaneous), drop infusion preparations<br>
or suppositories. For application by the ophthalmic mucous membrane route,<br>
compositions of the present invention may be formulated as eyedrops or eye<br>
ointments. These formulations may be prepared by conventional means, and, if<br>
desired, the compositions may be mixed with any conventional additive, such as an<br>
excipient, a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing<br>
agent, a suspension aid, an emulsifying agent or a coating agent.<br>
[0146]	In formulations of the subject invention, wetting agents, emulsifiers and<br>
lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring<br>
agents, release agents, coating agents, sweetening, flavoring and perfuming agents,<br>
preservatives and antioxidants may be present in the formulated agents.<br>
[0147]	Subject compositions may be suitable for oral, nasal, topical (including buccal<br>
and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The<br>
formulations may conveniently be presented in unit dosage form and may be prepared<br>
by any methods well known in the art of pharmacy. The amount of composition that<br>
may be combined with a carrier material to produce a single dose vary depending<br>
upon the subject being treated, and the particular mode of administration.<br>
[0148]	Methods of preparing these formulations include the step of bringing into<br>
association compositions of the present invention with the carrier and, optionally, one<br>
or more accessory ingredients. In general, the formulations are prepared by uniformly<br>
and intimately bringing into association agents with liquid carriers, or finely divided<br>
solid carriers, or both, and then, if necessary, shaping the product.<br>
-82-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0149]	Formulations suitable for oral administration may be in the form of capsules,<br>
cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or<br>
tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-<br>
aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or<br>
syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and<br>
acacia), each containing a predetermined amount of a subject composition thereof as<br>
an active ingredient Compositions of the present invention may also be administered<br>
as a bolus, electuary, or paste.<br>
[0150]	In solid dosage forms for oral administration (capsules, tablets, pills, dragees,<br>
powders, granules and the like), the subject composition is mixed with one or more<br>
pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate,<br>
and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose,<br>
glucose, mannitol, and/or silicic acid; (2) binders, such as, for example,<br>
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or<br>
acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar,<br>
calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium<br>
carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators,<br>
such as quaternary ammonium compounds; (7) wetting agents, such as, for example,<br>
acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite<br>
clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid<br>
polyethylene glycols, sodium lauryl sulfete, and mixtures thereof; and (10) coloring<br>
agents. In the case of capsules, tablets and pills, the compositions may also comprise<br>
buffering agents. Solid compositions of a similar type may also be employed as<br>
fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk<br>
sugars, as well as high molecular weight polyethylene glycols and the like.<br>
-83-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0151]	A tablet may be made by compression or molding, optionally with one or<br>
more accessory ingredients. Compressed tablets may be prepared using binder (for<br>
example, gelatin or hydroxypropyl methyl cellulose), lubricant, inert diluent,<br>
preservative, disintegrant (for example, sodium starch glycolate or cross-linked<br>
sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets<br>
may be made by molding in a suitable machine a mixture of the subject composition<br>
moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as<br>
dragees, capsules, pills and granules, may optionally be scored or prepared with<br>
coatings and shells, such as enteric coatings and other coatings well known in the<br>
pharmaceutical-formulating art.<br>
[0152]	Liquid dosage forms for oral administration include pharmaceutically<br>
acceptable emulsions, microemulsion, solutions, suspensions, syrups and elixirs. In<br>
addition to the subject composition, the liquid dosage forms may contain inert<br>
diluents commonly used in the art, such as, for example, water or other solvents,<br>
solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl<br>
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-<br>
butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor<br>
and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty.<br>
Suspensions, in addition to the subject composition, may contain suspending agents<br>
such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and<br>
sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-<br>
agar and tragacanth, and mixtures thereof.<br>
[0153]	Formulations for rectal or vaginal administration may be presented as a<br>
suppository, which may be prepared by mixing a subject composition with one or<br>
-84-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
more suitable non-irritating excipients or carriers comprising, for example, cocoa<br>
butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at<br>
room temperature, but liquid at body temperature and, therefore, will melt in the body<br>
cavity and release the active agent. Formulations which are suitable for vaginal<br>
administration also include pessaries, tampons, creams, gels, pastes, foams or spray<br>
formulations containing such carriers as are known in the art to be appropriate.<br>
[0154]	Dosage forms for transdermal administration of a subject composition<br>
includes powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches<br>
and inhalants. The active component may be mixed under sterile conditions with a<br>
pharmaceutically acceptable carrier, and with any preservatives, buffers, or<br>
propellants which may be required.<br>
[0155]	The ointments, pastes, creams and gels may contain, in addition to a subject<br>
composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins,<br>
starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites,<br>
silicic acid, talc and zinc oxide, or mixtures thereof.<br>
[0156]	Powders and sprays may contain, in addition to a subject composition,<br>
excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates<br>
and polyamide powder, or mixtures of these substances. Sprays may additionally<br>
contain customary propellants, such as chlorofluorohydrocarbons and volatile<br>
unsubstituted hydrocarbons, such as butane and propane.<br>
[0157]	Compositions of the present invention may alternatively be administered by<br>
aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation<br>
or solid particles containing the compound(s). A non-aqueous (e.g., fluorocarbon<br>
propellant) suspension could be used. Sonic nebulizers may be used because they<br>
-85-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
minimize exposing the agent to shear, which may result in degradation of the<br>
compounds contained in the subject compositions.<br>
[0158]	Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or<br>
suspension of a subject composition together with conventional pharmaceutically<br>
acceptable carriers and stabilizers. The carriers and stabilizers vary with the<br>
requirements of the particular subject composition, but typically include non-ionic<br>
surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like<br>
serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine,<br>
buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic<br>
solutions.<br>
[0159]	Pharmaceutical compositions of this invention suitable for parenteral<br>
administration comprise a subject composition in combination with one or more<br>
pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions,<br>
dispersions, suspensions or emulsions, or sterile powders which may be reconstituted<br>
into sterile injectable solutions or dispersions just prior to use, which may contain<br>
antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with<br>
the blood of the intended recipient or suspending or thickening agents.<br>
[0160]	Examples of suitable aqueous and non-aqueous carriers which may be<br>
employed in the pharmaceutical compositions of the invention include water, ethanol,<br>
polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and<br>
suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic<br>
esters, such as ethyl oleate. Proper fluidity may be maintained, for example, by the<br>
use of coating materials, such as lecithin, by the maintenance of the required particle<br>
size in the case of dispersions, and by the use of surfactants.<br>
-86-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0161]	Pharmaceutical formulations may also be extended or delayed release<br>
formulations where the active agents are released over an extended period of time.<br>
Dosages<br>
[0162]	Administration of the compositions of the present invention will be in an<br>
amount sufficient to achieve a therapeutic effect as recognized by one of ordinary<br>
skill in the art.<br>
[0163]	The dosage of any compositions of the present invention will vary depending<br>
on the symptoms, age and body weight of the patient, the nature and severity of the<br>
disorder to be treated or prevented, the route of administration, and the form of the<br>
subject composition. Any of the subject formulations may be administered in a single<br>
dose or in divided doses. Dosages for the compositions of the present invention may<br>
be readily determined by techniques known to those of skill in the art or as taught<br>
herein.<br>
[0164]	The dosage range for nebivolol ranges from about 0.1 mg to about 100 mg per<br>
day. In another embodiment, the dosage range may be from about 0.75 mg to about<br>
50 mg per day. In yet another embodiment, the dosage range may be from about 1.25<br>
mg to about 10 mg per day.<br>
[0165]	In certain embodiments, the dosage of the co-active compounds will generally<br>
be in the range of about 0.01 ng to about 1 g per kg body weight, specifically in the<br>
range of about 1 ng to about 0.1 g per kg, and more specifically in the range of about<br>
100 ng to about 10 mg per kg body weight.<br>
[0166]	An effective dose or amount, and any possible affects on the timing of<br>
administration of the formulation, may need to be identified for any particular<br>
-87-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
composition of the present invention. This may be accomplished by routine<br>
experiment as described herein, using one or more groups of animals (preferably at<br>
least 5 animals per group), or in human trials if appropriate. The effectiveness of any<br>
subject composition and method of treatment or prevention may be assessed by<br>
administering the composition and assessing the effect of the administration by<br>
measuring one or more applicable indices, and comparing the post-treatment values of<br>
these indices to the values of the same indices prior to treatment.<br>
[0167]	The precise time of administration and amount of any particular subject<br>
composition that will yield the most effective treatment in a given patient will depend<br>
upon the activity, pharmacokinetics, and bioavailability of a subject composition,<br>
physiological condition of the patient (including age, sex, disease type and stage,<br>
general physical condition, responsiveness to a given dosage and type of medication),<br>
route of administration, and the like. The guidelines presented herein may be used to<br>
optimize the treatment, e.g., determining the optimum time and/or amount of<br>
administration, which will require no more man routine experimentation consisting of<br>
monitoring the subject and adjusting the dosage and/or timing.<br>
[0168]	While the subject is being treated, the health of the patient may be monitored<br>
by measuring one or more of the relevant indices at predetermined times during the<br>
treatment period. Treatment, including composition, amounts, times of administration<br>
and formulation, may be optimized according to the results of such monitoring. The<br>
patient may be periodically reevaluated to determine the extent of improvement by<br>
measuring the same parameters. Adjustments to the amount(s) of subject composition<br>
administered and possibly to the time of administration may be made based on these<br>
reevaluations.<br>
-88-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
[0169]	Treatment may be initiated with smaller dosages which are less than the<br>
optimum dose of the compound. Thereafter, the dosage may be increased by small<br>
increments until the optimum therapeutic effect is attained.<br>
[0170]	The use of the subject compositions may reduce the required dosage for any<br>
individual agent contained in the compositions (e.g., the steroidal anti inflammatory<br>
drug) because the onset and duration of effect of the different agents may be<br>
complimentary.<br>
[0171]	Toxicity and therapeutic efficacy of subject compositions may be determined<br>
by standard pharmaceutical procedures in cell cultures or experimental animals, e.g.,<br>
for determining the LD50 and the ED50.<br>
[0172]	The data obtained from the cell culture assays and animal studies may be used<br>
in formulating a range of dosage for use in humans. The dosage of any subject<br>
composition lies preferably within a range of circulating concentrations that include<br>
the ED50 with little or no toxicity. The dosage may vary within this range depending<br>
upon the dosage form employed and the route of administration utilized. For<br>
compositions of the present invention, the therapeutically effective dose may be<br>
estimated initially from cell culture assays.<br>
[0173]	In general, the doses of an active agent will be chosen by a physician based on<br>
the age, physical condition, weight and other factors known in the medical arts.<br>
-89-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Efficacy of treatment<br>
[0174]	The efficacy of treatment with the subject compositions may be determined in<br>
a number of fashions known to those of skill in the art.<br>
[0175]	In one exemplary method, the median rate of decrease in inflammation for<br>
treatment with a subject composition may be compared to other forms of treatment<br>
with the particular cardiovascular agent contained in the subject composition, or with<br>
other cardiovascular agents. The decrease in inflammation for treatment with a<br>
subject composition as compared to treatment with another method may be 10,25, 50,<br>
75,100,150,200,300,400% greater or even more. The period of time for observing<br>
any such decrease may be about 1,3,5,10,15,30,60 or 90 or more hours. The<br>
comparison may be made against treatment with the particular cardiovascular agent<br>
contained in the subject composition, or with other cardiovascular agents, or<br>
administration of the same or different agents by a different method, or administration<br>
as part of a different drug delivery device than a subject composition. The<br>
comparison may be made against the same or a different effective dosage of the<br>
various agents.<br>
[0176]	Alternatively, a comparison of the different treatment regimens described<br>
above may be based on the effectiveness of the treatment, using standard indices<br>
known to those of skill in the art. One method of treatment may be 10%, 20%, 30%,<br>
50%, 75%, 100%, 150%, 200%, 300% more effective, than another method.<br>
[0177]	Alternatively, the different treatment regimens may be analyzed by comparing<br>
the therapeutic index for each of them, with treatment with a subject composition as<br>
-90-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
compared to another regimen having a therapeutic index two, three, five or seven<br>
times that of, or even one, two, three or more orders of magnitude greater than,<br>
treatment with another method using the same or different cardiovascular agents.<br>
Kits<br>
[0178]	This invention also provides kits for conveniently and effectively<br>
implementing the methods of this invention. Such kits comprise any subject<br>
composition, and a means for facilitating compliance with methods of this invention.<br>
Such kits provide a convenient and effective means for assuring mat the subject to be<br>
treated takes the appropriate active in the correct dosage in the correct manner. The<br>
compliance means of such kits includes any means which facilitates administering the<br>
actives according to a method of this invention. Such compliance means include<br>
instructions, packaging, and dispensing means, and combinations thereof. Kit<br>
components may be packaged for either manual or partially or wholly automated<br>
practice of the foregoing methods. In other embodiments involving kits, this<br>
invention contemplates a kit including compositions of the present invention, and<br>
optionally instructions for their use.<br>
Exemplification<br>
Example 1<br>
Measurements of NO Release from Human Endothelium<br>
[0179]	All measurements presented were recorded in vitro using a sensitive<br>
porphyrinic probe, as previously described. Malinski T, Taha Z., Nature.<br>
1992;358:676-678; Malinski T, Czuchajowski L, Methods in Nitric Oxide Research.<br>
1996:319-339. NO release was measured directly from HUVEC. HUVEC cells from<br>
Black and White donors were grown in Ham's F12K medium with 2 mM L-glutamine<br>
-91-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
adjusted to contain 1.5g/L sodium bicarbonate and supplemented with 0.1 mg/ml<br>
heparin and 0.03-0.05mg/ml endothelial cell growth supplement (ECGS) + 10% fetal<br>
bovine serum. The HUVEC cells were kept in an atmosphere of elevated CO2<br>
concentration (5%). Nebivolol was obtained from Mylan Laboratories (Morgantown,<br>
WV).<br>
[0180]	All measurements of endothelial NO release were conducted in Hank's<br>
balance solution at 37°C. Cell wells were transferred to a Faraday cage and a<br>
porphyrinic sensor (diameter 0.5mm) was positioned at a distance of 5±2um from the<br>
surface of the endothelial cells using an inverted microscope (Leica Microsystems,<br>
Wetzlar, Germany) and a computer-assisted micromanipulator. The sensor operated<br>
with a three-electrode system: nanosensor (working electrode), saturated calomel<br>
electrode (reference electrode) and platinum wire (counter electrode, 0.5mm<br>
diameter). The three electrodes were connected to a potentiostat/galvanostat PAR273.<br>
The baseline was stabilized after about 20 seconds. The test compounds were injected<br>
with a nanoinjector onto the surface of the cells following solubilization in buffer.<br>
Cells were incubated with the test compounds for a 24-hour period. The compounds<br>
were then washed out of the system before being immediately reintroduced in order to<br>
evaluate the consequences of chronic treatment on NO release from the cells. For<br>
additive experiments, cells were incubated with ACE inhibitor for 24 hours, the<br>
inhibitor was washed out of the system, nebivolol was added and the NO release<br>
measured. The current proportional to the NO concentration was measured with the<br>
sensor, which operated in amperometric mode at a constant potential of 0.63V. Data<br>
were acquired with the use of an IBM computer with custom software and<br>
amperograms (current vs. time curves) were recorded with a Guniry FAS1 Femtostat<br>
(Warminster, PA). Maximum release of NO was produced using a calcium agonist<br>
-92-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
(1μM). By increasing cytoplasmic levels of calcium, the ion can bind to calmodulin.<br>
The Ca2+-calmodulin complex is a cofactor for endothelial NO synthase, along with<br>
FAD, FMN, Heme and BH4.<br>
[0181]	Nanosensors were prepared from carbon fibers. The size of the tip of carbon<br>
fiber was reduced from 6um to less than 1 um by temperature controlled burning. The<br>
sensors were sensitized to NO by deposition of electrically conductive polymeric<br>
porphyrin and covered with a thin layer of Nation. The porphyrinic microsensor has a<br>
response time of 0.1 ms at a micromolar NO concentration and 10 ms at the detection<br>
limit of 1 nM.<br>
[0182]	The nanosensor for NO was calibrated using saturated solution (concentration<br>
1.82 mM verified with the coulometric method). Linear calibration curves were<br>
constructed for each sensor from 5 x 10-9 to 3 x l0-6M NO before and after<br>
measurements of cell activity. The concentration-dependent effects of nebivolol and<br>
certain ACE-inhibitors on NO releasing capacity were tested using a calcium<br>
ionophore (A23187) that stimulates NO release, independently of G-protein-coupled<br>
receptors. The data were presented as the mean ± SEM for each of the triplicate<br>
measurements. The data (calculation and plotting) were transferred to Microcal<br>
Origin Software (OriginLab Corp., Northampton, MA).<br>
[0183]	The HUVEC preparation is stable over the course of these experiments with<br>
the cells remaining viable in culture for &gt;24 hours. Under non-stimulating conditions,<br>
basal levels of NO release are very low (
function of treatment was conducted in individual endothelial cells. Multiple<br>
measurements of NO release can be conducted on single cells following a brief<br>
-93-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
refractory period. For robust statistical analysis, separate cells were used for each<br>
concentration and type of drug used in these analyses.<br>
[0184]	In Figure 1, the extent of NO release from Black and White donors was<br>
measured after chronic treatment with the ACE inhibitor, ramiprilat, followed by<br>
treatment with nebivolol (1 μM). At concentrations of 1,5, and 10 JJM ramiprilat,<br>
there were modest but significant effects in the ability of nebivolol to increase NO<br>
release from Black and White donor endothelial cells. The magnitude of the increase<br>
is greater in endothelial cells from Black donors.<br>
[0185]	In Figure 3, the extent of NO release from Black and White donors was<br>
measured with nebivolol (lμM) following chronic treatment with the ACE-inhibitor,<br>
enalapril. As observed with ramiprilat (above), enalapril significantly enhanced the<br>
ability of nebivolol to increase NO release at concentrations of 5 and 10 μM and 1,5<br>
and l0μM in Black and White donor cells, respectively. The magnitude of the<br>
increase is greater in endothelial cells from Blacks than Whites (Figure 4).<br>
[0186]	There were significant concentration dependent effects on the ability of<br>
nebivolol to enhance NO release from Black and White donor endothelial cells that<br>
had been chronically treated with ACE inhibitors. Additionally, this property of the<br>
drug appears to work independently of β1- adrenoceptor blockade. By promoting a<br>
more normal vascular physiology through an NO-dependent pathway, nebivolol<br>
treatment may have better efficacy and fewer side effects as compared to agents that<br>
only inhibit the sympathetic nervous system. These data further support the<br>
hypothesis that nebivolol may have distinct pharmacologic benefits through<br>
modulation of endothelial function and NO metabolism.<br>
-94-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Incorporation by Reference<br>
[0187]	All of the patents and publications cited herein are hereby incorporated by<br>
reference.<br>
Equivalents<br>
[0188]	Those skilled in the art will recognize, or be able to ascertain using no more<br>
than routine experimentation, many equivalents to the specific embodiments of the<br>
invention described herein.<br>
-95-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
Claims<br>
What is claimed is:<br>
1)	A composition comprising nebivolol and at least one other active agent.<br>
2)	The composition of claim 1 wherein at least one of the other active agents is a<br>
cardiovascular agent.<br>
3)	The composition of claim 2 wherein the cardiovascular agent is selected from the<br>
group consisting of ACE inhibitors, ARB's, adrenergic blockers, adrenergic agonists,<br>
agents for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants,<br>
antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium<br>
channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors,<br>
diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic<br>
agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers, AGE<br>
formation inhibitors, and mixtures thereof.<br>
4)	The composition of claim 2, wherein the cardiovascular agent is selected from the<br>
group consisting of an ACE inhibitor, an ARB, and mixtures thereof.<br>
5)	The composition of claim 4, wherein the cardiovascular agent is an ACE inhibitor.<br>
6)	The composition of claim 5 wherein the ACE inhibitor is selected from the group<br>
consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril,<br>
enalaprilat, fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat,<br>
spirapril, temocapril, trandolapril, and mixtures thereof.<br>
7)	The composition of claim 5 wherein the ACE inhibitor is selected from the group<br>
consisting of enalapril, ramipril and ramiprilat and mixtures thereof.<br>
-96-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
8)	The composition of claim 4 wherein the cardiovascular agent is an ARB.<br>
9)	The composition of claim 8 wherein the ARB is selected from the group consisting of<br>
candesartan, eprosartan, irbesartan, losartan, valsartan, and mixtures thereof.<br>
10)	The composition of claim 2, wherein the cardiovascular agent is selected from the<br>
group consisting of AGE crosslink breakers, AGE formation inhibitors, and mixtures<br>
thereof.<br>
11)	A composition comprising nebivolol and only one other active agent.<br>
12)	The composition of claim 11 wherein the other active agent is a cardiovascular agent.<br>
13)	The composition of claim 12 wherein the cardiovascular agent is selected from the<br>
group consisting of ACE inhibitors, ARB's, adrenergic blockers, adrenergic agonists,<br>
agents for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants,<br>
antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium<br>
channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors,<br>
diuretics, endofhelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic<br>
agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers, AGE<br>
formation inhibitors, and mixtures thereof.<br><br>
14)	The composition of claim 12 wherein the cardiovascular agent is selected from the<br>
group consisting of ACE inhibitors and ARB's.<br>
15)	The composition of claim 12 wherein the cardiovascular agent is an ACE inhibitor<br>
selected from the group consisting of alacepril, benazepril, captopril, ceronapril,<br>
cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, perindopril,<br>
quinapril, ramipril, ramiprilat, spirapril, temocapril, and trandolapril.<br>
-97-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
16)	The composition of claim 12, wherein the cardiovascular agent is an ARB selected<br>
from the group consisting of candesartan, eprosartan, irbesartan, losartan and<br>
valsartan.<br>
17)	The composition of claim 12 wherein the cardiovascular agent is selected from the<br>
group consisting of AGE crosslink breakers and AGE formation inhibitors.<br>
18)	A pharmaceutical composition comprising nebivolol and at least one other active<br>
agent, and a pharmaceutically-acceptable carrier.<br>
19)	The pharmaceutical composition of claim 18 wherein at least one of the other active<br>
agents is a cardiovascular agent.<br>
20)	The pharmaceutical composition of claim 19 wherein the cardiovascular agent is<br>
selected from the group consisting of ACE inhibitors, ARB's, adrenergic blockers,<br>
adrenergic agonists, agents forpheochromocytoma, antiarrhythmics, antiplatelet<br>
agents, anticoagulants, antihypertensives, antilipemic agents, antidiabetics,<br>
antiinflammatory agents, calcium channel blockers, CETP inhibitors, COX-2<br>
inhibitors, direct thrombin inhibitors, diuretics, endothelin receptor antagonists, HMG<br>
Co-A reductase inhibitors, inotropic agents, rennin inhibitors, vasodilators,<br>
vasopressors, AGE crosslink breakers, AGE formation inhibitors, and mixtures<br>
thereof.<br>
21)	The pharmaceutical composition of claim 19, wherein the cardiovascular agent is<br>
selected from the group consisting of ACE inhibitors, an ARB's, and mixtures<br>
thereof.<br>
22)	The pharmaceutical composition of claim 21, wherein the cardiovascular agent is an<br>
ACE inhibitor.<br>
-98-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
23)	The pharmaceutical composition of claim 22 wherein the ACE inhibitor is selected<br>
from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril,<br>
delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, perindopril, quinapril,<br>
ramipril, ramiprilat, spirapril, temocapril, trandolapril, and mixtures thereof.<br>
24)	The pharmaceutical composition of claim 23 wherein the ACE inhibitor is selected<br>
from the group consisting of enalapril, ramipril and ramiprilat and mixtures thereof<br>
25)	The pharmaceutical composition of claim 21 wherein the cardiovascular agent is an<br>
ARB.<br>
26)	The pharmaceutical composition of claim 25 wherein the ARB is selected from the<br>
group consisting of candesartan, eprosartan, irbesartan, losartan, valsartan, and<br>
mixtures thereof.<br>
27)	The pharmaceutical composition of claim 19, wherein the cardiovascular agent is<br>
selected from the group consisting of AGE crosslink breakers, AGE formation<br>
inhibitors, and mixtures thereof.<br>
28)	A method of treating and/or preventing a cardiovascular disorder comprising<br>
administering to a subject a therapeutically safe and effective amount of nebivolol and<br>
at least one other active agent, sufficient to treat said condition.<br>
29)	The method of claim 28 wherein the at least one other active agent is a cardiovascular<br>
agent.<br>
30)	The method of claim 29 wherein the cardiovascular agent is selected from the group<br>
consisting of ACE inhibitors, ARB's, adrenergic blockers, adrenergic agonists, agents<br>
for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants,<br>
-99-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
antihypertensives, antilipemic agents, antidiabetics, antiinfiammatory agents, calcium<br>
channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors,<br>
diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic<br>
agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers, AGE<br>
formation inhibitors, and mixtures thereof.<br>
31)	The method of claim 28 wherein the cardiovascular disorder is selected from the<br>
group consisting of congestive heart failure, hypertension, pulmonary hypertension,<br>
myocardial and cerebral infarctions, atherosclerosis, atherogenesis, thrombosis,<br>
ischemic heart disease, post-angioplasty restenosis, coronary artery diseases, renal<br>
failure, stable, unstable and variant (Prinzmetal) angina, cardiac edema, renal<br>
insufficiency, nephrotic edema, hepatic edema, stroke, transient ischemic attacks,<br>
cerebrovascular accidents, restenosis, controlling blood pressure in hypertension,<br>
platelet adhesion, platelet aggregation, smooth muscle cell proliferation, pulmonary<br>
edema, vascular complications associated with the use of medical devices, wounds<br>
associated with the use of medical devices, pulmonary thromboembolism, cerebral<br>
thromboembolism, thrombophlebitis, thrombocytopenia and bleeding disorders.<br>
32)	The method of claim 30 wherein the wherein the cardiovascular agent is selected from<br>
the group consisting of ACE inhibitors, an ARB's, and mixtures thereof.<br>
33)	The method of claim 32 wherein the cardiovascular agent is an ACE inhibitor.<br>
34)	The method of claim 32 wherein the cardiovascular agent is an ARB.<br>
35)	The method of claim 30 wherein the cardiovascular agent is selected from the group<br>
consisting of AGE crosslink breakers, AGE formation inhibitors, and mixtures<br>
thereof.<br>
-100-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
36)	The pharmaceutical composition as set forth in claims 18, wherein said composition<br>
comprises a pharmaceutical kit.<br>
37)	The composition of claim 2, wherein the cardiovascular agent is a vasodilator.<br>
38)	The composition of claim 37, wherein the vasodilator is selected from the group<br>
consisting of isosorbide dinitrate, isosorbide mononitrate, and a hydralazine<br>
compound, and mixtures thereof.<br>
39)	The composition of claim 1 wherein at least one of the other active agents is a<br>
flavonoid.<br>
40)	The composition of claim 39 wherein the flavonoid is selected from the group<br>
consisting of (-)-epictechin, (+)-catechin, procyanidin B2, quercetin dehydrate,<br>
taxifolin and resveratrol, and mixtures thereof.<br>
41)	The composition of claim 1 wherein at least one other active agent is selected from<br>
the group consisting of flavonoids, cartenoids, sulfonylureas, and niacin and related<br>
derivatives, and mixtures thereof.<br>
42)	The composition of claim 41 wherein at least one other active agent is a carotenoid.<br>
43)	The composition of claim 42 wherein the carotenoid is selected from the group<br>
consisting of astaxanthin, zeaxanthin, lutein, lycopene, beta-carotene, and mixtures<br>
thereof.<br>
44)	The composition of claim 41 wherein the at least one other active agent is a<br>
sulfonylurea.<br>
-101-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
45)	The composition of claim 44 wherein the sulfonylurea is selected from the group<br>
consisting of acetohexamide, DiaBeta, glibenclamide, gliclazide, glipizide,<br>
glyclopyramide, chlorpropamide, tolazamide, tolbutamide, glimepiride, tolbutamide<br>
and meglitinide analogues, and mixtures thereof.<br>
46)	The method of claim 29 wherein the cardiovascular agent is a vasodilator.<br>
47)	The method of claim 46 wherein the vasodilator is selected from the group consisting<br>
of isosorbide dinitrate, isosorbide mononitrate, isosorbide mononitrate and a<br>
hydralazine compound, and mixtures thereof.<br>
48)	The method of claim 47 wherein the hydralazine compound is selected from the group<br>
consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine,<br>
pildralazine and todralazine, or pharmaceutically acceptable salts thereof, and<br>
mixtures thereof.<br>
49)	The method of claim 28 wherein at least one other active agent is a flavonoid.<br>
50)	The method of claim 49 wherein the flavonoid is selected from the group consisting<br>
of (-)-epictechin, (+)-catechin, procyanidin B2, quercetin dehydrate, taxifolin and<br>
resveratrol, and mixtures thereof.<br>
51)	The method of claim 28 wherein at least one other active agent is selected from the<br>
group consisting of flavonoids, cartenoids, sulfonylureas, and niacin and related<br>
derivatives, and mixtures thereof.<br>
52)	A method of improving NO release in a black patient in need thereof comprising<br>
administering to the black patient a therapeutically safe and effective amount of<br>
-102-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
nebivolol or a pharmaceutically acceptable salt thereof and at least one other<br>
cardiovascular agent, sufficient to improve NO release.<br>
53)	The method of claim 52 wherein the at least one other cardiovascular agent is selected<br>
from the group consisting of ACE inhibitors, ARB's, adrenergic blockers, adrenergic<br>
agonists, agents forpheochromocytoma, antiarrhythmics, antiplatelet agents,<br>
anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory<br>
agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin<br>
inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors,<br>
inotropic agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink<br>
breakers, AGE formation inhibitors, and mixtures thereof.<br>
54)	The method of claim 53 wherein the at least one other cardiovascular agent is a<br>
vasodilator.<br>
55)	The method of claim 54 wherein the vasodilator is selected from the group consisting<br>
of isosorbide dinitrate, isosorbide mononitrate, a hydralazine compound, and mixtures<br>
thereof.<br>
56)	The method of claim 55 wherein the hydralazine compound is selected from the group<br>
consisting of budralazine, cadralazine, dihydralazine, endralazine, hydralazine,<br>
pildralazine and todralazine, or pharmaceutically acceptable salts thereof, and<br>
mixtures thereof.<br>
57)	A method of reducing mortality associated with cardiovascular disease in a black<br>
patient comprising administering to the black patient a therapeutically effective<br>
amount of:<br>
(i) nebivolol or a pharmaceutically salt thereof;<br>
-103-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
(ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof;<br>
(iii) at least one of isosorbide dinitrate and/or isosorbide mononitrate; and<br>
(iv) optionally, one or more compounds selected from the group consisting of a<br>
digitalis compound, a diuretic compound, potassium, an angiotensin-converting<br>
enzyme inhibitor, a beta-adrenergic blocker, a cholesterol reducer, a calcium channel<br>
blocker, an angiotensin II receptor antagonist, and an endothelin antagonist.<br>
58)	The method of claim 57 wherein the cardiovascular disorder is selected from the<br>
group consisting of congestive heart failure, hypertension, pulmonary hypertension,<br>
myocardial and cerebral infarctions, atherosclerosis, atherogenesis, thrombosis,<br>
ischemic heart disease, post-angioplasty restenosis, coronary artery diseases, renal<br>
failure, stable, unstable and variant (Prinzmetal) angina, cardiac edema, renal<br>
insufficiency, nephrotic edema, hepatic edema, stroke, transient ischemic attacks,<br>
cerebrovascular accidents, restenosis, controlling blood pressure in hypertension,<br>
platelet adhesion, platelet aggregation, smooth muscle cell proliferation, pulmonary<br>
edema, vascular complications associated with the use of medical devices, wounds<br>
associated with the use of medical devices, pulmonary thromboembolism, cerebral<br>
thromboembolism, thrombophlebitis, thrombocytopenia and bleeding disorders.<br>
59)	The method of claim 58, wherein the cardiovascular disorder is hypertension.<br>
60)	The method of claim 59, wherein the hydralazine compound is budralazine,<br>
cadralazine, dihydralazine, endralazine, hydralazine, pildralazine, todralazine or a<br>
pharmaceutically acceptable salt thereof, and mixtures thereof.<br>
61)	The method of claim 57 wherein the nebivolol is administered in an amount of from<br>
about 1 mg per day to about 10 mg per day.<br>
-104-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
62) A method for improving NO release in a black patient in need thereof comprising<br>
administering to the black patient a safe and therapeutically effective amount of:<br>
(i) nebivolol or a pharmaceutically salt thereof;<br>
(ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof;<br>
(iii) at least one of isosorbide dinitrate and/or isosorbide mononitrate; and<br>
(iv) optionally, one or more compounds selected from the group consisting of a<br>
digitalis compound, a diuretic compound, potassium, an angiotensin-converting<br>
enzyme inhibitor, a beta-adrenergic blocker, a cholesterol reducer, a calcium channel<br>
blocker, an angiotensin II receptor antagonist, and an endothelin antagonist.<br>
63)	The method of claim 62, wherein the cardiovascular disorder is hypertension.<br>
64)	The method of claim 62, wherein the hydralazine compound is budralazine,<br>
cadralazine, dihydralazine, endralazine, hydralazine, pildralazine, todralazine or a<br>
pharmaceutically acceptable salt thereof, and mixtures thereof.<br>
65)	The method of claim 64, wherein the hydralazine compound is hydralazine<br>
hydrochloride.<br>
66)	A method for improving exercise tolerance or for improving the quality of life in a<br>
black patient in need thereof comprising administering to the black patient a<br>
therapeutically effective amount of:<br>
(i) nebivolol or a pharmaceutically salt thereof;<br>
(ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof;<br>
(iii) at least one of isosorbide dinitrate and/or isosorbide mononitrate; and<br>
(iv) optionally, one or more compounds selected from the group consisting of a<br>
digitalis compound, a diuretic compound, potassium, an angiotensin-converting<br>
-105-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
enzyme inhibitor, a beta-adrenergic blocker, a cholesterol reducer, a calcium channel<br>
blocker, an angiotensin II receptor antagonist, and an endothelin antagonist.<br>
67)	The method of claim 66, wherein the hydralazine compound is budralazine,<br>
cadralazine, dihydralazine, endralazine, hydralazine hydrochloride, pildralazine,<br>
todralazine or a pharmaceutically acceptable salt thereof, and mixtures thereof.<br>
68)	The method of claim 67, wherein the hydralazine compound is hydralazine<br>
hydrochloride.<br>
69)	A method of improving NO release in a black patient in need thereof comprising<br>
administering to the black patient nebivolol or a pharmaceutically acceptable salt in<br>
an amount of about 1 mg per day to about 10 mg per day, and at least one other<br>
cardiovascular agent.<br>
70)	The method of claim 69 wherein the cardiovascular agent is selected from the group<br>
consisting of isosorbide dinitrate, isosorbide mononitrate, a hydralazine compound,<br>
and mixtures thereof.<br>
71)	A method for the treatment and/or prevention of cardiovascular diseases characterized<br>
by nitric oxide insufficiency, wherein said method comprises administering to a<br>
patient nebivolol, or a pharmaceutically acceptable salt, in an amount of about 1 mg<br>
per day to about 10 mg per day, and at least one other cardiovascular agent selected<br>
from the group consisting of isosorbide dinitrate, isosorbide mononitrate, a<br>
hydralazine compound, and mixtures thereof.<br>
72)	A method for improving exercise tolerance or for improving the quality of life in a<br>
black patient in need thereof comprising administering to the black patient a<br>
therapeutically effective amount of:<br>
-106-<br><br>
WO 2006/130174	PCT/US2005/041275<br>
(i) nebivolol or a pharmaceutically salt thereof in the amount of about 1 mg to about<br>
10 mg per day;<br>
(ii) at least one cardiovascular agent; and<br>
(iii) optionally, one or more compounds selected from the group consisting of a<br>
digitalis compound, a diuretic compound, potassium, an angiotensin-converting<br>
enzyme inhibitor, a beta-adrenergic blocker, a cholesterol reducer, a calcium channel<br>
blocker, an angiotensin II receptor antagonist, and an endothelin antagonist.<br>
73)	The method of claim 72 wherein the cardiovascular agent is selected from the group<br>
consisting of ACE inhibitors, ARB's, adrenergic blockers, adrenergic agonists, agents<br>
for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants,<br>
antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium<br>
channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors,<br>
diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic<br>
agents, rennin inhibitors, vasodilators, vasopressors, AGE crosslink breakers, AGE<br>
formation inhibitors, and mixtures thereof.<br>
74)	A composition comprising nebivolol, hydrochlorothiazide and at least one other<br>
additional active agent.<br>
-107-<br><br>
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive<br>
heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising<br>
nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1kcmF3aW5ncy5wZGY=" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ1MjYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">04526-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1BTk5FWFVSRSBUTyBGT1JNLTMucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-ANNEXURE TO FORM-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1EUkFXSU5HUy5wZGY=" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-DRAWINGS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1GT1JNLTEzLnBkZg==" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-FORM-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1PVEhFUlMgUENUIEZPUk0ucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-OTHERS PCT FORM.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy0xLnBkZg==" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-PETITION UNDER RULE 137-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LSgwNy0wNi0yMDEzKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-(07-06-2013)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIE9USEVSUyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-CORRESPONDENCE OTHERS 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">4526-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDUyNi1LT0xOUC0yMDA3LUZPUk0gMyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">4526-KOLNP-2007-FORM 3 1.1.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="260879-zeolitic-catalyst-with-a-controlled-doping-element-content-and-improved-process-for-processing-hydrocarbon-feeds.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="260881-a-pharmaceutical-composition-having-structure-of-there-branched-peg-g-csf-conjugate-comprising-three-branched-peg-and-g-csf-and-method-of-preparing-the-same.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>260880</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>4526/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>22/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>30-May-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>27-May-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>23-Nov-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>MYLAN LABORATORIES, INC</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>781 CHESTNUT RIDGE ROAD MORGANTOWN, WV</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ODONNELL JOHN</td>
											<td>24 HEATHER DRIVE, MORGANOWN, WV 26505</td>
										</tr>
										<tr>
											<td>2</td>
											<td>MASON PRESTON</td>
											<td>781 CHESTNUT RIDGE ROAD, MORGANTOWN, WV 26504</td>
										</tr>
										<tr>
											<td>3</td>
											<td>DAVIS ERIC</td>
											<td>12 COBUN RIDGE, MORGANTOWN, WV 26508</td>
										</tr>
										<tr>
											<td>4</td>
											<td>BOTTINI PETER BRUCE</td>
											<td>1460 WESTERN AVENUE, MORGANTOWN, WV 26505</td>
										</tr>
										<tr>
											<td>5</td>
											<td>SHAW ANDREW PRESTON</td>
											<td>781 CHESTNUT RIDGE ROAD, MORGANTOWN, WV 26504</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/352</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2005/041275</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-11-16</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>11/273992</td>
									<td>2005-11-15</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>11/141235</td>
									<td>2005-05-31</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>3</td>
									<td>11/272562</td>
									<td>2005-11-10</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/260880-compositions-comprising-nebivolol by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:14:35 GMT -->
</html>
